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ABSTRACT 
 
 Salmonella enterica subspecies enterica serovar Enteritidis (S. Enteritidis) has been 
identified as a significant cause of salmonellosis in humans.  Salmonella pathogenicity islands 1 
and 2 (SPI-1 and SPI-2) each encode a specialized type III secretion system (T3SS) that enables 
Salmonella to manipulate host cells at various stages of the invasion/infection process.  The SPI-
2 T3SS has been identified as vital for survival and replication of S. Typhimurium and S. 
Enteritidis in mouse macrophages, as well as full virulence in mice.  In order to test the ability of 
SE SPI-2 mutants to survive in vivo we used a chicken isolate of SE (Sal18).  In one study, we 
orally co-challenged 35-day-old specific pathogen free (SPF) chickens with two bacterial strains 
per group.  The control group received two versions of the wild-type (WT) strain Sal18: Sal18 
attTn7::tet and Sal18 attTn7::cat, while the other two groups received the WT strain (Sal18 
attTn7::tet) and one of two mutant strains (Sal18 attTn7::cat !spaS!ssaU or Sal18 !SPI-1!SPI-
2::cat).  From this study we conclude that S. Enteritidis deficient in the SPI-1 and SPI-2 systems 
are out-competed by the WT strain.  In a second study, groups of SPF chickens were challenged 
at 1 week of age with four different strains; a WT strain and three other strains missing either one 
or both of the SPI-1 and SPI-2 regions.  On days 1 and 2 post-challenge (PC) we observed a 
reduced systemic spread of the SPI-2 mutants, but by day 3 the mutants’ systemic distribution 
levels matched that of the WT strain.  Based on these two studies, we conclude that the SPI-2 
T3SS facilitates invasion and systemic spread of S. Enteritidis in chickens, but alternative 
mechanisms for these processes appear to exist. 
Several structural components of the T3SSs encoded by SPI-1 and SPI-2 are exposed to 
the host’s immune system prior to/during the infection/invasion process, making them potential 
vaccine candidates.  Several of these candidates genes were cloned, the proteins overproduced, 
purified, and formulated as vaccines for use in further studies.  SPI-2 T3SS proteins used for 
vaccine studies included the secretin, SsaC, the needle, SsaG, the filament, SseB, and a part of 
the translocon, SseD, as well as a number of effectors, SseI, SseL, SifA, and SifB.   The first 
vaccine study involved vaccination of SPF chickens with SseB and SseD, followed by challenge 
with the WT S. Enteritidis strain Sal18.  Additional studies evaluated whether hens vaccinated 
with SPI-2 T3SS structural or effector components could mount a significant humoral immune 
response (as measured by serum immunoglobulin Y [IgY] titres), whether these antibodies could 
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be transferred to progeny (as measured by egg yolk IgY titres), and whether vaccinates and 
progeny of vaccinates could be protected against challenge with the WT S. Enteritidis strain 
Sal8.  The results of our studies show that vaccinated chickens do produce high levels of SPI-2 
T3SS specific serum IgY that they are able to transfer to their progeny.  It was demonstrated that 
vaccinates and progeny of vaccinates had lower overall countable recovered SE per bird in most 
situations. 
In order to better identify the role of the SPI-2 T3SS in chickens, we used the well-known 
gentamicin protection assay with activated HD11 cells.  HD11 cells are a macrophage-like 
chicken cell line that can be stimulated with phorbol 12-myristate 13-acetate (PMA) to exhibit 
more macrophage-like morphology and greater production of reactive oxygen species (ROS).  
Activated HD11 cells were infected with a WT S. Typhimurium strain, a SPI-2 mutant S. 
Typhimurium strain, a WT S. Enteritidis strain, a SPI-2 mutant S. Enteritidis strain, or a non-
pathogenic Escherichia coli (E. coli) strain.  SPI-2 mutant strains were found to survive as well 
as their parent strain at all time points post-infection (PI) up to 24 h PI, while the E. coli strain 
was no longer recoverable by 3 h PI.  We can conclude from these observations that the SPI-2 
T3SS is not important for survival of Salmonella in the activated macrophage-like HD11 cell 
line, and that Salmonella must employ other mechanisms for survival in this environment as E. 
coli is effectively eliminated. 
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1.0 LITERATURE REVIEW 
 
1.1 Salmonella 
Salmonellae are motile, facultatively anaerobic, Gram-negative rods measuring 0.3-1.5 by 
1.0-2.5 µm in size.  The genus Salmonella was named for Dr. Daniel Salmon, a veterinary 
bacteriologist at the United States Department of Agriculture (USDA) [7, 8].  The Salmonella 
species are closely related to Escherichia, Yersinia, and Shigella, and contain a circular 
chromosome approximately 4.7 Mbp in size with an overall GC content of 52% [6, 7, 9]. 
 
1.1.1 Nomenclature 
The genus Salmonella lies within the kingdom Eubacteria, class Gammaproteobacteria, 
order Enterobacteriales, and family Enterobacteriaceae.  Salmonella is divided into two species, 
Salmonella bongori and Salmonella enterica.  Within Salmonella enterica there are 6 subspecies:  
salamae, arizonae, diarizonae, houtenae, indica and enterica [10].  These subspecies can be 
further classified into approximately 50 serogroups based on their lipopolysaccharide (LPS) O 
antigen component [11].  Salmonella bongori and most subspecies of Salmonella enterica 
colonize the environment and cold-blooded animals, and in some cases can cause disease in these 
animals.  The exception is Salmonella enterica subspecies enterica, which finds its niche in 
warm-blooded animals [12].  Salmonella enterica subspecies enterica can be further divided into 
over 2500 serovars based on their flagellar (H) antigen and LPS O antigen structures [10-13].  
Many of these serovars are host-adapted, although some are non-host-adapted.  Host-adapted 
serovars tend to cause life-threatening systemic disease in their host, while non-host-adapted 
strains tend to cause gastroenteritis in many different host species.  For the purposes of this 
document, serovars within Salmonella enterica subspecies enterica will be identified by an 
italicized S followed by a period and the serovar name.  For example, Salmonella enterica 
subspecies enterica serovar Enteritidis will be referred to simply as S. Enteritidis. Of note, 
serovars Typhi and Paratyphi (S. Typhi and S. Paratyphi) cause systemic disease in humans and 
some primates, while serovars Gallinarum and Pullorum (S. Gallinarum and S. Pullorum) 
produce systemic disease in chickens.  Serovar Dublin (S. Dublin) causes systemic disease in 
cattle, and Choleraesuis (S. Choleraesuis) in pigs.  Serovars Typhimurium (S. Typhimurium) and 
Enteritidis (S. Enteritidis) are non-host-adapted and are able to cause different disease outcome in 
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various host species [14-18].  S. Typhimurium and S. Enteritidis will be discussed further in 
section 1.1.2, and specific disease outcomes of S. Typhimurium and S. Enteritidis in various hosts 
will be discussed in section 1.4.4   Worldwide distributions of common Salmonella isolates from 
humans and animals are depicted in Figures 1.1 and 1.2, respectively. 
 
1.1.2 Salmonella enterica subspecies enterica serovars Typhimurium and Enteritidis 
Salmonella enterica subspecies enterica serovars Typhimurium and Enteritidis (S. 
Typhimurium and S. Enteritidis) are non-host-adapted strains, and can cause disease in a wide 
variety of host species.  They are able to induce a systemic infection in mice, young calves, 
chicks, and piglets.  However, they are also able to colonize poultry and adult cattle without 
symptoms [14-18].  In humans, infection with either of these serovars results in a self-limiting 
gastroenteritis (salmonellosis) involving fever, diarrhea, and abdominal pain.  In rare cases, 
typically in the very young or immunocompromised, the infection can become systemic and lead 
to hospitalization and even death.  A very small proportion of humans with salmonellosis can 
develop reactive arthritis (previously referred to as Reiter’s syndrome), which is initially 
characterized by joint pain, eye irritation, and pain during urination [18-20]. 
 
1.1.3 Human disease, animal reservoirs, and modes of transmission 
Infections by S. enterica are one of the most common causes of bacterial food-borne 
gastroenteritis (food poisoning) in the world, along with E. coli and Campylobacter infections 
[21].   Of the S. enterica serovars, S. Enteritidis and S. Typhimurium are the leading cause of 
salmonellosis in humans in most countries (Figure 1.1).  S. Enteritidis and S. Typhimurium are 
passed to humans via consumption of contaminated poultry meat, water and eggs.  S. Enteritidis 
is more often associated with salmonellosis acquired from eggs, as it has a greater tendency to 
colonize eggs and reproductive organs of poultry than S. Typhimurium [22].  Because chickens 
mostly do not show symptoms of disease, entire flocks can become colonized quite quickly and 
shed bacteria in their feces for extended periods of time [23-26].  Loss of consumer confidence in 
products because of Salmonella contamination can result in substantial economic loss to the 
poultry industry.  Additionally, human cases of salmonellosis place a significant burden on the 
health care system [18].  There are approximately 1.4 million cases of salmonellosis per year 
resulting in about 15,000 hospitalizations and 400 deaths per year in the United States of America  
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Figure 1.1  Human isolates of Salmonella (previous page) 
 
Distributions of the first and second most common human isolates of Salmonella are shown here.  
Regions that have the same top two isolates are similarly coloured.  All strains are isolates of 
Salmonella enterica subspecies enterica, and are represented by and S followed by the first 
letters of its serovar name.  Serovars shown are: Enteritidis (SE – marked by * when found as 
most common isolate), Typhimurium (ST – marked by ^ where found as most common isolate), 
Weltevreden (SW), Virchow (SV), Typhi (STy), Livingston (SL).  Adapted from [27]. 
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Figure 1.2  Animal isolates of Salmonella (previous page) 
 
Distributions of the first and second most common animal isolates of Salmonella are shown here.  
Regions that have the same #1 and #2 isolates are similarly coloured.  All strains are isolates of 
Salmonella enterica subspecies enterica, and are represented by and S followed by the first 
letters of its serovar name.  Serovars shown are: Enteritidis (SE – marked by * when found as 
most common isolate), Typhimurium (ST – marked by ^ where found as most common isolate), 
Kentucky (SK), II 1,4,12,.27 (SII), Infantis (SI), Anatum (SAn), Derby (SDe), Heidelberg (SH), 
Jedburgh (SJ), Bredeney (SB), Gallinarum (SG), Agona (SAg).  Adapted from [27]. !  
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(USA) [28].  Around 95% of these cases are caused by consumption of contaminated food 
products, and S. Enteritidis is responsible for at least 15% of these cases.  S. Enteritidis is the 
second most commonly isolated serovar in North America after S. Typhimurium, while S. 
Enteritidis is number one in the European Union (EU) (Figures 1.1 and 1.2) [15, 19, 27, 29, 30]. 
 
1.2 Salmonella virulence factors 
 
1.2.1 Flagella 
Flagella are complex motility structures found in members of Prokarya, Archaea, and 
Eukarya [31].  The presence of flagella has been associated with virulence in many pathogens, 
including Salmonella, which usually expresses between five and ten flagella at random on the 
cell surface [32, 33].  However, there is conflicting evidence for the contribution of flagella to 
virulence in S. Enteritidis.  Flagellar mutants have been shown to be less proficient in colonizing 
eggs than WT S. Enteritidis [34].  In 20-day-old chickens, Parker et al. observed that removal of 
the gene encoding FlhD (important for transcription of flagellar genes) caused enhanced 
invasiveness in these chickens when challenged orally [33].  Other studies have shown that S. 
Enteritidis strains with deletions in major flagellar genes had decreased adherence to chicken 
intestinal explants and human intestinal epithelial cell lines, suggesting that flagella are important 
in adherence of S. Enteritidis to intestinal epithelial cells prior to invasion [35, 36].  Allen-Vercoe 
et al. [37] also demonstrated that strains defective for production of flagella were recovered at 
lower numbers from the spleens and livers of 1-day-old orally challenged chicks than the WT 
strain, implicating a role for flagella in invasion.  This group also showed that flagellar mutants 
performed similarly to the WT strain in colonization of the ceca of 1- and 5-day-old chickens 
following oral challenge.  However, when mutant strains were given in conjunction with WT S. 
Enteritidis in a competition experiment, there was much greater shedding of the WT strain than 
the mutants, suggesting that flagella do provide a competitive survival advantage [38].  The 
structure of the flagellar system of Salmonella enterica resembles that of the T3SS; similarities 
and differences between the flagellar and T3S systems will be discussed further in section 1.3.  
 
1.2.2 Fimbriae 
Fimbriae, or pili, are typically 2-8 nm in width and extend 0.5-10 µm from the cell 
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surface.  Fimbriae play an important role in many bacteria, including biofilm formation and the 
persistence of bacteria in the environment, as well as contribute to colonization and invasion of 
the host.  Many fimbriae are conserved between the Salmonella serovars, while some are unique.  
As each fimbria is typically specific to a given receptor, the differences in fimbrial distribution 
among serovars may contribute to host specificity.  There are many known and predicted fimbrial 
operons in S. Enteritidis [11, 32, 39].  Fimbriae are composed of fimbrin proteins arranged in a 
helical fashion and can be divided into three classes based on their method of assembly.  
Fimbriae of the type IV class are assembled via a type IV secretion system (T4SS).  The only 
known type IV pilus in S. Enteritidis is encoded by the bfp (bundle forming pilus) operon and 
may be important in the formation of bacterial colonies on the intestinal epithelium prior to entry 
[32, 40].  Fimbrins belonging to the chaperone-usher class are bound by chaperones in the 
periplasm to prevent aggregation and ushered to the outer membrane where the fimbria is formed, 
while those belonging to the nucleator-dependent pathway are assembled extracellularly [32, 39]. 
There are many known operons encoding fimbriae of the chaperone-usher class in S. 
Enteritidis: bcf, fim, lpf, pef, saf, sef, stb, std, ste, peg, sti, stf and sth [6, 32].  The fimbrial usher 
BcfC is important in colonization in cattle and S. Enteritidis missing bcfC have a decreased 
ability to survive in chicken egg albumen [6, 23].  The fimbria encoded by the fim operon 
(SEF21) has been shown to be important for invasion of human and mouse intestinal epithelial 
cells in both S. Enteritidis and S. Typhimurium [36, 41].  In S. Typhimurium, SEF21 is important 
for cecal colonization of chicks, but not cattle [42].  The presence of SEF21 has also been shown 
to be important for S. Enteritidis colonization of eggshells, while the absence of SEF21 resulted 
in prolonged bacteremia, ovary colonization, and cecal shedding in chickens [43].   SEF14, 
encoded by the sef (Salmonella Enteritidis fimbriae) operon on Salmonella pathogenicity island 
(SPI) 10 (described in section 1.2.3.3), was not found to be involved in the invasion of human 
intestinal epithelial cells, and is only expressed by S. Enteritidis and poultry-associated serovars 
such as S. Dublin, S. Gallinarum, and S. Pullorum [32, 36].  The fact that SEF14 is only 
expressed by poultry-associated Salmonella serovars indicates that it may have some function in 
Salmonella survival and/or pathogenesis in poultry.  However, S. Enteritidis strains defective for 
SEF14 were just as adherent to chicken intestinal explants as the WT strain, and were recovered 
from liver and spleen of 1-day-old orally challenged chickens in similar numbers to the WT 
strain.  The strains missing SEF14 were shown to colonize the cecum of 1- to 5-day old chickens 
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at similar levels to the WT strain, so the role of SEF14 in poultry remains unclear.  The same 
results were observed for strains with defects in SEF21, plasmid encoded fimbriae (PEF, encoded 
by the pef operon) and long polar fimbriae (LPF, encoded by the lpf operon) [35-38].  The PEF of 
S. Typhimurium has been found to contribute to adhesion of bacteria to the small intestine of 
mice, but not human intestinal cell lines [32].  In accordance with these observations, 
Rajashekara et al. [44] observed similar results when testing SEF14 and SEF21 mutants in 
comparison to a WT S. Enteritidis strain, using two human intestinal epithelial cell lines, two 
chicken macrophage cell lines, and cecal colonization of 5-day-old chicks.  In their studies 
SEF14 and SEF21 mutants performed comparably to the WT strain in all situations both in vitro 
and in vivo.  A study by Clayton et al. [45] showed no difference in cecal colonization by 
fimbrial std, sti, stf, stf, sth, bcf, lpf, sef, fim, saf, or ste mutants compared to WT S. Enteritidis in 
orally infected 18-day-old chickens.  They did, however, observe a reduction in cecal 
colonization by fimbrial peg and stb mutants, in comparison with WT S. Enteritidis.  As in S. 
Enteritidis, stb of S. Typhimurium has been shown to be important for cecal colonization in 
chicks, as was sth, which is contrary to what is observed with S. Enteritidis [42]. 
There is only one nucleator-dependent type fimbriae expressed in S. Enteritidis, known as 
SEF17; previously known as thin aggregative fimbriae (tafi).  SEF17, which is encoded by the 
agf operons, is homologous to curli of E. coli (encoded by the csg operons), and is essential for 
biofilm formation and persistence of Salmonella in the environment [32, 39, 46].  Thin 
aggregative fimbriae of S. Typhimurium have been shown to be essential in the induction of a 
pro-inflammatory response in a bovine model, to enhance adherence and invasion of S. 
Enteritidis to human intestinal epithelial cells in vitro, and contribute to S. Enteritidis 
colonization of eggs [34, 36, 47].   However, results from a study by Rajashekara et al. indicated 
no difference between SEF17. 
 mutants and WT S. Enteritidis in regards to invasion of human intestinal epithelial cell 
lines, phagocytosis by chicken macrophage cell lines, or colonization of chicken ceca [44].  As 
with SEF14, SEF21, PEF, and LPF; SEF17 mutants did not differ in adherence to chicken 
intestinal epithelial explants or recovery from liver and spleen of 1-day-old chickens [35, 37].  
Furthermore, Clayton et al. did not observe a difference in SEF17 mutants compared to WT S. 
Enteritidis in cecal colonization of orally infected 18-day-old chickens [45].  Salmonella have 
developed a diverse set of fimbrial genes that vary from serovar to serovar.  Fimbriae contribute 
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to environmental survival and persistence, as well as virulence, and harbouring a unique set of 
fimbrial operons likely contributes to host specificity among different serovars. 
 
1.2.3 Salmonella pathogenicity islands 
Pathogenicity islands were first identified in uropathogenic E. coli (UPEC) in the late 
1980s, and have since been described in a wide variety of bacteria [48-50].  Pathogenicity islands 
have been identified in both Gram-negative and Gram-positive species, and are associated with 
plant, animal, and human pathogens, as well as non-pathogenic bacteria.  They typically harbour 
large clusters of genes (10 – 200 kb) related to virulence and/or survival and fitness, and have a 
different GC content in comparison to the rest of the genome.  Pathogenicity islands can often be 
mosaic in structure and are often bordered by transposon insertion sequences and direct repeats, 
as well as bacteriophage genes, indicating their insertion into the genome through single or 
multiple horizontal gene transfer events [50, 51].  To date there have been 21 Salmonella 
pathogenicity islands (SPIs) identified.  As expected, SPIs are often bordered by transposon 
insertion sequences or bacteriophage genes, and tend to have a different GC content in 
comparison to the rest of the genome.  SPIs also often contain clusters of genes that are 
associated with virulence [32, 52]. 
 
1.2.3.1 Salmonella pathogenicity island 1 
In S. Enteritidis, SPI-1 is located at the end of centisome (c.) 62.  It is 40.2 kb in length 
and has a GC content of 47% [9, 32].  There are 41 genes encoding a T3SS, T3SS regulatory 
genes, T3SS effectors, and a metal transport system encoded on SPI-1 (Figure 1.3) [6, 50, 53].  
SPI-1 is known to be important for cell invasion of intestinal epithelial cells as well as apoptosis 
of macrophages [54-56].  In S. Typhimurium, strains defective for InvC (a major structural 
component of the SPI-1 T3SS) have a 50% higher lethal dose when given orally to Balb/c mice, 
but perform similarly to WT strains when given intraperitoneally, indicating a role for SPI-1 in 
colonization and invasion during the initial phase of infection, but not during the systemic phase 
[57].  SPI-1 will be discussed further in section 1.3.2. 
 
1.2.3.2 Salmonella pathogenicity island 2 
In S. Enteritidis, SPI-2 is located at the end of c. 37.  At 39.8 kb in length it is similar in   
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size to SPI-1, with a GC content of 43%.  It is thought that SPI-2 is important for survival within 
the Salmonella containing vacuole (SCV) and the systemic phase of infection, and is known to be 
necessary for systemic infection in mice [58-61].  There are 44 genes encoded on SPI-2 including 
a T3SS, T3SS regulatory genes, T3SS effectors, and a tetrathionate reductase system (Figure 1.3) 
[6, 50].  SPI-2 will be discussed further in section 1.3.3. 
 
1.2.3.3 Other Salmonella pathogenicity islands 
To date, there have been 21 SPIs described in Salmonella enterica subspecies enterica.  
SPIs 1-5 have been fairly well characterized and are present in most serovars, while the majority 
of the others have only been characterized in S. Typhimurium and S. Typhi.  The distribution and 
composition of these other SPIs also varies among different serovars [6, 11, 60].  Following are 
brief descriptions of the 21 known SPIs, in order from SPI-3 to SPI-21.  For a complete list of 
these SPIs and their locations in the S. Enteritidis PT4 genome see Table 1.1. 
There are 10 genes contained on SPI-3, including mgtCB, misL, rmbA and slsA.  The 
whole of SPI-3 is necessary for S. Typhimurium virulence in mice, while different genes within 
SPI-3 are important for S. Typhimurium infection of calves and chicks [42, 50, 62].  MgtC and B 
are involved in magnesium (Mg2+) transport and are required for growth in low Mg2+ 
environments such as occurs in the SCV.  MisL is a large autotransporter protein, also known as 
a type V secretion system (T5SS), that has been shown to be important for infection of chicks, 
but not calves, by S. Typhimurium.  RmbA is a putative cytoplasmic protein that is important for 
S. Typhimurium colonization of calves, but not chicks, and SlsA is a putative inner membrane 
protein that is important for S. Typhimurium colonization of both calves and chicks  [42].  SPI-4 
encodes both a large non-fimbrial adhesion protein (SiiE) encoded by siiE, and it’s type I 
secretion system (T1SS), encoded by siiC, D and F.  SPI-4 is co-regulated with SPI-1, and, along 
with SPI-1, is important for S. Typhimurium to be able to facilitate uptake by polarized human 
epithelial cell in vitro by inducing membrane ruffles.  It has also been shown to be important for 
S. Typhimurium infection of calves, but not chicks [11, 42, 63].  SPI-5 harbours the genes for 
SopB (a SPI-1 T3SS secreted protein), PipA and PipB (SPI-2 T3SS secreted proteins), PipC 
(SopB’s chaperone), and PipD [9, 32].  SPI-5 has been shown to be important for S. Dublin 
infection and enteritis in cattle, but not systemic infection in mice [64].  SPI-5 is also not required 
for  S.  Typhimurium  infection  and  disease  in  cattle.    However,  mutations  in  pipB  decrease  
! %'!
 Salmonella pathogenicity islands Table 1.1
SPI Centisome Size (kb) Function Reference 
SPI-1 62/63 40.2 Invasion of the intestinal epithelium 
47% GC 
[6, 9, 32] 
SPI-2 37/38 39.8 Systemic infection of mice, survival in 
intestinal epithelial cells and macrophages 
43% GC 
[6, 9, 32] 
SPI-3 82/83 16.6 MgtC and B Mg2+ transporter, MisL T5SS 
Implicated in intramacrophage survival 
Certain components important S. Typhimurium 
infection of mice, calves and/or chicks 
47.5% GC 
[6, 32, 42, 
50, 62] 
SPI-4 93/94 25.0 T1SS (siiCDF) and large non-fimbrial adhesin 
SiiE 
Co-regulated with SPI-1 
Important for induction of membrane ruffling 
and entry of polarized epithelial cells in 
conjunction with the SPI-1 T3SS 
Implicated in S. Typhimurium infection of 
calves 
[6, 11, 42, 
63] 
SPI-5 23 6.6 SPI-1 T3SS effector SopB and its chaperone 
PipC 
SPI-2 T3SS effectors PipA and PipB 
PipD 
Important for S. Dublin (but not S. 
Typhimurium) induced enteritis in cattle 
Important for S. Typhimurium systemic 
infection in chicks 
[6, 9, 32, 
42, 64, 65] 
SPI-6 7/8 17.6 The saf fimbrial operon of chaperone usher 
class 
A T6SS and tcf fimbrial operon that are absent 
in S. Enteritidis 
Up to 44 kb in other serovars 
[6, 11, 32, 
66] 
SPI-7 Absent Up to 
134 
Vi capsule biosynthetic genes 
A type IV fimbrial operon 
SopE in S. Typhi 
Only present in S. Typhi, S. Paratyphi and 
some strains of S. Dublin 
Largest PI identified so far, varies in size 
between serovars 
[6, 11, 32, 
67] 
SPI-8 Absent 6 - 8 Resistance to bacteriocins 
Also absent in S. Typhimurium 
[6, 11, 32] 
SPI-9 60 16.3 T1SS, and a RTX-like protein 
The RTX protein is complete in S. Enteritidis, 
but not S. Typhimurium 
[6, 32] 
! %(!
SPI-10 98 10.0 Sef fimbrial operon (chaperone-usher class) in 
S. Enteritidis 
Larger in other serovars (up to 33 kb) 
[6, 11, 32] 
SPI-11 41 6.7 PagC, PagD and MsgA important for survival 
of S. Typhimurium in macrophages 
[6, 11] 
SPI-12 50 5.8 SPI-2 T3SS effector sspH2 
Important for full virulence of S. Typhimurium 
in mice 
[6, 11, 68] 
SPI-13 68/69 25.3 Important for systemic infection in mice by S. 
Typhimurium 
[6, 68, 69] 
SPI-14 19/20 6.8 Electron transfer and putative regulatory genes [6, 11] 
SPI-15 Absent N/A 5 hypothetical proteins 
Not present in either S. Enteritidis or S. 
Typhimurium 
[6, 11] 
SPI-16 13 3.3 LPS modification 
High homology to SPI-17 
[6, 11] 
SPI-17 54 3.6 LPS modification 
Present in S. Enteritidis and S. Typhi, but not S. 
Typhimurium 
High homology to SPI-16 
[6, 11] 
SPI-18 Absent Absent In S. Typhi encodes 2 genes for the cytolysin 
HlyE and the invasion TaiE 
Not present in either S. Enteritidis or S. 
Typhimurium 
[6, 11] 
SPI-19 24/25 14.1 T6SS likely non-functional in S. Enteritidis as 
most of island has been deleted 
Up to 45 kb in other serovars 
54.3% GC 
[6, 66] 
SPI-20 Absent 34 kb T6SS 
Only identified in Salmonella enterica subsp. 
arizonae 
53.1% GC 
[6, 66] 
SPI-21 Absent 55 kb T6SS 
Only identified in Salmonella enterica subsp. 
arizonae 
49.6% GC 
[6, 66] 
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virulence of S. Typhimurium in chicks [42, 65]. 
In S. Enteritidis, SPI-6 is 17.6 kb, but in other serovars can be 40 - 60 kb in length.  A full 
version of SPI-6 contains genes encoding a type VI secretion system (T6SS), as well as the saf 
and tcf fimbrial operons.  The shortened form of SPI-6 found in S. Enteritidis has only the saf 
fimbrial operon [11, 32, 66].  SPI-7 is only present in S. Typhi, S. Paratyphi, and some strains of 
S. Dublin.  It is a very large PI, up to 134 kb in length, with a mosaic structure.  SPI-7 includes Vi 
capsule biosynthesis genes, a type IV fimbrial operon, and sopE.  Although SPI-7 is not present 
in S. Typhimurium and S. Enteritidis, SopE is encoded elsewhere in the chromosomes of these 
serovars [11, 32, 67].  SPI-8 contains genes important for resistance to bacteriocins, but is also 
absent in S. Enteritidis and S. Typhimurium [11, 32]. 
A T1SS and an exported repeats in toxin (RTX) protein are encoded by SPI-9, although 
the gene encoding the RTX protein is complete only in S. Enteritidis, and not S. Typhimurium [6, 
32].  SPI-10 is 10 kb long in S. Enteritidis, and only contains the sef fimbrial operon.  In S. 
Typhimurium and S. Typhi, SPI-10 is much larger (up to 33 kb) and harbours many more genes 
[6, 11, 32].  SPI-11 is approximately 7 kb in S. Enteritidis, and contains pagC, pagD, msgA, 
envE, and the pseudogene envF.  In S. Typhimurium, the full envF gene is present.  EnvE and 
EnvF are lipoproteins, while PagC, PagD and MsgA are associated with S. Typhimurium survival 
in macrophages [6, 11].  SPI-12 is approximately 6 kb in S. Enteritidis, and contains the gene for 
the SPI-2 secreted effector SspH2.  It is over twice the size in S. Typhimurium, and is required 
for full virulence of S. Typhimurium in mice [6, 11, 68]. 
At 25kb, SPI-13 is important for systemic infection of mice by S. Typhimurium, as well 
as intracellular replication inside mouse macrophages [11, 68, 69].  SPI-14 encodes putative 
regulatory and electron transfer proteins and SPI-15 is a small pathogenicity island encoding five 
hypothetical proteins that is absent in both S. Enteritidis and S. Typhimurium [6, 11].  Both SPI-
16 and SPI-17 are quite small (3.3 and 3.6 kb respectively) and contain genes involved in LPS 
modification.  SPI-17 is present in S. Enteritidis and S. Typhi, but not S. Typhimurium [6, 11].  
SPI-18 encodes only two proteins in S. Typhi: the cytolysin HlyE, and TaiE, an invasin, but is not 
present in either S. Enteritidis or S. Typhimurium [11]. 
All three of the SPIs 19, 20, and 21 encode T6SSs.  SPI-19 is 45 kb long and also encodes 
two Hcp-like proteins and a VgrG homologue.  Most of SPI-19 has been deleted in S. Enteritidis, 
leaving only 16 kb.  Like SPI-19, SPI-20 also encodes a T6SS, Hcp-like and VgrG-like proteins, 
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and three ImpA homologues.  SPI-21 encodes T6SS components, three VgrG-like proteins, and 
includes some genes that are involved in resistance to bacteriocins.  Both SPIs 20 and 21 are 
absent in S. Enteritidis, and are, in fact, only present in Salmonella enterica subspecies arizonae 
[66]. 
 
1.2.4 Prophages 
There are many prophage-like elements within the S. Typhimurium and S. Enteritidis 
genomes, many of them encoding T3SS effectors.  These include genes for SopE, SopE2, and 
SspH1, which are secreted by the SPI-1 T3SS, as well as GogB, SseK3, SseI, and SspH2, which 
are secreted by the SPI-2 T3SS (Tables 1.2 and 1.3).  Of note, one prophage encodes SodCI, a 
superoxide dismutase that is important for survival of S. Typhimurium in macrophages [6]. 
 
1.2.5 Salmonella virulence plasmid 
The Salmonella virulence plasmid is found as a low copy (one to two copies per bacterial 
cell) plasmid of varying size (60 kb in S. Enteritidis and 90-96kb in S. Typhimurium).  This 
plasmid harbours the spv locus comprised of five genes (spvRABCD).  SpvR is a positive 
regulatory protein belonging to the LysR/MetR family that is responsible for the expression of 
the rest of the spv genes.  SpvB acts to ADP-ribosylate actin, contributing to the survival of 
Salmonella in the intracellular environment via manipulation of the host cell cytoskeleton [32, 
70].  The plasmid also harbours gens for pef (plasmid encoded fimbriae [PEF]), tlpA (a thermo 
sensor regulator), rck (resistance to complement killing), and rsk (regulation of serum killing) 
[32]. 
 
1.2.6 Other virulence determinants 
LPS is a major component of the outer membrane of Gram-negative bacteria, including 
Salmonella.  LPS is made up of a hydrophobic region (lipid A) that anchors it to the bacterial 
outer membrane, a non-repeated core oligosaccharide, and a repeated polysaccharide (O antigen).  
LPS helps to protect Salmonella from the harsh environment of the gastrointestinal tract and is 
responsible for a multitude of host immune responses.  Salmonella is capable of modifying the 
structure of LPS under certain environmental conditions.  These modifications may aid in 
protection of the bacteria from certain antimicrobial peptides produced by the host, and/or may 
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reduce the immunostimulatory potential.  When genes needed for the production of LPS are 
defective, S. Typhimurium virulence is reduced in both calves and chicks [32, 42, 71, 72].  S. 
Enteritidis also expresses a heat labile cytotoxin similar to the cholera toxin, and a Shigella 
dysenteriae 1-like toxin [32]. 
 
1.3 Type III Secretion Systems 
T3SSs act as ‘injectisomes’ and are used by bacteria to deliver effector proteins directly 
into the host cells cytoplasm.  The first T3SS was isolated in 1998, although it was first 
visualized in the 1980s and was initially thought to be an intermediate complex of the flagellar 
system during its biosynthesis [73, 74].  All T3SSs share significant genetic and protein 
homology and can be divided into five phylogenetic groups:  1) the Ysc group (such as the 
plasmid-encoded T3SSs of Yersinia species and Pseudomonas aeruginosa);  2) the Hrp1 group 
(plant pathogens Pseudomonas syringae and Erwinia species);  3) the Hrp2 group (such as the 
mega-plasmid-encoded T3SSs of the plant bacteria Ralstonia and Xanthamonas species, and one 
of the T3SSs of Burkholderia species);  4) the Inv/Mxi/Spa group (the SPI-1 T3SS of Salmonella 
enterica, the chromosomally-encoded T3SS of Shigella, the non-functional ETT2 T3SS of 
enterotoxigenic Escherichia coli [ETEC], and the second T3SS of Burkholderia species); and 5) 
the Esa/Ssa group (the locus of enterocyte effacement [LEE] T3SS of ETEC, the SPI-2 T3SS of 
Salmonella enterica, the chromosomally-encoded T3SS of Yersinia species, and the plasmid-
encoded T3SS of Shigella species) [75, 76].  T3SSs are encoded on large pathogenicity islands, 
located either within the chromosome or on a plasmid.  Flagellar genes, while clustered together 
in the same area of the chromosome, are not as tightly packed and are not located on 
pathogenicity islands [52, 77]. 
T3SSs are mainly found in pathogenic Gram-negative bacteria; however, there are a few 
exceptions.  For instance, T3SSs have been found in the Chlamydia/Verrucomivrobia super-
phylum that does not resemble either Gram-negative or Gram-positive bacteria.  As well, there 
are a few examples of non-pathogenic symbiotic bacteria of plants having T3SSs, and even a 
T3SS used for virulence by unicellular Protozoa [31, 78].  Flagella are associated with both 
pathogenic and non-pathogenic bacteria and are most often not involved in direct virulence as 
T3SSs are.  However, there are some cases where the flagellar apparatus is responsible for the 
secretion of virulence factors.  For instance, the flagellar apparatus of Campylobacter jejuni is 
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essential for its virulence and secretes Campylobacter invasion antigens (Cia), and the flagellar 
system of Bacillus thuringiensis can secrete the virulence factors hemolysin BL and 
phosphatidylcholine-preferring phospholipase C [73]. 
 
1.3.1 Flagella 
 
1.3.1.1 Structural components of flagella 
The flagellum of Salmonella enterica is made up of 22 structural proteins, six cytoplasmic 
proteins, four structural chaperones and three regulatory proteins (Figure 1.4).  The structure 
consists of a C ring (FliG, FliM and FliN) and an MS ring (FlgF and FliF) embedded in the 
cytoplasmic (inner) membrane.  An ATPase is located on the cytoplasmic side of the apparatus 
(FliI).  The P ring (FlgI) is located in the peptidoglycan layer and the L ring (FlgH) is in the outer 
membrane.  A rod spanning the two bacterial membranes made up of FliF connects the inner 
membrane and outer membrane rings, and other proteins (FliE, FlgB, FlgC, FlgF and FlgG) are 
also associated with the basal body.  A type three secretion (T3S) apparatus is located within the 
basal body structure (FliO, FliP, FliQ, FliR, FlhA, FlhB, FliH and the FliI ATPase).  The motor-
stator (MotA and MotB), which is the driving force for motion, is also located within the basal 
body.  MotA is located within the inner membrane and connects to MotB, which extends into the 
periplasm.  A hook (FlgE) extends from the L/P rings.  FliK acts as a ‘molecular ruler’ to control 
the length of the hook.   The hook is followed by the hook-filament junction (FlgK and FlgL) and 
is extended by a long filament (flagellin).  Salmonella encodes for two flagellin proteins (FliC 
and FljB) that make up the filament, but these two proteins are never expressed at the same time.  
This differential expression may aid Salmonella in escaping the host immune defenses by 
antigenic variation, and/or contribute to host specificity.  Finally, the filament is topped off by the 
capping protein, FlgD [32, 42, 77, 79-82]. 
 
1.3.1.2 Assembly and regulation of flagella 
Flagellar genes can be organized into three classes:  early, middle and late.  The early 
genes flhDC encode the master regulators FlhD and FlhC, which positively regulate gene 
expression of the middle genes.  The middle genes consist of those that make up the MS, C, P 
and L rings, the T3S export apparatus, the motor-stator, the rod and the hook [77, 83, 84].  The  
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Figure 1.4  Schematic representation of the flagellar system of Salmonella 
 
The molecular organization of the flagellar system is depicted above.  Stoichiometry of proteins 
was followed where known.  BIM – Bacterial inner membrane.  BOM – bacterial outer 
membrane.  HCM – host cell membrane.  Adapted and modified from [85].  
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MS ring is assembled first, followed by the T3S export apparatus and the motor-stator.  These 
steps are dependent on the Sec secretion system.  Next, the rod is formed (T3S-dependent), 
followed by the L and P rings (Sec-dependent).  Following the formation of the hook (T3S-
dependent), there is a switch to late gene expression including genes encoding the hook-filament 
junction, filament, and cap proteins [77, 84].  FliA (a flagella-specific '28) activates expression of 
the late genes.  FlgN act as a chaperone for the hook-filament junction proteins FlgK and FlgL, 
while FliT acts as the chaperone for FliD (the cap).  Once the hook-filament junction and the cap 
proteins have been depleted from the cytoplasm, indicating a completed flagellum, FlgN and FliT 
are freed.  FliT is then able to bind FlhC, which inhibits middle gene transcription, while free 
FlgN acts to enhance transcription of FlgM, an anti-'28 factor [84].  FlgM is actively transcribed 
during both middle and late gene expression.  During middle gene expression, FlgM binds FliA, 
resulting in the repression of late gene expression.  After assembly of the hook and hook-filament 
junction, FlgM is exported by the T3S apparatus, freeing FliA and allowing for late gene 
expression.  Stimulation of further expression of FlgM by free FlgN allows late gene expression 
to be terminated quickly upon completion of the flagella [84, 85]. 
 
1.3.2 Salmonella pathogenicity island 1 type III secretion system 
 
1.3.2.1 Structural components and effectors of the Salmonella pathogenicity island 1 type 
III secretion system 
The basal body of the SPI-1 T3SS (Figure 1.5) is composed of an inner membrane ring 
formed by PrgH and PrgK, many inner membrane proteins (SpaP, SpaQ, SpaR, SpaS and InvA), 
an ATPase (InvC) and an outer membrane secretin (InvG).  Extending from the outer membrane 
secretin is the needle formed by PrgI, topped by the translocon made up of SipB and SipC [74].  
The SPI-1 T3SS is responsible for the secretion of a specific set of effectors.  AvrA, SipA, SipB, 
SipC, SipD and SptP are all encoded on SPI-1, while the genes encoding GogB, SopE, SopE2 
and SspH1 are located on bacteriophages, the gene for SopB is located on SPI-5, and the genes 
for SopA, SopD, SlrP, SteA and SteB are located elsewhere within the chromosome.  GogB, 
SlrP, SspH1, SteA and SteB are also secreted by the SPI-2 T3SS [6, 7, 86, 87].  Chaperones of 
both the SPI-1 and SPI-2 T3SS tend to contain an amphipathic &-helix near the C-terminal end 
and  are  very  small  and  acidic  in  nature.    There  is  usually  no  sequence  similarity  between   
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Figure 1.5  Schematic representation of the Salmonella pathogenicity islands 1 and 2 type 
III secretion systems 
 
The molecular organization of the SPI-1 T3SS is shown on the left, and SPI-2 on the right.  
Stoichiometry of proteins was followed where known.  BIM – Bacterial inner membrane.  BOM 
– bacterial outer membrane.  HCM – host cell membrane.  Adapted and modified from [74, 78].   
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chaperones or signal sequences of SPI-1 and SPI-2 T3SS effector proteins [75, 88].  See Table 
1.2 for a list of all structural and effector components of the SPI-1 T3SS. 
 
1.3.2.2 Assembly and regulation of the Salmonella pathogenicity island 1 type III 
secretion system 
The assembly of the SPI-1 T3SS proceeds in a similar manner to the assembly of the 
flagella.  The inner membrane and outer membrane rings are formed first in a sec-dependent 
manner, followed by the association of the rings and formation of the remaining basal body 
components, including the ATPase.  Formation of the needle and translocon is T3S-dependent, 
and needle length is controlled by InvJ, which acts as a ‘molecular ruler’ [74, 75, 89]. 
Expression of the SPI-1 T3SS is regulated by many environmental and genetic signals. 
Environmental signals include pH, osmolarity, the presence of bile, Mg2+ concentration, and the 
presence of short chain fatty acids [90].  The preferred invasion site of Salmonella is the M-cells 
of the distal small intestine.  When bile is present, indicating the beginning of the small intestine, 
or when short-chain fatty acids are present, which are produced by microflora of the large 
intestine, SPI-1 expression is repressed.  These environmental signals indicate that the bacterium 
is not near its preferred site of entry.  SPI-1 expression is induced at near neutral pH, and high 
osmolarity [90, 91].  In the presence of Iron (Fe2+), the ferric uptake regulator (Fur) acts to 
increase the expression of HilD (A SPI-1 regulator, discussed further in the following text) in an 
unknown manner.  Once in the SCV, where there is limited Fe2+, this indirect activation of HilD 
by Fur is stopped [90, 92].  See Figure 1.6 for a diagram of the interaction of the regulation 
pathways outlined below, along with those outlined in sections 1.3.3.2 and 1.3.4. 
Nucleoid associated proteins (NAPs) affect supercoiling of DNA, and are thus able to 
alter gene expression.  The NAPs Hha and H-NS both repress transcription of many genes, 
including rtsA and the SPI-1 gene hilA under conditions of low osmolarity [70, 90, 93].  Hu, IHF 
and Fis are also NAPs, and are important for expression of SPI-1 genes [90, 94]. 
PhoP/PhoQ and BarA/SirA belong to two-component global regulatory systems that 
respond to environmental conditions.  In low Mg2+ conditions, for example within the SCV, PhoP 
can act to negatively regulate HilA, leading to the down regulation of the SPI-1 T3SS.  SirA 
positively regulates HilA, by regulating the expression of HilD [2, 51, 52, 90].  BarA/SirA also 
controls the csr system.  CsrA can bind mRNAs at their ribosomal binding site, thus stabilizing,  
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Table 1.2 Salmonella pathogenicity island 1 type III secretion system components 
Protein Gene Location Function Reference 
AvrA avrA SPI-1 SPI-1 T3SS effector protein:  
deubiquitinates of I$B& and %-catenin, 
thereby limiting inflammatory response 
[95, 96] 
HilA hilA SPI-1 Major SPI-1 transcriptional activator, acts 
on prg, sip, and inv/spa operons 
[90, 97] 
HilC hilC SPI-1 Regulatory protein: acts on hilA, hilC, 
and hilD 
[2, 90] 
HilD hilD SPI-1 Regulatory protein: acts on hilA, hilC, 
and hilD 
[2, 90] 
HilE hilE Outside SPI-1 Regulatory protein, negatively regulates 
HilA through HilD 
[2, 90, 98] 
IacP iacP SPI-1 Putative acyl carrier protein, involved in 
regulating translocation of other SPI-1 
T3SS effector proteins including SopA, 
SopB, and SopD 
[99] 
IagB iagB SPI-1 Invasion protein [6, 100] 
InvA invA SPI-1 SPI-1 T3SS structural component:  
needle complex export protein 
[75] 
InvB invB SPI-1 SPI-1 T3SS secretion chaperone:  
chaperone to SopA and SopE 
[101] 
InvC invC SPI-1 SPI-1 T3SS structural component:  
ATPase 
[102, 103] 
InvE invE SPI-1 Invasion protein:  controls protein 
translocation and order of effector 
translocation 
[104] 
InvF invF SPI-1 Regulatory protein:  acts on sip operon 
and sopB 
[90, 105] 
InvG invG SPI-1 SPI-1 T3SS structural component:  forms 
outer membrane pore 
[2, 105] 
InvH invH SPI-1 SPI-1 T3SS structural component, 
important for efficient assembly of InvG, 
PrgH, and PrgK 
[4] 
InvI invI SPI-1 Needle complex assembly protein, 
chaperone to InvJ 
[6, 106] 
InvJ invJ SPI-1 Molecular ruler:  controls length of SPI-1 
T3SS needle 
[107] 
OrgA orgA SPI-1 Needle complex assembly protein [3, 6] 
OrgB orgB SPI-1 Needle complex export protein, interacts 
with InvC ATPase 
[3, 108] 
OrgC orgC SPI-1 Putative SPI-1 effector [3, 108] 
PphB pphB SPI-1 Serine/threonine protein phosphatase 2 [6] 
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PrgH prgH SPI-1 SPI-1 T3SS structural component:  Inner 
membrane protein 
[75, 109] 
PrgI prgI SPI-1 SPI-1 T3SS structural component:  
needle complex major subunit 
[75, 110] 
PrgJ prgJ SPI-1 SPI-1 T3SS structural component:  
needle complex minor subunit (rod) 
[75, 109] 
PrgK prgK SPI-1 SPI-1 T3SS structural component:  
needle complex inner membrane 
lipoprotein 
[4, 109] 
SicA sicA SPI-1 SPI-1 T3SS secretion chaperone [6] 
SicP sicP SPI-1 SPI-1 T3SS secretion chaperone:  
chaperone to SptP 
[111] 
SitA sitA SPI-1 Metal transport system:  putative 
periplasmic binding protein 
[6, 53] 
SitB sitB SPI-1 Metal transport system:  putative ATP-
binding protein 
[6, 53] 
SitC sitC SPI-1 Metal transport system:  putative 
permease 
[6, 53] 
SitD sitD SPI-1 Metal transport system:  putative 
permease 
[6, 53] 
SipA sipA SPI-1 SPI-1 T3SS effector protein: involved in 
actin cytoskeleton rearrangement 
resulting in membrane ruffles during 
initial entry, disruption of intestinal 
epithelial cell tight junctions, and in SCV 
maturation and positioning through 
cooperation with SifA 
[96, 112-
114] 
SipB sipB SPI-1 SPI-1 T3SS structural component:  forms 
part of the translocon of the SPI-1 T3SS 
along with SipC and SipD, involved in 
autophagy, required for attachment to 
host epithelial cells 
Binds caspase 1 induces apoptosis  
[51, 115-
117] 
SipC sipC SPI-1 SPI-1 T3SS structural component:  forms 
part of the translocon of the SPI-1 T3SS 
along with SipB and SipD, involved in 
actin bundling, required for attachment to 
host epithelial cells 
[115, 116, 
118] 
SipD sipD SPI-1 SPI-1 T3SS structural component:  forms 
part of the translocon of the SPI-1 T3SS 
along with SipB and SipC, required for 
attachment to host epithelial cells 
[106, 112, 
115] 
SlrP slrP Outside SPI-1 SPI-1 T3SS effector protein:  
Ubiquitination of Trx1, involved in cell 
death 
[86, 95] 
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SopA sopA Outside SPI-1 SPI-1 T3SS effector protein:  involved in 
migration of PMN’s and escape of 
Salmonella from the SCV, can also be 
secreted by the flagellar system 
[119, 120] 
SopB sopB SPI-5 SPI-1 T3SS effector protein:  involved in 
actin polymerization during invasion, 
induction of pro-inflammatory cytokines, 
disruption of intestinal epithelial cell tight 
junctions, and SCV maturation and 
positioning 
[64, 96, 
114, 120] 
 
SopD sopD Outside SPI-1 SPI-1 T3SS effector protein:  involved in 
membrane fission, actin rearrangement 
during entry and SCV positioning 
[96, 120] 
SopE sopE Prophage 
!SE12, similar 
to Gifsy-2 
SPI-1 T3SS effector protein:  involved in 
actin polymerization, induction of 
inflammation, disruption of intestinal 
epithelial cell tight junctions, SCV 
maturation, and activation of caspase-1 in 
macrophages 
[6, 114, 
121] 
SopE2 sopE2 Bacteriophage SPI-1 T3SS effector protein:  involved in 
actin polymerization, disruption of 
intestinal epithelial cell tight junctions, 
and induction of inflammation 
[96, 114] 
SpaO spaO SPI-1 SPI-1 T3SS structural component:  
needle complex export 
[6, 75] 
SpaP spaP SPI-1 SPI-1 T3SS structural component:  
needle complex export 
[6, 75] 
SpaQ spaQ SPI-1 SPI-1 T3SS structural component:  
needle complex export 
[6, 75] 
SpaR spaR SPI-1 SPI-1 T3SS structural component:  
needle complex export 
[6, 75] 
SpaS spaS SPI-1 SPI-1 T3SS structural component:  
important for export of needle protein 
and switch between needle and 
translocon export 
[122] 
SptP sptP SPI-1 SPI-1 T3SS effector protein:  tyrosine 
phosphatase/GTPase activating protein, 
involved in down regulation of 
inflammation and induces cell to regain 
original state after invasion, preferentially 
expressed in the spleen of mice 
[96, 111, 
123, 124] 
SprB sprB SPI-1 Transcriptional regulator [6, 125] 
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SspH1 sspH1 Gifsy-3 
prophage in S. 
Typhimurium 
Remnant on 
!SE20 in S. 
Enteritidis 
SPI-1 T3SS effector:  E3 ubiquitin ligase, 
downregulates inflammation by 
inhibition of NF-$B expression 
Also secreted by SPI-2, not present in S. 
Enteritidis 
[6, 126, 
127] 
SteA steA Outside SPI-1 SPI-1 T3SS effector:  unknown function, 
localizes to Golgi 
[95] 
SteB steB Outside SPI-1 SPI-1 T3SS effector:  unknown function, 
required for full virulence 
[95] 
SEN2743 stm2904 SPI-1 Putative ABC-type transporter [6] 
SEN2744 stm2905 SPI-1 Putative acetyltransferase [6] 
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or alternatively, reducing, translation of SPI-1 T3SS proteins, likely at the level of HilD.  CsrB 
and C are small RNA molecules that bind and stop the action of CsrA.  BarA/SirA activate CsrB 
and C, keeping CsrA levels in check.  Optimal levels of all three molecules are needed for proper 
expression of SPI-1.  The EnvZ/OmpR system senses osmolarity and may act to regulate HilD 
post-translationally.  The PhoP/PhoQ and PhoR/PhoB systems can activate expression of HilE, 
which then acts to repress expression of SPI-1 genes, through direct binding to HilD.  The type 1 
fimbriae regulators FimZ and FimY have also been shown to negatively regulate transcription of 
SPI-1 genes, likely through activation of hilE, while the flagella regulator FliZ positively 
regulates expression of HilA post-transcriptionally [2, 90].  Mlc is a global regulator that detects 
the presence of sugars such as glucose and mannose, whereby Mlc can repress expression of hilE 
when sugars are readily available, such as in the small intestine [128].  The Lon protease 
(controlled by DnaK and '32), negatively regulates SPI-1 by degrading HilD in response to the 
stress of the SCV environment [129]. 
HilA belongs to the OmpR/ToxR family of transcriptional regulators, while InvF, HilC 
and D are in the AraC/XylS family.  The genes encoding these proteins (hilA, hilC, hilD and 
invF) are located on SPI-1 [50, 51].  Expression of HilD is likely induced by environmental 
conditions, and leads to expression of HilC and RtsA.  RtsA and HilC can also activate 
expression of themselves, and each other.  RtsA activates hilA expression directly, as well as the 
expression of slrP (a SPI-1 T3SS effector) and dsbA, which is needed for assembly of T3SS.  
HilC and D act to derepress transcription of hilA and rtsA by relieving silencing by H-NS and 
Hha.  HilA is then free to activate transcription of the prg/org and inv/spa operons (including 
invF).  RtsA, HilD and HilC can also activate transcription of the inv/spa operon independently 
of HilA, but to a lower degree than HilA.  InvF activates transcription of the sic/sip (including 
sicA) operon of SPI-1, as well as genes within SPI-4 and SPI-5 (sopB) [2, 50, 51, 70, 90, 93].  
SicA is the chaperone for the translocator proteins SipB and C.  Once the translocon has been 
secreted, SicA is free and can activate expression of invF, creating a positive feedback loop of 
secreted effector gene expression once the SPI-1 T3SS is fully formed [70, 75]. 
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1.3.3 Salmonella pathogenicity island 2 type III secretion system 
 
1.3.3.1 Structural components and effectors of the Salmonella pathogenicity island 2 type 
III secretion system 
The SPI-2 T3SS (Figure 1.5) is composed of an inner membrane ring that, in conjunction 
with many other inner membrane proteins, makes up the basal body.  These include SsaD, SsaR, 
SsaS, SsaT, SsaU and SsaV.  The cytoplasmic ATPase is SsaN.  The outer membrane secretin is 
made up of SsaC, and is connected to the inner membrane components via SsaJ.  A small needle 
extends from the outer membrane secretin (SsaG) and is extended by a larger filament (SseB); in 
comparison, many other T3SSs do not have a filament extension.  The filament is topped off by 
the translocon proteins SseC and SseD [74, 78, 79].  SsaP, which acts as a ‘molecular ruler’, 
controls the length of the needle, just as InvJ of the SPI-1 T3SS [130]. 
The SPI-2 T3SS has been shown to secrete many effectors (GogB, PipB, PipB2, SifA, 
SifB, SopD2, SseF, SlrP, SseG, SseI, SseJ, SseK1, SseK2, SseL, SspH1, SspH2, SteA, SteB and 
SteC), although the functions of many are still unknown at this time.  Some of the genes 
encoding these proteins are located directly on the chromosome in the SPI-2 region, but some are 
located elsewhere on the chromosome, within lysogenic phages (e.g. Gifsy-1, -2 and -3) or on the 
Salmonella virulence plasmid.  While these proteins are secreted by the SPI-2 T3SS, GogB, SlrP, 
SspH1, SteA and SteB are also known to be secreted by the SPI-1 T3SS [7, 86, 87].  The 
functions of these effectors in Salmonella pathogenesis will be discussed further in section 1.4.1.  
A complete list of SPI-2 T3SS components, including effectors known to be secreted by the SPI-
2 T3SS, can be found in Table 1.3. 
 
1.3.3.2 Assembly and regulation of the Salmonella pathogenicity island 2 type III 
secretion system 
As with the assembly of the flagellar apparatus and the SPI-1 T3SS, The SPI-2 T3SS is 
assembled in a step-wise manner involving first the insertion of the inner membrane ring (SsaU) 
and outer membrane secretin in a sec-dependent manner.  Association of the inner membrane and 
outer membrane rings, placement of further basal body components and recruitment of the 
ATPase takes place, followed by the subsequent assembly of the rest of the apparatus in a T3S-
dependent manner [75, 84, 89].  
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Table 1.3 Salmonella pathogenicity island 2 type III secretion system components 
Protein Gene Location Function Reference 
GogB gogB Gifsy-1 
prophage 
SPI-2 T3SS effector protein, expressed 
intracellularly 
[131] 
Orf32 orf32 SPI-2 Putative proline iminopeptidase [6] 
Orf48 orf48 SPI-2 Putative amino acid permease [6] 
Orf70 orf70 SPI-2 Putative cytoplasmic protein [6] 
Orf242 orf242 SPI-2 Putative regulatory protein [6] 
Orf245 orf245 SPI-2 Putative cytoplasmic protein [6] 
Orf319 orf319 SPI-2 Putative inner membrane protein [6] 
Orf408 orf408 SPI-2 Putative regulatory protein [6] 
PipB pipB SPI-5 SPI-2 T3SS effector protein:  associated 
with Sif formation and the SCV, but not 
required for virulence 
[64, 95, 
132] 
PipB2 pipB2 Outside SPI-2 SPI-2 T3SS effector protein:  recruits 
kinsin-1 to SCV, involved in sif 
formation 
[95, 133, 
134] 
SifA sifA Outside SPI-2 SPI-2 T3SS effector protein:  required for 
positioning of Sifs and positioning of the 
SCV 
[135, 136] 
SifB sifB Outside SPI-2 SPI-2 T3SS effector protein:  involved 
(but not essential) in the formation of Sifs 
[137, 138] 
SopD2 sopD2 Outside SPI-2 SPI-2 T3SS effector protein:  Involved in 
Sif and SCV formation 
[95, 139] 
SsaB 
(SpiC) 
ssaB 
(spiC) 
SPI-2 SPI-2 T3SS effector protein:  prevents 
fusion of late endosomes with the SCV, 
acts with SsaM to initiate switch between 
secretion of translocon components and 
effectors 
[140-142] 
SpvB spvB Salmonella 
virulence 
plasmid (spv) 
SPI-2 T3SS effector protein:  inhibits 
actin polymerization associated with the 
SCV 
[96, 143] 
SpvC spvC spv Plasmid SPI-2 T3SS effector protein:  
Phosphothreonine lysase of MAPK 
proteins, involved in down regulation of 
inflammation 
[95, 144] 
SrfH srfH 
 
Outside SPI-2 SPI-2 T3SS effector protein:  involved in 
macrophage motility; important for early 
dissemination of Salmonella to spleens of 
mice 
[95] 
SsaC ssaC SPI-2 SPI-2 structural component:  forms outer 
membrane pore of the SPI-2 T3SS 
[58, 130] 
SsaD ssaD SPI-2 SPI-2 T3SS structural component [6] 
SsaE ssaE SPI-2 SPI-2 T3SS chaperone to SseB and PipB [145] ! !
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SsaG ssaG SPI-2 SPI-2 structural component: forms the 
needle of the SPI-2 T3SS 
[79, 146] 
SsaH ssaH SPI-2 SPI-2 T3SS structural component [6, 147] 
SsaI ssaI SPI-2 SPI-2 T3SS structural component: needle 
complex minor subunit (rod) 
[6, 148] 
SsaJ ssaJ SPI-2 SPI-2 T3SS structural component:  
needle complex inner membrane 
lipoprotein, required for systemic 
infection of mice 
[1, 6, 149] 
SsaK ssaK SPI-2 SPI-2 T3SS structural component [1, 6] 
SsaL ssaL SPI-2 SPI-2 T3SS structural component:  
required for secretion of SPI-2 encoded 
effectors, but not for effectors encoded 
outside SPI-2 
[6, 150] 
SsaM ssaM SPI-2 SPI-2 T3SS structural component:  acts 
with SsaM to initiate switch between 
secretion of translocon components and 
effectors 
[6, 142] 
SsaV ssaV SPI-2 SPI-2 T3SS structural component:  
needle complex export protein 
[1, 6] 
SsaN ssaN SPI-2 SPI-2 T3SS structural component:  
ATPase 
[1, 6] 
SsaO ssaO SPI-2 SPI-2 T3SS structural component [1, 6] 
SsaP ssaP SPI-2 SPI-2 T3SS structural component [1, 6] 
SsaQ ssaQ SPI-2 SPI-2 T3SS structural component:  
needle complex export 
[1, 6] 
SsaR ssaR SPI-2 SPI-2 T3SS structural component:  
needle complex export 
[1, 6] 
SsaS ssaS SPI-2 SPI-2 T3SS structural component:  
needle complex export 
[1, 6] 
SsaT ssaT SPI-2 SPI-2 T3SS structural component:  
needle complex export 
[1, 6] 
SsaU ssaU SPI-2 SPI-2 T3SS structural component:  
similar to SpaS, so likely also involved in 
switch between needle and translocon 
export 
[1, 6] 
SscA sscA SPI-2 SPI-2 T3SS secretion chaperone:  
chaperone of SseC 
[140] 
SscB sscB SPI-2 SPI-2 T3SS secretion chaperone:  
chaperone of SseF 
[151] 
SseA sseA SPI-2 SPI-2 T3SS secretion chaperone:  
chaperone of SseB 
[152] 
SseB sseB SPI-2 SPI-2 structural component:  forms the 
needle filament of the SPI-2 T3SS 
[146, 153] ! !
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SseC sseC SPI-2 SPI-2 structural component:  forms part 
of the SPI-2 T3SS translocon along with 
SseD 
[146, 153] 
SseD sseD SPI-2 SPI-2 structural component:  forms part 
of the SPI-2 T3SS translocon along with 
SseC 
[146, 153] 
SseE sseE SPI-2 SPI-2 T3SS effector protein [6] 
SseF sseF SPI-2 SPI-2 T3SS effector protein:  involved in 
SCV formation and positioning 
[96, 154] 
SseG sseG SPI-2 SPI-2 T3SS effector protein:  involved in 
SCV formation and positioning 
[95, 96, 
154] 
SseI sseI Prophage 
!SE10 
(Similar to 
Gifsy-2) 
SPI-2 effector protein:  involved in actin 
remodeling, inhibits host cell migration 
[6, 137, 
155] 
SseJ sseJ Outside SPI-2 SPI-2 T3SS effector protein:  cholesterol 
acetyltransferase, involved in 
maintenance of the SCV membrane and 
sif formation 
[95, 133, 
138] 
SseK1 sseK1 Outside SP1-2 SPI-2 T3SS effector protein:  localizes to 
host cell cytoplasm 
[156] 
SseK2 sseK2 Outside SPI-2 SPI-2 T3SS effector protein:  unknown 
function, localizes to host cell cytoplasm 
[95, 156] 
SseK3 sseK3 Bacteriophage SPI-2 T3SS effector protein [6, 156] 
SseL sseL Outside SPI-2 SPI-2 T3SS effector protein:  
deubiquitinates I$B&, which results in 
inhibition of NF-$B activity and is 
associated with host cell death 
[95, 157, 
158] 
SspH1 sspH1 Gifsy-3 
prophage in S. 
Typhimurium 
Remnant on 
!SE20 in S. 
Enteritidis 
SPI-2 T3SS effector:  E3 ubiquitin ligase, 
downregulates inflammation by 
inhibition of NF-$B expression 
Also secreted by SPI-1, not present in S. 
Enteritidis  
[6, 126, 
127] 
SspH2 sspH2 Bacteriophage SPI-2 T3SS effector protein:  E3 
ubiquitin ligase, Involved in inhibition of 
actin polymerization associated with the 
SCV 
[95, 127, 
159]  
SsrA ssrA SPI-2 SPI-2 encoded 2-component regulatory 
system:  sensor kinase 
[6, 160, 
161] 
SsrB ssrB SPI-2 SPI-2 encoded 2-component regulatory 
system:  transcriptional activator 
[6, 160, 
161] 
SteC steC Outside SPI-2 SPI-2 T3SS effector protein:  
serine/threonine kinase, involved in actin 
formation surrounding the SCV 
[95] 
! !
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SEN1635 sen1635 SPI-2 Putative cytoplasmic protein [6] 
TtrA ttrA SPI-2 Tetrathionate reductase complex:  subunit 
A 
[6] 
TtrB ttrB SPI-2 Tetrathionate reductase complex:  subunit 
B 
[6] 
TtrC ttrC SPI-2 Tetrathionate reductase complex:  subunit 
C 
[6] 
TtrR ttrR SPI-2 Response regulator [6] 
TtrS ttrS SPI-2 Sensory histidine kinase [6] 
 !  
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Like the SPI-1 T3SS, expression of the SPI-2 T3SS is regulated by many environmental 
and genetic signals.  Environmental signals that mimic the environment of the SCV (low Mg2+ 
concentration and acidic pH between 4 and 5) are SPI-2-inducing.  The preferred replication site 
of Salmonella is within the SCV of macrophages [61, 70, 94, 162]. 
As with the SPI-1 T3SS, expression of SPI-2 genes is affected by the global two-
component regulatory systems PhoP/PhoQ and EnvZ/OmpR.  Under conditions of low Mg2+ and 
calcium (Ca2+) PhoP induces SPI-2 gene expression by direct interaction with the ssrB gene, and 
post-transcriptional action on SsrA.  In the presence of low osmolarity and acidic pH, OmpR can 
directly bind both the ssrA and ssrB promoters, activating transcription.  OmpR can also act in 
conjunction with SsrB to activate transcription of the non-SPI-2-encoded effector SseI [5, 91, 94, 
163, 164]. 
SPI-2 encodes its own two-component regulatory system, SsrA/SsrB.  SsrB is able to bind 
to all SPI-2 promoters, including those of ssrA, ssrB, and many effectors located outside of SPI-2 
[5, 94].  As with SPI-1, H-NS silences the expression of SPI-2 genes by binding directly to many 
SPI-2 promoters.  This binding can be relieved by the SPI-1 protein HilD under certain 
conditions, such as stationary phase growth in LB, and may also be relieved by SsrB and/or SlyA 
[5, 94, 165].  The transcription of SPI-2 genes can also be repressed by the NAPs Hha and YdgT.  
Fis, a NAP that is able to bind the promoter regions of ssr and ssa operons, is also important for 
expression of SPI-2 as well as SPI-1 genes.  Proper levels of Fis are important for activation of 
ssrA.  Fis may also induce SPI-2 gene expression indirectly through controlling expression of 
PhoP.  IHF, another NAP, is also important for expression of both SPI-2 and SPI-1 genes [94].  
Some of the mechanisms controlling regulation of SPI-2 are outlined in Figure 1.6. 
 
1.3.4 Cross-talk between the Salmonella flagellar and pathogenicity islands 1 and 2 type 
III secretion systems 
The complex regulation of the T3SSs ensures that each system is only expressed under 
the correct conditions.  Expression of multiple versions of each T3SS simultaneously would be 
energetically expensive, so coordinated expression of the three systems under specific conditions 
where they are required is desirable.  Global regulation by two-component regulatory systems 
that sense divalent cation concentrations, osmolarity and pH are, in part, responsible for the 
changes in expression between the flagellar, the SPI-1, and the SPI-2 T3SSs.  The SPI-1 T3SS is 
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preferentially within the distal small intestine, which has low oxygen, high osmolarity, a pH of 8, 
divalent cations, and is rich in nutrients.  The environment of the SCV is much different having 
low osmolarity, low divalent cation concentration, a pH between 4 and 5, and is nutrient poor.   
In these conditions, the SPI-2 T3SS is preferentially expressed [75]. 
The BarA/SirA system positively regulates expression of SPI-1 genes, but negatively 
regulates expression of flagellar genes.  Therefore, in environmental conditions that activate 
BarA/SirA, the SPI-1 T3SS will be expressed while the flagellar system is downregulated.  RtsA 
and RtsB have also been proposed to be involved in the switch from expression of flagella to 
expression of the SPI-1 T3SS.  RtsA is important for SPI-1 expression, while RtsB represses 
expression of flagellar genes by interfering with the flhDC promoter [166].  In conditions of low 
divalent cation concentration, PhoP suppresses expression of SPI-1 genes while activating 
expression of SPI-2 genes.  This ensures that once in the SCV, when the SPI-1 T3SS is no longer 
needed for invasion of non-phagocytic cells, the SPI-2 T3SS expression is induced while the SPI-
1 T3SS is downregulated [70]. 
Interspecies and interkingdom quorum sensing may also be involved in regulating 
expression of these three systems.  In the presence of host norepinephrine, there is an 
upregulation of flagellar genes in S. Typhimurium.  S. Typhimurium encodes a putative 
regulatory protein, YhcS, which has high amino acid similarity to QseA of E. coli.  QseA 
activates expression of the LEE T3SS by E. coli in response to AI-3 quorum sensing molecules 
produced by intestinal flora, as well as epinephrine and norepinephrine produced by the host.  
YhcS may act similarly to QseA in E. coli by activating expression of either (or both of) the SPI-
1 or SPI-2 T3SSs [167-169].  Under certain growth conditions, HilD can relieve H-NS-mediated 
repression of SPI-2 genes [165].  This may account for the fact that SPI-2 is expressed to some 
extent along with SPI-1 in the intestinal lumen, and that SPI-1 is expressed for a short time in 
macrophages before the complete switch to SPI-2 expression.  The expression of the SPI-2 T3SS 
before invasion of intestinal epithelial cells would allow the bacteria to ready itself for the SCV 
environment.  Furthermore, the expression of the SPI-1 T3SS is important for inducing 
macrophage apoptosis during the initial stage of infection while the bacteria is replicating, and 
before spread to the rest of the body.  Interplay between regulation of SPI-1 and SPI-2 can be 
visualized in Figure 1.6. 
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1.3.5 Evolution of the type III secretion system 
The flagellar systems of Prokarya are completely different from those of Archaea and 
Eukarya, suggesting that they evolved convergently in parallel to a structure serving the same 
function [31, 80].  However, prokaryotic flagellar systems that have a chemotaxis apparatus for 
sensing environmental signals that lead to changes in the direction of motion share their 
chemotaxis system with archaeal flagellar systems [80, 82].  As some members of Prokarya do 
not have this chemotaxis system, it may have been acquired by horizontal transfer from a 
member of Archaea or may have been present for sensing environmental signals before the 
diversification of Prokarya and Archaea, and has since been lost in some prokaryotic families. 
While the flagellar systems of Prokarya maintain many of the same genes and proteins 
among members, they can be quite diverse in their function.  For instance, the flagella of 
Spirochaetes are located in the periplasm, between the cell membrane and outer membrane 
sheath, while Vibrio species express both polar and lateral flagellar systems that share a 
chemotaxis transduction system but use different motive forces (Na+ or H+).  Flagella can also 
serve in either swarming or swimming type motility, and can rotate either only clockwise or 
counterclockwise, or be able to switch direction depending on environmental signals.  
Furthermore, some flagella are always expressed while others are expressed only under certain 
environmental conditions [73, 80, 82, 170].  Many of the flagellar proteins are homologous, 
however, not all flagellar system proteins are conserved among all bacterial species.  For 
example, the flagellar structures of Gram-positive bacteria do not have the L and P rings (which 
would be located in the outer membrane of Gram-negative bacteria).  Spirochaetes do not have 
the L and P ring either, as their flagella are located in the periplasm.  Some of the structural genes 
(flgH, flgI, fliD, fliE and fliH) are missing in some bacteria; this could indicate a later evolution of 
these genes combined with limited horizontal transfer, or be an example of sporadic loss of genes 
from some bacterial families.  The latter explanation seems more likely in this case as there are 
many families of bacteria that contain these genes, and only a few who are lacking [170]. 
The flagella phylogenetic tree is directly related to that of the bacterial speciation genetic 
tree based on 16S ribosomal RNA.  This suggests that flagella have been in existence since 
before the diversification of bacteria, and have been maintained throughout vertical evolution 
[81].  Liu and Ochman propose that the entire flagellar system is actually evolved from a single 
gene.  They suggest, based on sequence similarities, that all of the flagellar genes arose from 
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random duplications and reassortments of a single precursor gene in the ancestor of modern 
bacteria [80, 170].  This seems quite unlikely; although there may be sequence similarities 
between an inner membrane component and an outer membrane component, this does not mean 
that they are related on an evolutionary scale.  Convergent evolution is a more likely explanation 
for this, in which two different proteins have evolved to serve a similar function – in this case to 
be embedded in the bacterial membrane. 
Unlike flagellar systems, the T3SS phylogenetic tree is not related to that of 16S 
ribosomal RNA, suggesting that T3SSs were acquired at some point after the diversification of 
bacteria, and evolved via horizontal transfer events [31, 76, 80, 171].  T3SSs are encoded on 
large pathogenicity islands, while flagellar genes are encoded on the chromosome [32, 52, 77].  It 
is thought that SPI-2 may have arrived in two separate events, with the ttr operon arriving first, 
followed by the rest of SPI-2 [9]. 
The effectors of T3SSs are highly variable between species of bacteria, and are quite often 
encoded on different regions of the chromosome than the pathogenicity island-encoded T3SSs.  
The effectors and their evolution will not be discussed here, but information on this topic can be 
found in a review by Stavrinides et al. [88].  In general, there are about 10 core proteins of the 
flagellar T3SS apparatus and the injectisome T3SSs that are highly similar in gene sequence, 
amino acid sequence, and function (Figures 1.4 and 1.5).  For the purposes of this discussion, the 
flagellar system will be compared only with the two Salmonella T3SSs, with homologous 
proteins given in the order flagella/SPI-1/SPI-2.  These homologous proteins are: the cytoplasmic 
ATPase (FliI/InvC/SsaN), the T3S apparatus (FliH/PrgH/SsaK, FliN/SpaO/SsaQ, 
FliP/SpaP/SsaR, FliQ/SpaQ/SsaS, FliR/SpaR/SsaT, FlhB/SpaS/SsaU and FlhA/InvA/SsaV), part 
of the connecting rod (FliF/PrgK/SsaJ), and the needle/hook ‘molecular ruler’ (FliK/InvJ/SsaP) 
[1, 75, 78, 130, 172, 173]. 
The structure of the flagellar apparatus and T3SSs begin to differ more markedly starting 
at the outer membrane (besides the motor-stator which is only present in the basal body of the 
flagellar system).  The MS ring of the flagellar system is larger than that of the outer membrane 
secretin of the T3SS [79].  The secretin of the T3SS belongs to the same family of proteins that 
make up the T2SS and T4SS secretins, and the pore used by filamentous phages, suggesting that 
filamentous phages either introduced this type of protein to bacteria, or acquired it from them 
[171].  The T3SS needle is straight and thin, as is its filament, although the filament is slightly 
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larger, and notably rigid.  The flagellar hook apparatus is larger and curved, and its filament is 
quite long and flexible.  These structures lack significant amino acid and genetic homology, but 
do share helical symmetry, and overall assembly mechanisms.  They are both assembled by 
stepwise polymerization of individual small monomers.  The flagellum contains approximately 
5.6 subunits of flagellin per turn, with an axial rise of 4.7 Å.  To compare, the filament of the 
LEE T3SS in E. coli contains 5.5 subunits of EspA per turn, and has an axial rise 4.6 Å [73, 78, 
79, 174].  The inner diameter of the T3SS filament is between 2 and 3 nm, similar to the inner 
channel of the flagellum [73, 78, 172].  The action of the ‘molecular rulers’ is likely different as 
well.  It has been proposed that the method for measuring hook length in flagella is more 
‘measuring cup’-like than ‘molecular ruler’-like.  Journet suggests that the motor-stator switch 
area of the flagellum acts as a measuring cup, filling with FliK.  FliK acts as an accessory to the 
hook protein, and is secreted at the same time.  Once the ‘cup’ empties of FliK, the apparatus 
switches its secretion preference from the hook protein (FlgE) to the flagellin protein (FliC or 
FljB), completing assembly of the flagellum.  In contrast, the InvJ and SsaP proteins (similar to 
the ‘molecular rulers’ of other bacterial T3SSs) act more like a ruler.  It has been suggested that 
dimers of these proteins are located outside the cell, with one attached to the outer membrane, 
and the second extending from that.  Once the needle complex (PrgI/SsaG) reaches the same 
height as the InvJ/SsaP dimer, the T3SS switches to secretion and assembly of the translocon of 
SPI-1 (SipB, C and D) or filament of SPI-2 (SseB) [73]. 
Another key area in which the T3SSs and flagellar systems differ is in their chaperones.  
Although both systems tend to have specific chaperones for specific proteins, the T3SS proteins 
are recognized by their chaperones at an N-terminal region, while flagellar system chaperones 
bind at the C-terminal region [170].  Although the flagellar and T3SS chaperones are different, in 
some cases the three systems can secrete each other’s proteins.  For example, both the SPI-1 and 
SPI-2 T3SSs can secrete the flagellar protein FliC, while the flagellar system can secrete the SPI-
1 T3SS effector proteins SptP and SopE (if the SptP and SopE chaperones are absent), and in 
some instances effectors from T3SSs of other bacterial species [73, 78]. 
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1.4 Pathogenesis and host response 
 
1.4.1 Pathogenesis of Salmonella 
Salmonella can enter host cells in at least two ways.  The first involves uptake into 
phagocytic cells (macrophages), while the second is more complicated and involves the action of 
the SPI-1 T3SS on non-phagocytic cells.  After attachment to epithelial cells, the SPI-1 T3SS 
induces membrane ruffling by secreting effectors into the host cell to trigger cytoskeleton 
rearrangement.  Once inside the epithelial cell, some of these same effectors ‘switch off’ the 
membrane ruffling, returning the host cell membrane to its original state [7, 96, 137, 175].  Entry 
into the host cell (epithelial or macrophage) results in the bacteria being encased within an SCV.  
While the goal of many intracellular pathogens would be to escape this vacuolar space into the 
cell cytoplasm, Salmonella takes advantage of this space and remains in the SCV [7, 96, 176]. 
Once inside the SCV, the SPI-2 T3SS is expressed and begins secreting effector proteins, 
which are used to manipulate the intracellular environment [61, 96, 177].  Approximately one 
hour after entry into the host cell, the SCV switches from early endosomal markers, such as early 
endosome marker 1 (EE-1), to late endosomal/lysosomal markers, such as lysosomal-associated 
membrane protein (LAMP-1) and lysosomal glycoproteins (lgps).  One important factor that the 
SCV acquires during this switch is the V-ATPase, which facilitates the acidification of the SCV.  
This acidification is an important factor for the induction of Salmonella virulence/survival genes 
[7, 87, 96, 176-178].  Another important factor for Salmonella survival within host cells is iron 
acquisition.  Salmonella releases two siderophores for sequestering Fe2+ from the host cell, 
enterobactin and salmochelin [96].  As the SCV matures, it moves along host cell microtubules 
towards the Golgi apparatus.  This process is dependent on many effectors, including SifA, SifB, 
SopD2, SseF, SseG, SseI, SseJ, SseL, PipB, and PipB2 [87, 96, 177].  SsaB is also important in 
blocking the fusion of the SCV with lysosomes during this process, which would result in 
bacterial killing [178].  Movement along the microtubules involves recruitment of a dynein-
dynactin motor complex by SifA, SseF, SseG and PipB2.  PipB2 interacts with the motor protein 
kinesin, while the other three proteins have also been shown to be responsible for keeping the 
SCV localized to the Golgi apparatus in an unknown manner.  These proteins are also very 
important in Salmonella-induced filament (sif) formation, which will be discussed in the 
following paragraph.  SCV membrane integrity is important, and is controlled by a number of 
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SPI-2 T3SS effectors, including SspH2, SseI, SteC, and the Salmonella virulence plasmid-
encoded protein SpvB.  The interaction of these proteins with host filamen and actin causes the 
formation of an actin-mesh around the SCV [87, 177, 178].  Another function of the SPI-2 T3SS 
may be to stop the formation of the NADPH phagocytic oxidase (phox) and inducible nitric oxide 
synthase (iNOS) on the SCV membrane, ultimately resulting in protection of Salmonella from 
reactive oxygen and nitrogen species (ROS and RNS, respectively) [7, 87, 179].  A superoxide 
dismutase encoded by the Gifsy-2 lysogenic phage helps Salmonella survive the oxidative burst, 
which involves production of ROS and RNS by phagocytic cells that can damage bacteria, and is 
therefore important for bacterial survival within the SCV [7, 96]. 
The maturation/movement process of the SCV can take around 4 to 6 hours.  At this 
point, when the SCV has been altered to suit the bacteria, Salmonella begin to replicate [87, 180].  
Replication of Salmonella is associated with the formation of sifs.  Sifs have similar markers to 
the SCV, and many of the same proteins are responsible for their formation/membrane integrity 
(SifA, SifB, SseF, SseG, SseJ, SseL, SspH2, SpvB, PipB and PipB2).  The SPI-1 effector SipA 
has also been shown to be important in sif formation.  These sifs extend from the SCV towards 
the host cell membrane, and other SCVs, if there are multiple SCVs in one cell [96, 177, 178]. 
The AvrA effector secreted by the SPI-1 T3SS deubiquitinates both I$B-& and "-catenin, 
which stabilizes the proteins and results in the continued repression of NF$B-mediated gene 
transcription.  This delays apoptosis of intestinal epithelial cells, thereby allowing Salmonella to 
survive within them for longer [86, 96, 176, 181].  SlrP also mediates ubiquitination of certain 
host proteins including Thioredoxin-1 (Trx1).  Trx1 can activate the NF$B transcription factor, 
and has functions among other host cell proteins as well.  Binding of SlrP to Trx1 stops its action, 
which under some conditions can lead to apoptotic cell death, although the exact mechanisms of 
this need to be studied further [86, 176, 177].  SspH1 can also inhibit NF$B transcription [96, 
177, 178]. 
 
1.4.2 Innate immune response to Salmonella 
The innate immune system is the first line of defense between the host and microbes from 
the environment, including parasites, fungi, bacteria, and viruses.  The most complex portion of 
the innate immune system is that of the intestines.  The intestinal surface consists of a single layer 
of columnar epithelial cells that form tight junctions with each other, and is covered by a thick 
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layer of mucous, and acts as a physical barrier preventing the access of microbes to the 
underlying tissue [182, 183].  Furthermore, the large amount of commensal bacteria in the 
intestine may act to prevent Salmonella from invading intestinal epithelial cells by competing for 
nutrients and/or the production of antimicrobial peptides [183, 184].  In fact, recent studies have 
shown that the inflammatory process is necessary for Salmonella to outcompete commensal 
bacteria and colonize the intestinal tract, and that the SPI-1 and SPI-2 T3SSs are very important 
in this process [185-188]. 
Within the intestine there are areas referred to as gut-associated lymphoid tissue (GALT), 
which consist of Peyer’s patches (PPs) and mesenteric lymph nodes (MLNs). The PPs contain B 
cell follicles and T cell areas, and are infiltrated by large numbers of macrophages and dendritic 
cells.  The cells of the follicular associated epithelium overlying the PPs have a less pronounced 
brush border and are covered by a lighter layer of mucous than the other intestinal epithelial cells.  
Microfold (M) cells that reside within the follicular associated epithelium have no surface villi, 
and do not produce mucous.  These cells can pass on antigens to underlying dendritic cells and 
macrophages within the subepithelial dome [183, 189, 190]. 
Intestinal epithelial cells and paneth cells are capable of secreting antimicrobial peptides 
such as defensins, cathelicidins, and calprotectins.  These antimicrobial peptides can act on a 
broad spectrum of bacteria (including Salmonella) by creating pores in the bacterial cell wall, 
ultimately leading to the destruction of the bacteria [182, 183].  It has been shown that these 
antimicrobial peptides are dependent on bacterial contact to act, and are generally restricted to 
within the layer of mucous.  Pathogenic bacteria, like Salmonella, come into contact with these 
antimicrobial peptides when penetrating the mucous layer [191, 192]. 
Intestinal epithelial cells, dendritic cells and macrophages possess special pattern 
recognition receptors (PRRs) that are capable of recognizing microbes.  These are the Toll-like 
receptors (TLRs) and nucleotide-binding oligomerization domain-like receptors (NLRs).  TLRs 
can be found on the plasma membrane of cells and endosomal membranes while NLRs are found 
within the cytoplasm [181, 184].  Of particular importance in the recognition and clearance of 
pathogens is TLR5, which binds to the core-conserved portion of bacterial flagellin [193, 194].  
Salmonella secretes two forms of flagellin, FliC and FljB, both of which are recognized by TLR5 
and the NLR Ipaf.  Salmonella can trigger translocation of secreted flagellin across the epithelium 
to the basolateral side where TLR5 is expressed.  This translocation process is dependent on both 
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the SPI-1 and SPI-2 T3SSs.  This suggests that Salmonella has evolved to take advantage of 
TLR5 signaling and the subsequent inflammatory reaction produced [181, 193, 195, 196].  SPI-2 
T3SS dependent transport of flagellin through the epithelial cell, and subsequent binding of 
flagellin to TLR5, activates myeloid differentiation primary response gene 88 (MyD88), which 
goes on to activate interleukin (IL) receptor associated kinase 4 (IRAK-4).  IRAK-4 activates the 
mitogen activated protein (MAP) kinases p38 and ERK, as well as the I$B kinase, which results 
in the activation of NF$B-mediated expression of pro-inflammatory factors such as IL-8, IL-1%, 
IL-12, IL-18, and tumour necrosis factor & (TNF&).  Anti-apoptotic factors are also induced via 
this pathway, resulting in the delayed cell death of intestinal epithelial cells harbouring 
Salmonella [181, 184, 197].  SPI-1 T3SS-mediated binding of flagellin by the NLR Ipaf results in 
activation of caspase-1, which in turn results in pyroptosis of macrophages and the release of pro-
inflammatory cytokines such as IL-1%, IL-12, and IL-18 [184, 196, 197].   Salmonella mutants 
that do not produce FliC and FljB are inhibited in their ability to cause inflammation in the host, 
indicating the importance of flagellin in the infection outcome [184, 196].  Furthermore, mice 
that do not express TLR5 are resistant to colonization by Salmonella, another indication that the 
induction of an inflammatory response by flagellin binding to TLR5 is important in colonization 
by Salmonella [194]. 
dendritic cells that reside within the lamina propria can extend dendrites out through the 
tight junctions of intestinal epithelial cells in order to sample the content of the intestinal lumen, 
including pathogenic bacteria such as Salmonella.  This process is dependent on CX3 chemokine 
receptor 1 (CX3CR1), and if the gene coding for this receptor is knocked out in mice, they show 
a higher susceptibility to typhoid-like infection by Salmonella [183, 194].  This indicates that a 
functional innate immune system is essential for control of Salmonella before the infection 
becomes systemic.  Alternately, dendritic cells may also capture bacteria, and serve as another 
mechanism for Salmonella to traverse the intestinal epithelial cell barrier [198].  
Although Salmonella can invade any intestinal epithelial cells, an ideal spot for entry is 
through the M cells, as the mucous layer coating these cells is thinner, and there are fewer 
antimicrobial peptides for the bacteria to come into contact with [194, 196, 198].  Once through 
the epithelial layer, Salmonella comes into contact with resident or recruited macrophages and 
dendritic cells.  Macrophages and dendritic cells phagocytize the bacteria, and then begin to 
migrate.  The ability of Salmonella to survive within the SCV in these cells is important for 
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dissemination of the bacteria to the liver and spleen in the case of systemic infection [194, 196].  
However, systemic infection caused by S. Typhimurium and S. Enteritidis does not normally 
occur in healthy human adults, who will experience a self-limiting gastroenteritis instead.  An 
effective innate immune response is necessary to clear Salmonella from the intestinal tract and 
stop systemic spread.  Recruited macrophages, natural killer (NK) cells, and dendritic cells are 
major mediators of this response [184, 185, 194].  When dendritic cells that reside in the lamina 
propria are stimulated with flagellin produced by Salmonella they stop producing IL-10 and 
TNF&, and instead switch to producing IL-6 and IL-12, which induces an inflammatory response.  
Salmonella produces effectors that can both induce and inhibit the production of pro-
inflammatory cytokines, depending on the stage of infection [184, 194]. 
Intestinal epithelial cells can regulate the function of dendritic cells and macrophages by 
secreting cytokines such as thymic stromal lymphopoeitin (TSLP), prostaglandin E2, and 
transforming growth factor % (TGF%).  TGF% suppresses NF$B activation in macrophages and 
dendritic cells, thereby limiting expression of pro-inflammatory cytokines.  In the presence of 
TSLP, macrophages and dendritic cells fail to produce IL-12 when they come into contact with 
bacteria, and instead produce IL-10 [182, 189, 199].  IL-12 can activate NK cells to produce 
interferon # (IFN#), which in turn activates macrophages to kill intracellular bacteria.  In contrast, 
IL-10 is a suppressive cytokine that acts on both macrophages and dendritic cells to inhibit their 
production of IL-12, resulting in a feedback loop that limits inflammation.  Therefore, when 
secretion of IL-12 is inhibited, Salmonella can survive longer within macrophages and dendritic 
cells.  Both IL-10 and IL-12 can also regulate the type of immune response by the adaptive 
immune system (discussed further in section 1.4.3).  Production of TNF&, IL-1, and other 
chemokines by intestinal epithelial cells and macrophages also act to recruit leukocytes to the site 
of infection, which are important in limiting systemic spread of Salmonella [182, 189, 194, 198]. 
Salmonella is able to both induce and inhibit the innate inflammatory response in the 
intestinal mucosa of its host.  This is beneficial not only to regulating the infection process as 
described above, but can benefit the bacteria on a population-wide scale.  Inflammation leading 
to diarrhea facilitates the spread of the bacteria to new hosts.  Induction of autophagy and/or 
pyroptosis in some phagocytic cells may help in systemic spread if intact bacteria located within 
membrane compartments are then taken up by other macrophages and dendritic cells [184, 194, 
195].  The SPI-1 T3SS effector SopE is important in activation of NF$B signaling and therefore 
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pro-inflammatory cytokine production.  A second SPI-1 T3SS effector, SptP, is secreted later and 
acts to stop this effect.  This further suggests that Salmonella initially takes advantage of the 
innate inflammatory response, but must dampen that response before it succeeds in clearing the 
bacteria [195].  Salmonella can induce macrophage cell death, termed pyroptosis, in both a SPI-1- 
and SPI-2-dependent manner.  The SPI-1 T3SS effector SipB, flagellin, and the host cell protein 
caspase-1 mediate rapid macrophage death shortly after entry of Salmonella into macrophages.  
The active form of caspase-1 acts to process the pro-inflammatory cytokines IL-1% and IL-19 
into their mature form, and induces formation of membrane pores in the macrophage.  Delayed 
macrophage death by pyroptosis can also be induced by the SPI-2 T3SS and caspase-1 in the 
same manner [198, 200-202].  Death of macrophages early on in infection allows replicating 
Salmonella to spread further to uninfected macrophages and dendritic cells, while delayed 
macrophage death enables Salmonella to disseminate to, and invade, cells at systemic sites like 
the liver and spleen.  Proper regulation and cross-talk between the flagellar, SPI-1, and SPI-2 
T3SSs are essential for successful coordination of these events.  A recent study showed that 
caspase-1-deficient mice were more resistant to colonization by Salmonella, indicating that 
activation of caspase-1, and thereby the innate inflammatory response, is important for 
Salmonella to spread within the host [184, 194]. 
A side effect of this inflammatory process is the disruption of tight junctions between 
intestinal epithelial cells, providing Salmonella with easier access to underlying tissue, while 
subsequent recruitment of macrophages and dendritic cells gives Salmonella a place in which to 
replicate (within the SCV) and disseminate throughout the host [187].  The SPI-2 T3SS effector 
SseI interacts with the host cell protein TRIP6 to stimulate motility of macrophages and dendritic 
cells, facilitating the systemic spread of the bacteria [195].  As well, the release of antimicrobial 
peptides into the intestinal lumen may disrupt the growth of normal commensal bacteria, clearing 
the way for Salmonella to invade intestinal epithelial cells.  Inflammation also causes the release 
of certain nutrients from mucous that Salmonella can take advantage of to speed bacterial growth 
[187]. 
The innate immune response to Salmonella is very complex, and not completely 
understood.  There is contradictory evidence about whether the mucosal inflammatory response 
facilitates or limits the spread and invasion of Salmonella.  It is likely that the answer is not 
black-and-white, and that Salmonella needs to strike a balance between induction of 
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inflammation and control of this response.  The inflammatory response allows Salmonella to 
more effectively compete with the resident commensal bacteria, cause diarrhea facilitating its 
spread to other hosts, and bring in macrophages and dendritic cells.  Salmonella can then enter 
macrophages and dendritic cells and disseminate throughout the host.  However, the bacteria 
must also ensure that the inflammatory response subsides before it can act to clear the infection 
and activate an adaptive immune response.  The level of innate immune response induced by 
Salmonella likely determines the differing disease outcomes caused by different serovars in 
different hosts; be it an asymptomatic infection, gastroenteritis, or systemic disease. 
 
1.4.3 Adaptive immune response to Salmonella 
In comparison to the innate immune response to Salmonella, Much less is known about 
the adaptive immune response and its role in disease outcome.  Most studies regarding the 
adaptive immune response to Salmonella have been done in mice [203, 204].  Early in infection, 
dendritic cells can respond to LPS and flagellin of Salmonella by increasing their expression of 
major histocompatibility complex (MHC) class II and other co-stimulatory molecules.  These 
dendritic cells are a major link between the innate and adaptive immune response, and can 
stimulate the proliferation of Th1 CD4+ T cells [190, 198].  Macrophages (and dendritic cells) are 
also important for production of IL-18 and IL-1% in response to SPI-1-/caspase-1-mediated 
pyroptosis early on in the infection process.  IL-18 stimulates naïve and memory Th1 CD8+ &/% 
T cells, and NK cells, to produce IFN#, which in turn stimulates macrophages to become more 
efficient killers [188, 205].  Macrophages and dendritic cells can also produce IL-15 and IL-23, 
which stimulates proliferation of #/( T cells, NK like T cells, and Th17 CD4+ &/% memory T 
cells.  Th17 T cells produce IL-17 and IL-22; dendritic cells and NK-like T cells can also produce 
IL-22 [188, 206].  IL-17 activates neutrophils, and IL-22 is important in stimulating the 
production of antimicrobial peptides by epithelial cells [188, 207].  CD4+ &/% memory type T 
cells are important in the later stages of infection, during systemic disease.  Without these T cells, 
persistent infection can develop and lead to eventual fatality [206]. 
In addition to T cells, B cells have also been shown to be important in protection against 
infection with Salmonella after vaccination in mice.  This is likely through their interaction with 
Th1 memory T cells as they are not important in clearance of primary infection with Salmonella.  
In fact, a protective Th1 response does not take place in mice depleted of B cells, and humans 
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with immunodeficiencies in B cells or antibody production are much more susceptible to severe 
infections by Salmonella [198, 204, 206].  Early after infection, Salmonella-specific IgM is 
produced, followed by IgG in the serum and at the intestinal mucosa.  Interestingly, IgA appears 
only to be produced in the intestine if Salmonella specifically enters the PP through M-cells [206, 
208].  There is evidence that Salmonella-specific antibodies contribute to disease resolution and 
protection in secondary infection in both humans and mice.  However, passive transfer of these 
antibodies to naïve mice does not confer full protection against infection with Salmonella.  These 
antibodies may aid in controlling extracellular bacteria through opsinization, leading to faster 
uptake and bacterial killing by professional phagocytes [204, 209-211].  However, it is unclear 
whether all Salmonella actually go through an extracellular phase in systemic disease [198].  It 
may be that after initial entry into professional phagocytes in the PP, Salmonella stays protected 
within these cells.  After inducing SPI-1- or SPI-2-mediated pyroptosis of macrophages and 
dendritic cells, Salmonella may stay contained within host cell membrane fragments, which 
would be taken up by other professional phagocytes.  In this case, Salmonella would not need to 
enter an extracellular state until it had reached the liver or spleen, and only then if entry into non-
phagocytic cells was beneficial. 
 
1.4.4 Disease outcome 
The outcome of disease is dependent on the serovar, host, and host immune response [13, 
198, 204].  For instance, the host-adapted serovars S. Typhi and S. Paratyphi cause typhoid fever 
in humans and some primates, while other host-adapted serovars like S. Choleraesuis (pigs) and 
S. Dublin (cattle) are capable of causing bacteremia in humans, as well as typhoid-like disease in 
their respective hosts.  The non-host-adapted strains S. Typhimurium and S. Enteritidis can cause 
a variety of diseases in a variety of hosts.  S. Typhimurium and S. Enteritidis are capable of 
causing gastroenteritis in cows and pigs.  In humans, S. Typhimurium and S. Enteritidis generally 
produce self-limiting gastroenteritis, but in rare occasions can instead cause typhoid-like systemic 
disease.  In susceptible mice, S. Typhimurium and S. Enteritidis cause a lethal typhoid-like 
disease while resistant mice can develop chronic infection.  In streptomycin pre-treated or 
gnotobiotic mice, S. Typhimurium and S. Enteritidis cause symptoms resembling gastroenteritis.  
In contrast, infection with S. Typhimurium and S. Enteritidis results in an asymptomatic carrier 
state in most healthy adult chickens [13, 181, 204]. 
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Typhoid fever results when Salmonella are able to traverse the intestinal epithelial cell 
barrier without causing a major inflammatory response, and disseminate to systemic sites via 
macrophages, dendritic cells, and other professional phagocytes.  In humans, typhoid disease 
occurs one to two weeks after ingestion of Salmonella, and results in fever, malaise and 
abdominal pain.  Disease typically resolves after a period of weeks, but can result in carriage and 
spread of the bacteria for months and even years.  In chickens, S. Typhimurium and S. Enteritidis 
infections are asymptomatic, and often result in a carrier state with animals shedding bacteria for 
long periods of time.  Systemic disease in chickens follows infection by S. Gallinarum (fowl 
typhoid) and SP (Pullorum disease).  S. Typhi and S. Paratyphi cause typhoid fever in humans, 
while a typhoid-like systemic disease resulting from S. Typhimurium and S. Enteritidis occurs 
only rarely, usually in the immunocompromised individual.  Typhoid-like disease in mice is 
caused by both S. Typhimurium and S. Enteritidis infection, and is the primary model for 
understand typhoid in humans [15, 198, 203, 204, 212]. 
The progression of systemic disease can be roughly broken down into four phases.  Phase 
1 is the initial stage of systemic infection that occurs after invasion of Salmonella across the 
intestinal epithelium and into dendritic cells and macrophages in the PP.  Clearance of bacteria 
during phase 1 is usually rapid, and occurs in the first day of infection.  An appropriate effective 
innate immune response (one that doesn’t result in symptoms of gastroenteritis) is required for 
clearance of the bacteria at this point.  Phase 2 occurs between days 2 and 7, and involves growth 
of the bacteria in phagocytes, and dissemination to, and growth at, systemic sites such as the liver 
and spleen.  Recruitment of macrophages, dendritic cells, neutrophils, and NK cells is required 
for control of infection at this stage.  In immunocompromised individuals, failure to control the 
disease at this stage leads to massive bacterial replication and death of the host.  Phase 3 can last 
up to a month, and involves a plateau in bacterial numbers.  Without proper control at this point, 
the host can become a prolonged carrier, instead of clearing the bacteria, and relapse of disease 
and fatality can also occur.  Phase 4 involves clearance of bacteria that requires the action of T 
cells.  Control at this point requires an appropriate adaptive immune response mainly involving 
Th1 CD4+ &/% T cells [203, 204, 210, 212, 213]. 
  Gastroenteritis occurs as a result of an innate immune inflammatory response at the 
intestinal mucosa and very rarely results in systemic spread.  In humans, gastroenteritis occurs 6 
to 72 hours post-ingestion of large amounts of bacteria and is marked by abdominal pain and 
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cramps, diarrhea and vomiting.  Disease is self-limiting, and typically resolves within a week in 
healthy adults, but can progress to systemic disease in the immunocompromised [13, 198, 203, 
204].  Controlling disease before onset of systemic infection requires an appropriate innate 
immune response.  People with innate immune system defects, including IFN#, IL-12, or phox 
deficiencies, are prone to severe systemic infection with S. Typhimurium and S. Enteritidis [13, 
206]. 
When infected by Salmonella, chickens produce both a cell-mediated and humoral 
immune response when infected with Salmonella.  In response to S. Typhimurium and S. 
Enteritidis, Salmonella-specific antibodies (IgY, IgA and IgM) are produced, and proliferation of 
CD4+ T cells and B cells in both the spleen and cecal tonsils is induced.  As well, macrophages 
and Salmonella-specific T cells can be found in the ovaries, and correspond with a decline in 
bacterial numbers [214-216].  Both a strong Salmonella-specific T cell response and production 
of IFN# have been found to be important for clearance of S. Typhimurium and S. Enteritidis in 
resistant chickens [217, 218].  In mice, S. Typhimurium and S. Enteritidis cause a systemic 
typhoid-like infection; however, in the streptomycin pre-treated mouse model, mice develop 
disease more reminiscent of gastroenteritis.  In this model, CD3+ T cells are in part responsible 
for the outcome of disease, enhancing inflammation and therefore symptoms of enteritis [198, 
219]. 
It is clear that a balanced immune response involving both the innate and adaptive 
immune system are required to control the outcomes of Salmonella infection.  Better 
understanding of how different serovars manipulate the host’s immune system, and how resistant 
hosts differ from susceptible hosts, will improve our ability to intervene in both human and 
animal disease caused by Salmonella. 
 
1.5 Control and treatment of Salmonella 
 
1.5.1 Treatment of infections caused by serovars Typhimurium and Enteritidis 
In humans, gastroenteritis caused by S. Typhimurium and S. Enteritidis is usually self-
limiting and antibiotic intervention is not needed, although fluid replacement to combat 
dehydration is recommended.   When systemic spread of the disease is a concern, such as in the 
immunocompromised, antibiotics are warranted.  S. Typhimurium and S. Enteritidis can be 
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treated with chloramphenicol or antibiotics from the cephalosporin (ceftriaxone), fluoroquinilone 
(ciprofloxacin), penicillin (ampicillin), sulfonamide (trimethoprim-sulfamethoxazole), or 
cephalosporin (broad spectrum like ceftriaxone) groups [13, 220].  However, antibiotic resistance 
in Salmonella is becoming a major concern.  Multiple-drug-resistant strains of both S. 
Typhimurium and S. Enteritidis, like S. Typhimurium phage-type DT104 (which is resistant to 
ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline), are being found 
with increasing frequency.  Recently, an S. Enteritidis strain was isolated from poultry in Korea 
that was resistant to 15 out of 21 antimicrobials tested, including antibiotics from the 
aminoglycoside, cephalosporin, fluoroquinilone, penicillin, sulfonamide, and tetracycline groups 
[221, 222]. 
 
1.5.2 Prevention of infection 
In the past, there was widespread antibiotic use in feed animals at sub-therapeutic levels 
as growth enhancers, and to reduce levels of enteric pathogens.  Recently, with the development 
of more multi-drug-resistant strains, it has been recognized that this antibiotic ‘abuse’ is a large 
factor in multi-drug-resistant strain development and has resulted in bans on antibiotic use in 
food animals in some regions.  As more multi-drug-resistant strains of Salmonella are 
developing, the need for an effective strategy to control the spread of Salmonella, without 
reliance on antibiotics, needs to be developed [223-226]. 
 
1.5.2.1 Producer practices and consumer education 
At the producer level there are many methods that can be employed to reduce levels of 
Salmonella in poultry flocks.  Disinfectants like iodophore, peroxygen and 
formaldehyde/glutaraldehyde have been shown to reduce levels of Salmonella in the 
environment, but rodent and pest carriage of Salmonella remains a problem as they can 
reintroduce Salmonella to disinfected areas [227, 228].  Proper housing to ensure animals are in a 
clean and reduced stress environment are also important factors.  Choice of chicken line can also 
be important, as some chicken lines are genetically resistant to colonization by Salmonella [229, 
230].  Vaccination of flocks can also be an effective way to control Salmonella in poultry flocks 
(see section 1.5.2.4).  Salmonella can be introduced into the food supply during packaging.  
Contamination of eggs and egg packing plants, as well as poultry meat and poultry meat packing 
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plants, can often be high, however, proper disinfection of surfaces and sterilization of products 
can reduce these levels.  Passing products briefly through high temperature water (80 - 100°C), 
immersion in baths containing chlorine, iodine, hydrogen peroxide, ozonated water, electrolyzed 
water, organic acids, and UV light treatment have been somewhat successful in reducing levels of 
Salmonella on poultry products. [226, 231, 232].  As well, the type of equipment used can play a 
role in contamination; certain types of conveyor belts used in egg facilities harbour more 
Salmonella than others, even disinfection [233].  Organizations like the USDA and Canadian 
Food Inspection Agency (CFIA) have introduced Hazard Analysis of Critical Control Points 
(HACCP) programs.  These programs outline a series of regulations that require monitoring of 
the production process at a series of critical control points, including controls at the farm level, 
transport, packaging and processing of poultry products, to distribution.  The generic HACCP 
model for poultry slaughter in Canada can be found on the CFIA website [234].  For fairly 
comprehensive reviews on the types of disinfectant techniques and management practices that 
can be successful for reducing Salmonella levels in poultry flocks, and in packing plants, see 
Ricke et al. [226], Dinçer and Baysal [235], and Doyle and Erickson [236].  In order to maintain 
proper management practices, regulations and standards should be in place, as well as regular 
testing of poultry farms and packing plants [29, 229, 237-239]. 
Proper food handling and completely cooking poultry and eggs is essential to prevent the 
spread of Salmonella in humans.  Humans can contract salmonellosis from products subject to 
improper handling or environmental contamination, as well as through direct interaction with 
animals carrying Salmonella.  Salmonella has been isolated from numerous raw fruits and 
vegetables, juices, sauces, unpasteurized dairy products, seafood, chocolate, peanut butter, and 
even pet treats, among other products.  Agencies like the CFIA, Center for Disease Control 
(CDC), World Health Organization (WHO), and the USDA, are trying to increase public 
education about food safety.  One of their strategies includes a ‘4-point plan’, with the four points 
being CLEAN (wash hands and surfaces), SEPARATE (keep raw and cooked foods separate), 
COOK (cook foods to the appropriate and safe internal temperature) and CHILL (keep opened 
jars and cooked foods refrigerated after use and during transport).  Implementation of these 
proper hygiene techniques in the general public can be difficult as HACCP models can not be 
enforced on the general public.  Therefore, public education remains the only option for 
implementing proper food handling and hygiene [220, 238, 240-244].  
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1.5.2.2 Feed additives, probiotics, prebiotics, and competitive exclusion 
In response to the development of multi-drug-resistant strains, research is being carried 
out on methods to stop the spread of Salmonella that do not involve antibiotics.  The area of 
prebiotics and probiotics, for both humans and animals, is a popular area of research, along with 
feed additives to boost the host’s immune system [224, 225].  For example, % 1-4 mannobiose has 
been shown to enhance the killing activity of chicken macrophages against S. Enteritidis, and so 
has potential as a feed additive [224].  Mannan oligosaccharides (MOS), %-glucan, and butyric 
acid-based feed additives also have promise as they have been shown to reduce the colonization 
levels of young chicks by Salmonella [245-247].  MOS bind to a mannose-specific lectin in type 
1 fimbriae-producing Gram-negative bacteria.  This interaction results in expulsion of bacteria 
like Salmonella from the gastrointestinal tract [225, 247].  Short-chain fatty acids, like butyric 
acid, have a bacteriostatic effect on Gram-negative bacteria.  When added to feed, this results in a 
reduction of shedding of Salmonella by colonized chickens [225, 246]. 
The gastrointestinal environment is home to around 1014 commensal bacteria termed the 
host microbiota [183, 225, 248].  In order for proper development of the PPs and MLNs, 
commensal bacteria must be present shortly after birth; as illustrated by the poorly developed PPs 
and immune deficiencies of gnotobiotic mice [183, 187, 248].  The method of discrimination 
used by the intestinal innate immune system is just beginning to be understood, and improper 
distinction between harmful and commensal pathogens by the immune system is thought to be 
responsible for chronic inflammatory disorders such as irritable bowel syndrome and Crohn’s 
disease [183, 192, 199].  In feed animals, the levels of beneficial bacteria in gastrointestinal tract 
have been shown to change during periods of stress such as feed withdrawal, transport, or 
temperature change.  Therefore, proper balance of the host’s microbiota must be maintained for 
optimal gastrointestinal health, and the use of probiotics can help to maintain this balance [225]. 
Prebiotics and probiotics are easy to produce and are an inexpensive method to help 
combat the spread of Salmonella from feed animals to humans.  Probiotics involve 
supplementation of a host with live bacteria that have a positive health benefit to that host.  
Bacteria of the Lactobacillus and Bifidobacterium genera have been shown to be protective 
against gastrointestinal infections, and are common food additives in yoghurt for human 
consumption [225, 249].  As the microbiota are part of the host’s initial line of defense, proper 
levels of beneficial bacteria in the gastrointestinal tract can help protect chickens against 
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colonization by enteric pathogens like S. Typhimurium and S. Enteritidis.  The microbiota can 
limit the growth of harmful bacteria within the host through competition for nutrients and/or the 
production of antimicrobial peptides and short-chain fatty acids [183, 184, 249]. The main 
probiotics used in poultry are Lactobacillus, Enterococcus, Bacillus and Saccharomyces [225].  
Prebiotics are food additives that are non-digestible by the host and beneficial to probiotic 
organisms.  Prebiotics can stimulate growth and/or the activity of the host’s beneficial bacteria 
and add to the effectiveness of probiotics [225, 249]. 
Currently, competitive exclusion is the probiotic method of choice in poultry.  Newly 
hatched chicks, which are most prone to infection by S. Typhimurium and S. Enteritidis, are 
given an oral dose of microbiota that has been isolated from a healthy adult chicken.  There are 
several competitive exclusion preparations commercially available for the reduction of 
Salmonella in chickens including Avifree™, Aviguard™, Broilact, MSC™ and Preempt™ [225, 
249, 250].  There are a few concerns regarding the use of probiotic strains: mainly, full 
characterization of strains in the preparation as well as full disclosure of the strains therein, and 
the possibility of virulence gene transfer between pathogenic bacteria and the introduced 
probiotic strains [225, 250]. 
 
1.5.2.3 Bacteriophages 
Bacteriophages, also known as phages, are DNA or RNA viruses that target bacteria.  
Phages can be either lytic or lysogenic.  Lytic phages replicate at a rapid pace within the 
bacterium, resulting in bacterial lysis, while lysogenic phages can integrate into the host 
(prophages), or exist within the bacterium as a plasmid.  Lysogenic phages are major contributors 
to bacterial genetic evolution as they are capable of introducing new genes and/or transferring 
virulence genes between species of bacteria.  In fact, many SPI-1 and SPI-2 effectors lie within 
prophage regions.  In contrast to lysogenic phages, lytic phages are an attractive method to treat 
bacterial infection because of their properties, especially in light of the development of multi-
drug-resistant bacterial strains [6, 220, 223, 251]. 
Despite its potential, there are drawbacks to phage therapy.  For instance, phages tend to 
infect a narrow range of bacteria; so specific treatment regimens would have to be developed on a 
case-by-case basis.  This specificity can be seen as an advantage, however, as treatment with 
these phages would not likely result in killing of the host microbiota.  Alternatively, a preparation 
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containing multiple phage types could used to target the typical agents of disease producing the 
observed symptoms.  A second drawback is that phages tend to be cleared from the hosts’ 
bloodstream fairly quickly, and oral administration would result in the inactivation of many 
phages by stomach acid.  Some work has consequently been done to isolate phages (specifically 
" of E. coli and )22 of S. Typhimurium) that last in circulation much longer than the WT phages, 
making them better treatment candidates.  Administration of stomach acid inhibitors would also 
improve oral inoculation conditions for the survival of the phage, potentially rendering the 
treatment more effective [223, 251, 252]. 
Phages have been used in human medical treatment since the 1930s, primarily in the 
historical Soviet Union.  In fact, it has been reported that phages were used to treat dysentery and 
wound infections of Russian soldiers during World War II.  Phage therapy on humans continues 
to be practiced in Poland and the Republic of Georgia, and is gaining attention elsewhere as 
multi-drug-resistant bacterial strains continue to develop [223, 251].  Beyond their potential for 
treatment of disease in humans, there have been a few studies to date regarding phage therapy in 
the prevention of S. Typhimurium and S. Enteritidis in chickens.  A study in the early 1990s 
showed that, after inoculation with a S. Typhimurium-specific phage, young chicks were 
protected from fatal infection by S. Typhimurium [253].  A more recent study by Atterbury et al. 
showed that broiler chickens inoculated orally with S. Enteritidis-specific )151 or S. 
Typhimurium-specific )10 shed less bacteria in their feces upon challenge with S. Enteritidis or 
S. Typhimurium [254].  The few other studies using phage as treatment of S. Enteritidis or S. 
Typhimurium colonization of chickens have had variable results, and, in most cases, bacterial 
clearance was transient [223].  With so few studies regarding the use of phage therapy in 
chickens to prevent S. Typhimurium or S. Enteritidis colonization, it is clear that more research 
should be done in this area, especially in light of promising results with other enteric bacteria 
such as E. coli, reviewed in Johnson et al. [223]. 
 
1.5.2.4 Vaccination 
 
1.5.2.4.1 Live vaccines 
Effective live vaccines can induce a potent humoral and cell-mediated immune response, 
including generation of mucosal IgA.  These types of vaccines often produce long-lasting 
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immunity, but fear of reversion to virulence and release of genetically engineered organisms into 
the environment can be a major concern.  Spread of these organisms in the environment can also 
be a desirable quality, especially when vaccinating wild animal populations where not all animals 
can be reached for vaccination.  In some cases the attenuated strain can cause disease in an 
immunocompromised host, which is also undesirable.  Most live vaccines can be administered 
orally, allowing for ease of distribution to animals, including poultry, through drinking water.  
Attenuated strains should be able to survive within the host for long enough to sufficiently 
stimulate the hosts’ immune system, but should not cause any symptoms of disease.  Ideally, the 
vaccine should confer protection against more than one serovar [15, 206, 220]. 
A number of live attenuated vaccine strains have been tested in chickens.  An S. 
Enteritidis phoP/fliC mutant was able to reduce colonization of chickens with S. Enteritidis.  The 
phoP gene encodes the key global regulatory protein PhoP, while fliC encodes one of the 
flagellin subunits of Salmonella (FliC) [255].  Using a S. Gallinarum strain with deletions of the 
cobS and cbiA genes, which are involved in the vitamin B12 biosynthetic pathway, colonization of 
chickens by both S. Gallinarum and S. Enteritidis was reduced [256].  An S. Typhimurium strain 
with deletions of the adenylate cyclase (cya) and cyclic AMP receptor (crp), which are involved 
in carbohydrate utilization and cell surface expression of fimbriae and flagella, has also shown 
promise in reducing colonization by both S. Typhimurium and S. Enteritidis [257].  Finally, a S. 
Enteritidis aroA mutant was successful in reducing colonization of chickens by S. Enteritidis, but 
not S. Typhimurium; AroA being a key component in the aromatic biosynthetic pathway [258]. 
Live attenuated vaccines are available in North America, but are often not used.  
However, in light of recent S. Typhimurium and S. Enteritidis outbreaks and the successes in the 
EU at controlling the spread of S. Typhimurium and S. Enteritidis though vaccination, the use of 
live attenuated vaccines is becoming more attractive to North American producers [19, 259].  
Gallivac® Se (also known as Salmovac S. Enteritidis) is a live attenuated S. Enteritidis strain that 
is an adenine-histidine auxotroph.  Gallivac® confers significant protection of chickens against 
colonization by S. Enteritidis [260].  Megan®Vac 1 is a live attenuated S. Typhimurium cya/crp 
mutant that has been successful in reducing colonization levels of chickens by both S. 
Typhimurium and S. Enteritidis [261, 262].  TAD Salmonella vac® E (a live attenuated S. 
Enteritidis strain) and TAD Salmonella vac® T (a live attenuated S. Typhimurium strain) are 
both ‘metabolic drift mutants’ that carry mutations affecting essential enzymes and metabolism 
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genes and are capable of reducing colonization of chickens (and eggs) by S. Enteritidis and S. 
Typhimurium.  As well, it has been demonstrated that TAD Salmonella vac® T has potential for 
cross-protection against S. Enteritidis [263]. 
 
1.5.2.4.2 Inactivated vaccines 
Inactivated bacteria vaccines (also known as bacterins) and subunit protein-based 
vaccines (discussed in section 1.5.2.4.3) are capable of inducing a strong humoral response, 
especially when coupled with an appropriate adjuvant.  They are attractive compared to live 
vaccines as there is no chance of reactivated virulence or of live genetically modified bacteria 
entering the environment.  The drawback of these types of vaccines is that they often do not 
induce production of mucosal IgA, or elicit a potent cell-mediated immune response.  
Furthermore, higher loads of antigen need to be delivered, often over multiple doses.  As well, 
many inactivated vaccines and most subunit vaccines require needle delivery, making them 
harder to distribute to poultry [220]. 
There are a number of inactivated Salmonella vaccines available.  Gallimune® is an 
inactivated bacterial vaccine composed of both S. Typhimurium and S. Enteritidis.  When used in 
combination with Gallivac®, laying hens can be protected against colonization by S. 
Typhimurium and/or S. Enteritidis [260].  Layermune S. Enteritidis is a bacterin containing 
multiple S. Enteritidis strains that can help reduce colonization of chickens by S. Enteritidis, 
especially when used in combination with one of the live vaccines [25].  Corymune 4K is a 
multivalent vaccine composed of several inactivated strains: Avibacterium paragallinarum 
serotypes A, B and C, and one S. Enteritidis strain.  Corymune 7K contains the same strains as 
Corymune 4K, but also inactivated forms of Newcastle disease virus, infectious bronchitis virus, 
and egg drop syndrome virus.  Vaccination with Corymune 4K and Corymune 7K confers 
moderate protection against colonization of chickens by S. Enteritidis [25].  Salenvac is an S. 
Enteritidis iron-restricted mutant bacterin that has been successful in reducing colonization of 
chickens by S. Enteritidis [264]. 
 
1.5.2.4.3 Subunit vaccines 
There have been very few studies on the efficacy of subunit protein based vaccines for 
protection of poultry against colonization with Salmonella.  One such study demonstrated that 
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chickens vaccinated with certain outer membrane proteins or FliC produce a strong serum 
antibody response, and have lower numbers of S. Enteritidis in their cecum [265-267].  A study 
by Kaneshige et al. explored the efficacy of the siderophore receptor IroN as a vaccine, and 
found that vaccinated chickens had a strong serum antibody response to the vaccine, as well as a 
lower mortality rate compared to non-vaccinates when challenged intravenously with heavy loads 
of S. Enteritidis [268].  Laying hens vaccinated with type 1 fimbriae of S. Enteritidis had less 
colonization of reproductive organs than control hens after challenge with S. Enteritidis, and eggs 
from vaccinates were less often contaminated by S. Enteritidis when compared to those of non-
vaccinates [269]. 
 
1.5.2.4.4 Other immunization methods 
Passive immunization involves transfer of serum containing microbe-specific antibodies 
from an exposed or vaccinated host to a naïve recipient.  This transfer can be active (involving 
drawing of blood from one host and transfer to the recipient) or passive (as in maternal transfer of 
antibodies to progeny) [220].  Vaccinated hens pass large amounts of antibody to eggs, which can 
be purified for injection into naïve recipients, or may protect newly hatched chicks against 
colonization by Salmonella [270, 271].  Progeny of hens vaccinated with avirulent S. 
Typhimurium or S. Enteritidis strains have lower levels of colonization by S. Typhimurium or S. 
Enteritidis than progeny of non-vaccinates [271, 272]. 
DNA vaccines involve direct injection of a plasmid into the host cells (skin or muscle).  
These host cells go on to express the antigen of interest, exposing it to the local immune system 
where a response can be mounted.  Defective infectious single-cycle (DISC) virus vaccines 
involve immunization with a virus that can only undergo one round of replication within the host.  
This type of system is intended to emulate the first stages of natural infection, resulting in a 
protective immune response without progression to disease.  This type of strategy could be useful 
for viral diseases as well as for delivery of protein subunit type vaccines using the DISC virus as 
a delivery method for the antigen [220].  There is almost no research in these areas in regards to 
the development of a poultry vaccine to combat Salmonella colonization.  However, one recent 
study showed that when a DNA vaccine encoding the SopB protein of S. Typhimurium was 
administered to mice in conjunction with a live attenuated vaccine S. Typhimurium strain, greater 
protection of the mice against fatal S. Typhimurium infection was achieved than with the live 
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attenuated strain alone [273]. 
 
1.5.2.4.5 Salmonella as vaccine vectors 
A plethora of studies have recently explored the potential of attenuated Salmonella strains 
as vaccine vectors for other pathogens.  Most of these studies involve delivery of plasmid-
encoded antigens by Salmonella T2SSs and T3SSs to the host.  Using attenuated Salmonella 
strains that can be delivered orally and still cross the intestinal epithelial cell barrier and progress 
to deeper systemic sites can help ensure production of a memory T cell response against the 
desired antigen.  These types of attenuated Salmonella strains are excellent at inducing long-
lasting protective immunity at both mucosal and systemic sites, but are difficult to develop while 
still ensuring vaccine strain safety [274, 275].  There are also studies involving integration of the 
antigen into the Salmonella genome by fusion to secreted T3SS effectors of SPI-1 and/or SPI-2.  
This method has been used to study the delivery of both anti-microbial and anti-tumor antigens, 
as well as the delivery of anti-inflammatory cytokines for the treatment of inflammatory diseases 
[276, 277].  There have also been studies involving Salmonella delivery of protective 
Streptococcus pneumoniae, Mycobacterium tuberculosis and human immunodeficiency virus 
(HIV) antigens, among others [278-280].  For recent comprehensive reviews of these strategies 
see Curtiss et al.[274], Shahabi et al. [275], and Chmekh [276]. 
Live Salmonella strains that can induce protective immunity against the antigen it is 
delivering as well as immunity to Salmonella would be an effective tool for the poultry industry 
in preventing the spread of food-borne pathogens and promoting the health of immunized 
animals.  For instance, a live attenuated S. Typhimurium vaccine strain, harbouring a plasmid 
coding for a truncated protein of Clostridium perferingens that is already known to reduce 
necrotizing enteritis in chickens, could also protect chickens against colonization with S. 
Typhimurium and S. Enteritidis [281].  There have been studies involving Salmonella delivery of 
protective Streptococcus pneumoniae, Mycobacterium tuberculosis and human 
immunodeficiency virus (HIV) antigens, among others [278-280]. 
 
1.5.3 Comprehensive approach 
As with most multi-host pathogens, no one method of control on its own will eliminate 
Salmonella.  While certain vaccination regimes and disinfection can reduce Salmonella on the 
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farm, consumer education about proper food handling and storage is still needed.  A combination 
of proper hygiene at the farm and consumer levels, coupled with vaccination regimes, and/or pre- 
and probiotics, could help to reduce the levels of S. Typhimurium and S. Enteritidis in poultry, 
and therefore, prevent the spread of Salmonella gastroenteritis to humans.  For a comprehensive 
review on Salmonella reduction strategies in the food supply, see Doyle and Erickson [236]
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2.0 HYPOTHESIS AND OBJECTIVES 
 
2.1 Hypothesis 
The Salmonella enterica subspecies enterica serovar Enteritidis (S. Enteritidis) 
Salmonella pathogenicity island (SPI) 2 type III secretion system (T3SS) is important for 
colonization of chickens and systemic spread, as well as survival of S. Enteritidis in chicken 
macrophages.  Immunization with S. Enteritidis SPI-2 T3SS proteins will have a protective effect 
against S. Enteritidis colonization of chickens. 
 
2.2 Rationale 
Infections by Salmonella enterica subspecies enterica serovars Typhimurium (S. 
Typhimurium) and Enteritidis (S. Enteritidis) are one of the most common causes of bacterial 
food borne gastroenteritis (food poisoning) in humans worldwide. Salmonella uses two T3SSs, 
encoded on SPI-1 and SPI-2, to cause disease and spread systemically throughout the host.  The 
SPI-2 T3SS has been shown to be necessary for systemic infection and survival of Salmonella in 
macrophages, however much of this work has been done in mice who develop a typhoid-like 
illness, and not in chickens who usually become asymptomatic carriers.  Because S. 
Typhimurium and S. Enteritidis are passed to humans via consumption of contaminated poultry 
meat, water, and eggs, there is a need for control of Salmonella colonization of chickens.  Many 
live vaccines have been shown to confer protection against colonization of chickens by S. 
Typhimurium and S. Enteritidis, however, there are many safety concerns associated with live 
vaccines.  Thus, we sought to better understand the role of the SPI-2 T3SS in survival of 
Salmonella in chicken macrophages.  Furthermore, we examined the role of the SPI-2 T3SS in 
cecal colonization and systemic spread of S. Enteritidis in chickens.  Finally, we examined the 
potential of various SPI-2 T3SS structural and effector protein vaccines to protect chickens 
against colonization by S. Enteritidis. 
 
2.3 Objectives 
1. To construct mutants of S. Enteritidis strain Sal18 missing the entirety of SPI-
2, and test the ability of these mutants to colonize chickens in comparison to 
the wild-type (WT) strain. 
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2. To clone genes encoding potential vaccine candidates, overproduce, and purify 
said products, and test their ability to protect chickens against colonization by 
S. Enteritidis. 
3. To test the ability of the SPI-2 mutant strains to survive in macrophages in 
comparison to the WT strain. 
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3.0 THE ROLE OF THE S. ENTERITIDIS PATHOGENICITY ISLAND 2 TYPE III 
SECRETION SYSTEM IN INTESTINAL COLONIZATION OF CHICKENS AND 
SYSTEMIC SPREAD 
 
The information presented in this chapter has been previously published in Microbiology 
[282]. 
 
3.1 Introduction 
Salmonella enterica subspecies enterica serovar Enteritidis (S. Enteritidis) is an important 
human pathogen that causes salmonellosis in humans.  S. Enteritidis is passed to humans mainly 
via poultry meat contaminated at the time of slaughter and by consumption of contaminated 
water.  In addition, eggs are often heavily colonized by S. Enteritidis, and humans can contract 
salmonellosis via consumption of raw or partially cooked eggs.  Chickens colonized with S. 
Enteritidis typically do not show disease symptoms, and whole flocks can become colonized 
quickly, shedding bacteria in their feces for months [23, 24]. 
Infection caused by Salmonella enterica is the second most common cause of bacterial 
gastroenteritis (food poisoning) in the developed world, resulting in significant economic loss to 
the poultry industry and a substantial burden on the health care system [24, 265].  Because there 
is a need to control the spread of S. Enteritidis, the aim of our research was to focus efforts at the 
beginning of the chain of infection, colonization of the chicken.  It has been estimated that there 
are approximately 1.4 million cases of salmonellosis per year in the USA, resulting in 
approximately 15,000 hospitalizations, and 400 deaths per year [28].  An estimated 95% of those 
cases are contracted from contaminated food or food products [29].  Of those 95%, 15% of those 
cases are caused by S. Enteritidis.  S. Enteritidis is the second most common serovar isolated 
from poultry in North America, and is the most common serovar isolated from humans in the EU 
[27, 283].  As S. Enteritidis is passed to humans mainly through consumption of contaminated 
poultry meat and eggs, it is important to better understand the pathogenesis of S. Enteritidis in 
chickens in order to prevent it. 
S. Enteritidis is known to use two specialized type III secretion systems (T3SS) that are 
encoded within Salmonella pathogenicity islands 1 and 2 (SPI-1 and SPI-2), and are thought to 
facilitate invasion and survival within the host cell.  These two T3SSs are encoded within 
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Salmonella pathogenicity islands 1, and 2 (SPI-1 and SPI-2).  The T3SSs secrete effectors into 
the host cell, triggering a number of events in the infected cell that culminate in the symptoms of 
gastroenteritis in humans: fever, diarrhea, and abdominal pain.  It is the current view that the SPI-
1 T3SS is mainly involved in invasion of the host cell, while the SPI-2 T3SS plays a role in 
survival within the host cell and maintenance of the Salmonella containing vesicle (SCV) [284, 
285]. 
SPI-2 is a region of approximately 40 kb located at centisome 37 in S. Enteritidis, and has 
been reported to be necessary for systemic infection [55].  The SPI-2 region encodes 44 proteins 
that are essential for intracellular proliferation, survival, and maintenance of the SCV, as well as 
its own regulatory system: SsrA/B [286-288].  SPI-2 effectors are secreted across the SCV 
membrane and stop fusion of lysosomes with the SCV, thereby avoiding reactive oxygen species- 
(ROS-) and NADPH oxidase-mediated killing of the bacteria [178, 289, 290].  Effectors facilitate 
systemic spread and the maturation of the SCV, and can act as pro- or anti-inflammatory factors 
[291, 292].  Once in the mature SCV, Salmonella is able to proliferate, can traverse the epithelial 
cell, and can invade underlying tissue after being released on the basolateral side [293, 294]. 
Mutations that disrupt the SPI-2 T3SS have been shown to result in highly attenuated 
virulence, as well as defective growth in macrophages and epithelial cells [55, 178, 295].  
Optimal SPI-2 T3SS expression in culture occurs under acidic, low osmolarity, low Ca2+, 
minimal nutrient conditions which mimic the environment within the SCV [55, 150, 285].  
Unlike the SPI-1 T3SS, the SPI-2 needle is extended by a filament composed of SseB subunits 
that is required for secretion of the translocation proteins SseC and SseD [137, 178, 285, 296, 
297].  There are at least 19 effectors secreted by the SPI-2 T3SS, most encoded by genes located 
outside of the SPI-2 locus [137, 178, 292]. 
Until recently, it was widely accepted that, of the two T3SSs, SPI-1 was alone in its 
expression in the intestinal lumen, while SPI-2 expression was only induced after entry of 
Salmonella had entered into the host cells and established it’s position within the SCV.  
However, a study in mice showed that the SPI-2 T3SS is expressed in the intestinal lumen prior 
to attachment and entry of the bacteria, albeit to a much lower extent than SPI-1.  This is 
probably an attempt by the bacteria to prepare its invasion arsenal [284].  There have also been 
studies showing that the SPI-1 T3SS continues to be expressed once Salmonella is inside the 
SCV, and that some of the SPI-1 effector proteins work in conjunction with SPI-2 effector 
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proteins to manipulate the host cell [298-300].  To date, many studies examining the reduction of 
colonization and shedding of Salmonella in chickens have been carried out; however, the 
majority of these studies involve Salmonella enterica subspecies enterica serovars Typhimurium 
(S. Typhimurium), Pullorum (S. Pullorum), and Gallinarum (S. Gallinarum), and not serovar 
Enteritidis (S. Enteritidis) [71, 301-305]. 
The reduced ability of S. Enteritidis SPI-2 knockout mutants produced in our lab to 
colonize chickens has provided us with knowledge about the importance of the SPI-2 T3SS in the 
colonization process.  Using these mutants, we have observed that in a co-challenge situation the 
wild-type (WT) Salmonella strain out-competes the mutant for systemic spread, as measured by 
recovering the bacteria from liver and spleen.  Using a single-challenge model, we have observed 
that although the SPI-2 T3SS plays an important role in systemic infection, it is not the only 
factor involved in this process. 
 
3.2 Materials and methods 
 
3.2.1 Bacterial strains and plasmids 
Bacterial strains and plasmids used in this study are described in Tables 3.1 and 3.2, 
respectively.  Standard growth procedures were followed using Luria-Bertani (LB) broth and agar 
at 37°C.  Media was supplemented with 100 or 50 µg/ml ampicillin, 10 or 5 µg/ml tetracycline, 
30 or 9 µg/ml chloramphenicol, or 25 µg/ml streptomycin when called for.  All antibiotics were 
obtained from Sigma-Aldritch. 
 
3.2.2 Primers 
All primers used in this study (Table 3.3) were designed based on the S. Enteritidis PT4 
(phage type 4) sequence provided by Wellcome Trust Sanger Institute (UK), GenBank accession 
number AM933172 [6] and synthesized by Invitrogen. 
 
3.2.3 Polymerase chain reaction 
All Polymerase Chain Reactions (PCR) were carried out using New England Biolabs 
(NEB) Taq Polymerase, applying reaction conditions as suggested by the supplier. 
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Table 3.1 Bacterial strain list 
Bacterial strain Relevant properties Source 
E. coli BL-21 
(DE3) 
For protein expression, relA1F-, dcm, ompT, hsdSB(rB-, mB-), 
gal, "(DE3) 
Invitrogen 
E. coli BL-21 
(DE3) pLysS 
For expression of toxic proteins, F-, dcm, ompT, hsdSB(rB-, 
mB-), gal, "(DE3), [pLysS CamR] 
Invitrogen 
E. coli DH5& F-, #80dlacZ$M15, $(lacZYA-argF)U169, deoR, recA1, 
endA1, hsdR17(rK-, mK+), phoA, supE44, %-, thi-1, gyrA96, 
relA1 
Invitrogen 
E. coli M15 For expression of toxic proteins, F-, thi, lac, ara, gal+, mtl, 
recA+, uvr+, lon+, [pREP4 KanR] 
Qiagen 
E. coli SG13009 For expression of toxic proteins, F-, thi, lac, ara, gal+, mtl, 
recA+, uvr+, lon+, [pREP4 KanR] 
Qiagen 
WT S. Enteritidis 
Sal8 
Virulent for birds.  Invades spleen, liver and colonizes gut. Dr. W. 
Kay1 
WT S. Enteritidis 
Sal18 
Virulent for birds.  Invades spleen, liver and colonizes gut. Dr. C. 
Poppe2 
S. Enteritidis Sal18 
(pKD46) 
WT S. Enteritidis Sal18 harbouring the pKD46 plasmid for 
use in the "Red system. 
This study 
Sal18 attTn7::cat WT S. Enteritidis Sal18 with a chloramphenicol resistance 
gene inserted at the glmS site using the "Red system. 
This study 
Sal18 attTn7::tet WT S. Enteritidis Sal18 with a tetracycline resistance 
cassette inserted at the glmS site using the "Red system. 
This study 
Sal18 attTn7::cat 
!spaS!ssaU 
Sal18 with deletion of the SPI-1 spaS and SPI-2 ssaU genes 
as well as a chloramphenicol resistance gene inserted at the 
glmS site using the "Red system. 
This study 
Sal18 !SPI-2::cat Sal18 with the whole SPI-2 region deleted and replaced by a 
chloramphenicol resistance gene using the "Red system. 
This study 
Sal18 !SPI-2 Derivative of Sal18 !SPI-2::cat with the chloramphenicol 
resistance gene deleted using the "Red system. 
This study 
Sal18 !SPI-1!SPI-
2::cat 
Sal18 with the whole SPI-1 region deleted and the entire 
SPI-2 region deleted and replaced by a chloramphenicol 
resistance gene using the "Red system. 
This study 
WT S. 
Typhimurium 
SL1344 
WT S. Typhimurium, streptomycin resistant. Dr. B. 
Finlay3 
 
  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Dr. W. Kay, Department of Biochemistry and Microbiology, University of Victoria, Victoria, 
British Columbia 
2 Dr. C. Poppe, Laboratory for Foodborne Zoonoses, Health Canada, Guelph, Ontario 
3 Dr. B. Finlay, University of British Columbia, Vancouver, British Colombia 
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Table 3.2 Plasmid list 
Plasmid Relevant properties Source 
pBR322 Cloning vector, ampicillin and tetracycline resistance. NEB 
pET-15b His-tag protein expression vector, ampicillin resistance. Novagen 
pGEM-T Single 3´-T overhangs at the insertion site that greatly 
improve the efficiency of ligation of a PCR product into the 
plasmid by preventing recircularization of the vector and 
providing a compatible overhang for ligation of PCR products 
generated by certain thermostable polymerases.  Can be used 
for Blue/White screening.  Ampicillin resistance 
Promega 
pHSG415 Temperature sensitive.  Ampicillin, chloramphenicol and 
kanamycin resistance. 
Dr. A. White4 
and Dr. M. 
Surette5 
pKD3 Used in the "Red system, chloramphenicol resistance. Dr. A. White( 
and Dr. M. 
Surette5 
pKD46 Used in the "Red system. Dr. A. White( 
and Dr. M. 
Surette5 
pQE-30-UA His-tag protein expression vector, has single 3´-T overhangs 
at the insertion site for improved efficiency of direct ligation 
of PCR products into the plasmid. 
Qiagen 
!
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4 Dr. A. White, formerly: University of Calgary, Calgary, Alberta; currently: VIDO, University 
of Saskatchewan, Saskatoon, Saskatchewan 
5 Dr. M. Surette, formerly: University of Calgary, Calgary, Alberta; currently: McMaster 
University, Hamilton, Ontario 
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Table 3.3 Primer list 
Primer name Primer sequence (5’ !  3’) Restriction site 
"Red SPI-1 Fwd GCTGTCGCGTATGAAGCGATTGGGTATTGATA
AAGACGCGTTAGCGTAAGTGTAGGCTGGAGCT
GCTTC 
None 
"Red SPI-1 Rev ATATGGTCTTAATTATATCATGATGAGTTCAG
CCAACGGTGATATGGCCCATATGAATATCCTC
CTTA 
None 
"Red SPI-2 Fwd TCCAGGACGCGTGGTATTGGCATATCGGTGGG
ATGATAGCCAAGACAAACGTGTAGGCTGGAG
CTGCTTC 
None 
"Red SPI-2 Rev TGCCTCGCTCTAAGGATAGGTGACATCGAAAG
AGCGTGCAGAGGAATGTGCATATGAATATCCA
CCTTAG 
None 
glmSABC Fwd AGCGCAGGTAGGCGTAGCACCTCTTAGTCGCT
CTTCAGCCACCATAGAGAGTGTAGGCTGGAGC
TGCTTC 
None 
glmSABC Rev GGCCGTCGATAGACGGCCTTTTTTTGTGCGCC
GTGACAGGCGCTGTTCTTATATGAATATCCTC
CTTA 
None 
pBR322 tet Fwd AGATCTGTTTGACAGCTTATCATCGATAGGC BglII 
pBR322 tet Rev GGTACCAATTCTTGGAGTGGTGAATC KpnI 
sifA Fwd ATGCCGATTACTATAGGGAATGG None 
sifA Rev TTGAGAAAGCGTCGTCTG None 
sifB Fwd ATGCCAATTACTATCGGGAGAGG None 
sifB Rev GTGATCAACTCTGGTGATGAG None 
sipD Fwd AAGGGAGATTGGATCCTTAATTAGTAATGTG
GG 
BamHI 
sipD Rev TATTTTGGAAGCTTTTATGCGCGACTCTG HindIII 
SPI-2 Flank 1 Fwd AAGCTTGGACATGGCTGCCGTCGCTATC HindIII 
SPI-2 Flank 1 Rev GGTACCTCTGTTGCGGTAGTGCGTAATC KpnI 
SPI-2 Flank 2 Fwd AGATCTGCGACGGCGATTTC BglII 
SPI-2 Flank 2 Rev GAATTCCGCGCATTATACGCTG EcoRI 
spaS Flank 1 Fwd TATAAGCTTGCCTCAGCGAGGCGCGG HindIII 
spaS Flank 1 Rev GCTCTAGAGGCAGTAGCGATGTATTC XbaI 
spaS Flank 2 Fwd TGTCTAGATTATTCGAGGACATGCGTC XbaI 
spaS Flank 2 Rev GTGAATTCATGCTGAACAGGCATCT EcoRI 
ssaC Fwd GGGTGGGGTATCATATGGTA NdeI 
ssaC Rev CAGGATCCCTTTGGATTAACC BamHI 
ssaG Fwd AAGGACAAGCCATATGGATATTGC NdeI 
ssaG Rev GGATCCTTCAGATTTTAGCAATGA BamHI 
ssaU Flank 1 Fwd GTAAGCTTCTACAACGTCAGCCGTCC HindIII 
ssaU Flank 1 Rev CGTCTAGATGCTTTTGGTATGCTTC XbaI 
ssaU Flank 2 Fwd TCTCTAGACAGATGGAAACCAGTC XbaI 
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ssaU Flank 2 Rev TCGAATTCAGCAGCAACAGG EcoRI 
sseBCD Fwd AACCGCAGCGTACACGTAGT None 
sseBCD Rev CCTCCTGCCATGAGGCGTAA None 
sseB Fwd CATATGTCTTCAGGAAACATCTT NdeI 
sseB Rev GGATCCTCATGAGTACGTTTTC BamHI 
sseD Fwd CATATGGCGAGTAACGTA NdeI 
sseD Rev GGATCCTTACCTCGTTAATG BamHI 
sseI Fwd ATGCCCTTTCATATTGG None 
sseI Rev TGCGCTTACATTTTACC None 
sseL Fwd GACAGGAGGGTACCATGAGCGATGAGGCGCT
TGCGTTGTTG 
None 
sseL Rev TTACGCATAAGCTTTTACTGGAGACTGTATTC
ATATATTTG 
None 
!
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3.2.4 Cloning 
Flanking regions of spaS and ssaU were amplified using the following primers: spaS 
Flank 1 Fwd and Rev; spaS Flank 2 Fwd and Rev; ssaU flank 1 Fwd and Rev; and ssaU flank 2 
Fwd and Rev.  Restriction sites were added to these flanking regions during PCR, resulting in the 
products HindIII-Flank 1-XbaI and XbaI-Flank 2-EcoRI.  These products were inserted into the 
pGEM-T vector (Promega) for confirmation of the correct sequence (data not shown).  The 
resulting two plasmids, one harboring the left flanking region and one with the right flanking 
region of the gene of interest, were digested with the restriction enzymes XbaI and ScaI.  The 
fragments of the plasmids containing the flanking regions were then ligated together to create a 
plasmid containing both the right and left flanking regions of the gene of interest.  All regions of 
the pGEM-T vector remained intact, including the ampicillin resistance gene and the origin of 
replication.  The combined right/left flanking regions were excised from the pGEM-T vector and 
placed into the temperature sensitive plasmid pHSG415 using the HindIII and EcoRI restriction 
sites.  The resulting plasmid was electroporated into WT Sal18 competent cells with an Electro 
Cell Manipulator 630 (BTX Harvard Apparatus), using standard techniques.  Recombination of 
the pHSG415 plasmid harboring the flanking regions of the genes of interest was induced as 
described previously [306], and the correct recombinants were selected (Figure 3.1). 
The flanking regions of SPI-2 were amplified by PCR (using primers: SPI-2 Flank 1 Fwd 
and Rev, and SPI-2 Flank 2 Fwd and Rev) along with the tetracycline resistance gene (tet) from 
plasmid pBR322 (using primers: pBR322 tet Fwd and Rev).  The SPI-2 flanking regions and tet 
gene were then assembled into the pGEM-T vector as above. The resulting plasmid contained the 
amplified products in the following order: SPI-2 Flank 1 – tetracycline resistance cassette – SPI-2 
Flank 2.  The tetracycline resistance cassette including the flanking regions was then amplified 
via PCR, using primers SPI-2 Flank 1 Fwd and SPI-2 Flank 2 Rev, and the resulting PCR product 
of 4286 bp used in the Lambda Red (%Red) system [307]. 
For protein expression purposes, the sseB gene was amplified by PCR, using primers 
sseBCD Fwd and Rev, and sseB Fwd and Rev, and cloned into the pGEM-T vector for 
sequencing.  Once the presence of the genes was confirmed by sequencing and restriction gel 
analysis (data not shown), the genes were excised and inserted into the pET-15b vector 
(Novagen) using the BamHI and NcoI restriction sites. !  
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Figure 3.1  Schematic representation of the pHSG415 method for gene replacement 
 
Flanking regions of genes of interest were amplified via PCR.  The resulting products were 
inserted into the pGEM-T vector (Promega) for confirmation of the correct sequence (data not 
shown).  The plasmids harboring both the right and left flanking regions were digested with XbaI 
and ScaI prior to ligation.  This created a single plasmid containing both the right and left 
flanking regions of the gene of interest.  The combined right/left flanking regions were excised 
from the pGEM-T vector and placed into the temperature-sensitive plasmid pHSG415 using the 
HindIII and EcoRI restriction sites.  The resulting plasmid was then electroporated into WT S. 
Enteritidis Sal18, and successful recombinants were selected.  
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3.2.5 Construction of Salmonella pathogenicity island 2 mutants using the "Red system 
The %Red system is an efficient and widely used method for the inactivation of 
chromosomal genes in E. coli and S. Typhimurium [307-310].  This system was used to produce 
two SPI-2 knockout mutants.  The SPI-2 knockout mutant (Sal18 $SPI-2::cat) was produced 
using primers ("Red SPI-2 Fwd and Rev) designed based on the protocol originally described by 
Datsenko and Wanner [307].  A SPI-1 knockout mutant (Sal18 $SPI-1::cat) and SPI-1/SPI-2 
knockout mutant (Sal18 $SPI-1$SPI-2::cat) were also produced using the same method (SPI-1 
primers: "Red SPI-1 Fwd and Rev).  A chloramphenicol resistance marker was also added to WT 
Sal18 (Sal18 attTn7::cat) and the $spaS$ssaU strain (Sal18 attTn7::cat $spaS$ssaU) by 
inserting the chloramphenicol resistance gene into an intergenic region downstream of the 
glucosamine-6-phosphate synthetase (glmS) gene using the %Red method.  This site was chosen 
because it represents the Tn7 insertion site, and insertions at this position are unlikely to interfere 
with cellular functions [311].  Briefly, PCR primers were designed that recognized the intergenic 
region downstream of the glmS gene (glmSABC Fwd and Rev) based on the S. Enteritidis PT4 
sequence provided by Wellcome Trust Sanger Institute (UK), GenBank accession number 
AM933172 [6], and the chloramphenicol resistance gene encoded on the pKD3 plasmid [307].  A 
tetracycline resistance gene from pBR322 was also added to WT Sal18 (Sal18 attTn7::tet) in the 
same manner. 
 
3.2.6 Strain and construct confirmation 
DNA sequencing was carried out at on all constructs and PCR products at the Plant 
Biotechnology Institute (PBI) using a 3730 XL DNA analyzer (Applied Biosystems). 
 
3.2.7 Animal handling and treatment 
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use. 
 
3.2.8 Protein expression and antibody production 
The SseB protein was expressed and purified as an N-terminal His-tag fusion protein 
using standard protocols as described [312] and antisera raised in New Zealand white rabbits 
obtained from Charles River Canada. Rabbits were immunized subcutaneously on days 0 (with 
! +%!
100 µg protein in Freund’s complete adjuvant), 21, and 42 (with 50 µg protein in Freund’s 
incomplete adjuvant). Blood was collected from the rabbits on day 52 and serum IgG antibody 
titres were determined using enzyme linked immunosorbent assay (ELISA). 
 
3.2.9 Induction of Salmonella pathogenicity island 2 type III secretion system expression, 
and Western blot 
Strains were subjected to SPI-2 inducing conditions as previously described [150] with 
minor modifications.  Briefly, Strains were grown overnight in a rotation shaker (220 rpm) at 
37°C in LB medium.  The next day, 25 ml of LB was inoculated with 1/50 of the overnight 
culture.  Cultures were grown to an OD600 of approximately 0.600.  Cells were sedimented by 
centrifugation for 10 minutes at 6000 g.  Cells were washed by gentle resuspension in low 
phosphate, low magnesium media (LPM) and subject to centrifugation for 5 minutes at 1000 g.  
LPM is made up of 5 mM KCl, 7.5 mM (NH4)2SO4, 0.5 mM K2SO4, 8 µM MgCl2, 337 µM PO43-
, 38 mM glycerol, 80 mM 2-(N-morpholino)ethanesulfonic acid (MES) and brought to a pH of 
5.8.  LPM was supplemented with 1% casamino acids.  After growth in LPM for 6 hours, the 
cells were pelleted by centrifugation at 3800 x g for 10 minutes at 4°C, the supernatants were 
filtered and secreted proteins were precipitated with 20% trichloroacetic acid (TCA) overnight.  
The precipitated proteins were subjected to centrifugation at 21000 g for 30 minutes at 4°C and 
the TCA supernatant was subsequently removed.  A mixture of 5 ml 1X phosphate buffered 
saline A (PBSA) pH 7.3 (8.0 g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HPO4, 0.2 g/L KH2PO4), 0.2 
ml 1.5 M TRIS pH 8.8, and 5 ml ice cold acetone were added to wash the sediment.  This mixture 
was centrifuged at 21000 x g for 15 minutes at 4°C and the supernatant was subsequently 
discarded.  The resulting sediment was washed with 2 ml ice cold acetone, and centrifuged at 
21000 x g for 5 minutes at 4°C.  After removing the acetone supernatant, the sedimented proteins 
were dried at which point a visible pellet was seen.  The cell lysate (pellet), total membrane, and 
culture supernatant (secreted) fractions were isolated using standard techniques and separated by 
sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis (PAGE) prior to being 
visualized by staining with Coomassie Brilliant Blue G-250 (Bio-Rad).  Proteins of the pellet and 
secreted fractions were transferred to nitrocellulose membranes (Bio-Rad) using a Semi-Dry 
Transfer Cell (Bio-Rad) according to instructions provided by the supplier.  Western blot analysis 
was carried out as suggested for the Odyssey Infrared Imaging System (LI-COR Biosciences).  
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Primary antibodies used were rabbit polyclonal anti-SseB (raised in rabbits in-house) and mouse 
monoclonal anti-DnaK supplied by Kirkegaard and Perry Laboratories (KPL).  Secondary 
antibodies used were IRDye 680CW-conjugated goat polyclonal anti-rabbit IgG and IRDye 
800CW-conjugated goat polyclonal anti-mouse IgG supplied by LI-COR Biosciences.  Once dry, 
membranes were scanned with an Odyssey infrared imaging system. 
 
3.2.10 Passage of Salmonella strains 
Strains of interest were streaked for single colonies and grown overnight in LB broth 
supplemented with antibiotics to an OD600 (optical density at 600 nm) of 0.7.  The bacterial cell 
culture was centrifuged at 3500 x g for 10 minutes, and the resulting cell pellet was resuspended 
in saline for a final count of 2 x 1010 Colony forming units (CFU)/ml in 1 ml total volume.  
Chickens (two birds per strain) were orally challenged with 0.5 ml of the above bacterial culture.  
On days 2 and 4 after challenge, birds were euthanized and tested for the presence of the bacterial 
strain of interest by swabbing the insides of sampled organs (liver, spleen, and cecum) and 
plating on Brilliant Green (BG) agar.  After incubation of the agar plates for 24 hours, resulting 
Salmonella colonies were tested by colony PCR to confirm the identity of each challenge strain.  
Strains were stocked in 50% glycerol (v/v) and stored at -80!C for use in following trials. 
 
3.2.11 Recovery of Salmonella on Brilliant Green agar 
All strains used in the trials below were first subject to plating on BG and LB agar, with 
and without antibiotics, to determine plating efficiency and strain fitness.  Recovery of 
Salmonella on BG agar by direct plating is approximately 40% compared to recovery on LB agar.  
As the addition of antibiotics to BG agar further reduces the recovery rate by an additional 10% 
to 20%, it was decided not to use antibiotics with BG agar for recovery of Salmonella from 
chickens used in the following trials.  Addition of antibiotics to LB agar did not affect recovery.  
Further, there was no difference in the recovery and plating efficiency between any of the strains 
used on either BG or LB agar, or in their growth kinetics in LB broth (data not shown).  In order 
to determine total numbers of chickens positive for Salmonella, samples of liver, spleen, and 
cecum were taken, placed in saline, and weighed.  Liver and spleen samples were homogenized 
using a hand homogenizer and cecum samples were vortexed to mix.  Portions (1 ml) of all 
samples (liver, spleen, and cecum) were enriched in selenite broth and incubated overnight at 
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37°C in order to determine the total numbers of birds positive for Salmonella. 
 
3.2.12 Co-challenge trial 
Specific Pathogen Free (SPF) chickens were obtained from Charles River Laboratories, 
Inc. (USA) and placed in isolation rooms at the Vaccine and Infectious Disease Organization 
(VIDO).  At 35 days of age, birds were separated into three groups of 21 birds each and co-
challenged orally with two strains equaling 1 x 1010 bacteria total (0.5 x 1010 bacteria per strain) 
in 0.5 ml. Previous trials with SPF chickens were used to determine the appropriate dose (data 
not shown).  Birds received either Sal18 attTn7::tet + Sal18 attTn7::cat, Sal18 attTn7::tet + Sal18 
attTn7::cat $spaS$ssaU, or Sal18 attTn7::tet + Sal18 $SPI-1$SPI-2::cat.  The challenge was 
subject to plating on BG agar with subsequent re-streaking of colonies onto LB agar containing 
tetracycline and LB agar containing chloramphenicol in order to confirm that the challenge was, 
in fact, a 50/50% (CFU/CFU) mixture of the two strains in question (data not shown).  Birds 
were euthanized on days 1, 2, and 4 after challenge and their liver, spleen, and cecum tested for 
the presence of the strains of interest.  Samples of liver and spleen were weighed and 
homogenized in 10 ml of phosphate buffered saline (PBS).  Portions (100 µl) of homogenized 
liver and spleen were plated on BG agar, and CFU/g were calculated for each strain.  Cecal 
contents were weighed, vortexed in 5 ml of PBS, and 25 µl of 100, 10-1, 10-2, 10-3, 10-4, and 10-5 
serial dilutions plated on BG agar.  Colonies recovered by direct plating on BG agar were re-
streaked onto both LB agar plates containing tetracycline and LB containing chloramphenicol in 
order to differentiate the strains recovered.  CFU/g were calculated for each strain.  As the 
recovery of Salmonella on BG agar is only 40%, samples from the liver, spleen, and cecum of 
each bird were enriched in selenite broth, and incubated at 37°C overnight.  The next day a loop 
of each culture was plated on BG agar.  This data was used to determine the total number of 
samples and birds positive for Salmonella. 
 
3.2.13 Single-challenge trial 
SPF chicken eggs were obtained from Charles River Laboratories (USA), and were 
incubated for 21 days until hatch at the Department of Poultry Science (University of 
Saskatchewan).  On the day of hatching, birds were transferred to isolation rooms at VIDO.  One 
week after transfer, 20 birds were euthanized, and their ceca collected and tested for the presence 
! +(!
of Salmonella by plating on BG agar.  At this time, five swabs per room were taken, again to test 
for the presence of contaminating Salmonella as identified by plating on BG agar.  Groups of 40 
birds were challenged orally at 7 days of age (Day 0) with one of the following strains: Sal18 
attTn7::cat, Sal18 $SPI-1::cat, Sal18 $SPI-2::cat or Sal18 $SPI-1$SPI-2::cat, at a dose of 1010 
CFU in 0.5 ml.  On days 1, 2, 3, and 4 after challenge ten birds per group were euthanized and 
their liver, spleen, and cecum sampled, enriched, and plated as described above.  Results 
pertaining to the group that received the total SPI-1 mutant (Sal18 !SPI-1::cat) were reported 
previously [312]. 
 
3.2.14 Statistical analysis 
All statistical analyses were performed using GraphPad Prism® 5.0.  For the co-infection 
trial, Wilcoxon signed rank test was used to determine the difference between colonization levels 
of each strain within the groups.  For the single-infection trial, the one-way analysis of variance 
(ANOVA) Kruskal-Wallis test was performed on the CFU/g data followed by Dunn’s multiple 
comparison test when significance was observed.  Enrichment data was subjected to the chi-
square test followed by Fisher’s exact test when significance was observed.  p-values < 0.05 were 
considered significant. 
 
3.3 Results 
 
3.3.1 Detection of Salmonella pathogenicity island 2 type III secretion system proteins by 
Western blot 
As expected, WT S. Enteritidis Sal18 and its derivatives (Sal18 attTn7::cat and Sal18 
attTn7::tet) were positive for SseB in both the pellet fraction and the total membrane fraction 
(Figure 3.2, lanes 1-3).  The S. Enteritidis strains missing the entire SPI-2 region were found to 
be negative for production of SseB (Figure 3.2, lanes 4 and 7).   These results, along with those 
of DNA sequencing of PCR products, confirmed that Sal18 !SPI-2::cat and Sal18 !SPI-1!SPI-
2::cat were devoid of the SPI-2 region.  The strain with the ssaU gene deleted within the SPI-2 
region was found to be positive for production of SseB; SseB was found in both the pellet and 
total membrane fractions of this strain (Figure. 3.2, lane 6).   Since only the SsaU protein is 
absent in this strain, it is likely that the rest of the basal components (structural Ssa proteins and 
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the ATPase [adenosine triphosphatase] SsaN) are assembled at the inner membrane.  It is possible 
that SseB is still directed to the base of the incomplete SPI-2 T3SS by its chaperone, as in the WT 
strain, and is therefore associated with the total membrane fraction, as well as found free in the 
cytoplasm.  Alternatively, SseB that is not secreted might form aggregates that co-purify with the 
total membrane fraction.  Despite its presence in the pellet and total membrane fractions, SseB 
was not found in the secreted fraction of any strains.  This is expected, as SseB is a part of the 
apparatus and not a true secreted protein.  It has been previously reported that strains missing the 
ssaU gene do not secrete SPI-2 effectors [303].   DnaK was used as a loading control and was 
found in the pellet fraction, but not the secreted fraction, as expected. Although DnaK is not 
normally associated with the membrane, except under certain shock conditions [313], it was also 
found in the total membrane fraction in our study.  However, as the bacteria were under a certain 
amount of stress when they were switched from LB broth to SPI-2 inducing LPM, which has a 
low pH (5.6) and a different salt concentration compared to LB, it is not surprising that DnaK 
was found associated with the total membrane fraction in this case. 
 
3.3.2 Co-challenge trial 
The co-challenge trial was carried out as described in materials and methods, and the 
CFU/g calculated for Salmonella recovered from the liver, spleen, and cecal contents of each bird 
(Figure 3.3).  Colonies were re-streaked on antibiotic-containing plates to determine the 
percentage of WT strain versus mutant strain in all organs sampled.  On days 1, 3, and 4 post- 
challenge (PC) there was no significant difference observed between the colonization levels of 
the two WT strains in the liver, spleen, and cecum, as determined by Wilcoxon signed rank test. 
This indicates that the antibiotic resistance markers inserted into the WT genome downstream of 
the glmS gene had no effect on the strains’ ability to colonize the cecum and to spread 
systemically.  There were also no significant differences observed between the WT colonization 
levels and the mutant strain levels on day 1 PC.  Although there was still no difference in cecal 
colonization on day 2 PC, a significant difference (p-value = 0.01562) between the WT strain and 
the $spaS$ssaU strain was observed, with the WT strain outnumbering the mutant.  Results of 
previous trials undertaken by our group established that insertion of an antibiotic marker alone in 
the chromosome did not affect the performance of strains compared to the WT (data not shown).  
Therefore, the  results  seen  in this  trial  are  due  only  to  the introduced  mutations, and not the  
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Figure 3.2  Detection of SseB in the pellet and total membrane fraction 
 
The pellet and total membrane fractions of all strains shown in this figure were subjected to 
Western blot analysis to detect SseB and DnaK using specific antibodies.  Panel A shows both 
DnaK and SseB detected in the pellet fraction and panel B displays the same proteins detected in 
the total membrane fraction.  Lanes are as follows: M – Marker, 1 – WT Sal18, 2 – WT Sal18 
attTn7::cat, 3 – WT Sal18 attTn7::tet, 4 – Sal18 !SPI-2, 5 – Sal18 !SPI-2::cat, 6 – Sal18 
attTn7::cat !spaS!ssaU, and 7 – Sal18 !SPI-1!SPI-2::cat.  
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Figure 3.3  Co-challenge trial:  Recovery of Salmonella from liver, spleen, and cecum  
 
Panel A shows the calculated CFU/g for recovered bacteria in the liver, spleen and cecum of 
birds challenged with WT Sal18 attTn7::cat and WT Sal18 attTn7::tet on days 1, 2, and 4 PC.  
Panel B shows the calculated CFU/g in the liver, spleen and cecum of birds challenged with WT 
Sal18 attTn7::tet and Sal18 attTn7::cat !spaS!ssaU on days 1, 2, and 4 PC and Panel C shows 
the calculated CFU/g in the liver, spleen and cecum of birds challenged with WT Sal18 
attTn7::tet and Sal18 !SPI-1!SPI-2::cat on days 1, 2, and 4 PC. We cannot detect Salmonella 
counts below 101 CFU/g by direct plating with our sampling method.  A dotted line has been 
placed indicating this, and birds negative for countable CFU after direct plating on BG agar were 
assigned a value of 1 for graphical purposes.  *, p-value < 0.05; **, p-value < 0.01; ***, p-value 
< 0.001.  
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introduction of different antibiotic markers.  A significant difference was also observed (p-value 
= 0.03125) on day 2 PC between the WT strain and the $SPI-1$SPI-2 strain, again with the WT 
strain higher in colonization levels.  By day 4 we saw a trend towards clearance of the mutant 
strain in the liver and spleen, with 100% of the recovered colonies at this point belonging to the 
WT strain (Figure 3.4).  Although strains were mixed equally before challenge, only one strain 
was recovered from spleens of the group that received the WT strain and the !spaS!ssaU strains 
after enrichment. This is likely a result of the poor recovery rate of Salmonella on BG agar as 
well as the small amount of sample used for enrichment (1 ml out of 10 ml total), as prior to 
enrichment both strains were found in the spleen (Figure 3.3, panel C). 
 
3.3.3 Single-challenge trial 
The single-challenge trial was carried out as described in materials and methods.  CFU/g 
were determined for Salmonella isolated from liver, spleen and cecum of all birds (Figure 3.5).  
Samples were also enriched in selenite broth to identify samples with numbers of Salmonella too 
low to be detected by direct plating (Figure 3.6).  One-way ANOVA Kruskal-Wallis tests were 
performed on the CFU/g data of the liver, spleen, and cecum.  Chi-square Fisher’s exact test was 
performed on the positive/negative results in order to determine if there were significant 
differences between the colonization levels of each strain on days 1, 2, 3, and 4 PC.  On day 1 
PC, no significant difference was observed between the CFU/g of the WT strain and either of the 
mutant strains.  There was, however, a statistically significant difference in the number of birds 
that tested positive for Salmonella in the liver between the WT strain and the $SPI-2 strain (p-
value = 0.0198), as well as between the WT strain and the $SPI-1$SPI-2 strain (p-value = 
0.0011).  In both cases, the number of birds positive for Salmonella was higher in the group 
challenged with the WT strain as opposed to the groups challenged with the mutant strains.  On 
day 2 PC, we saw a significant difference in the cecal CFU/g between the group challenged with 
the WT strain and the group challenged with the $SPI-2 strain (p-value = 0.0111).  The same was 
observed in the liver (p-value = 0.0001) and the spleen (p-value = 0.0108).  The number of birds 
positive for Salmonella after enrichment coincides with this data, showing a higher number of 
birds with livers testing positive in the WT group versus the $SPI-2 group (p-value = 0.0001).  
The same was observed in the spleen (p-value = 0.0198).  There was also a significant difference 
between the CFU/g of the WT group versus the $SPI-1$SPI-2 group in both the liver (p-value =  
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Figure 3.4  Co-challenge trial:  Strain distribution in liver, spleen, and cecum 
 
Panel A shows the type of Salmonella colonies found in the liver on Days 1, 2, and 4 PC with 
equal amounts of either: WT Sal18 attTn7::tet and WT Sal18 attTn7::cat (left 3 bars),  WT Sal18 
attTn7::tet and Sal18 attTn7::cat &spaS&ssaU (middle 3 bars) or WT Sal18 attTn7::tet and Sal18 
&SPI-1&SPI-2::cat  (right 3 bars).  Panels B and C have the same data arrangement, but depict 
the colonization profiles of the spleen and cecum, respectively.  
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Figure 3.5  Single-challenge trial:  Recovery of Salmonella from liver, spleen, and cecum 
 
Panel A shows the calculated CFU/g in the livers of birds challenged with either WT Sal18 
attTn7::tet, Sal18 $SPI-2::cat or Sal18 $SPI-1$SPI-2::cat on days 1, 2, 3, and 4 PC.  Panels B 
and C show the CFU/g in the spleen and cecum of birds. We cannot detect Salmonella counts 
below 101 CFU/g by direct plating with our sampling method and a dotted line has been placed 
indicating this.  Birds negative for countable CFU after direct plating on BG agar were assigned a 
value of 1 for graphical purposes.  *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001. !  
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Figure 3.6  Single-challenge trial:  Colonization levels after enrichment 
 
Panel A depicts the number of birds positive or negative for the challenge strain in the liver on 
days 1, 2, 3, and 4 PC, while Panel B depicts the number of birds positive or negative for the 
challenge strain in the spleen.  *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001.  
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0.0001) and the spleen (p-value = 0.0108).  Again, enrichment data supports this observation, 
showing a higher number of birds with livers and spleens testing positive in the WT group than 
those in the $SPI-1$SPI-2 group (p-value = 0.0011 and 0.0198, respectively).  Based on either 
CFU/g or enrichment data, no significant differences between the strains were observed on days 
3 and 4 PC. 
 
3.4 Discussion 
Prior to this study, no knockout mutants of the complete SPI-2 region in S. Enteritidis had 
been reported.  However, some recent work by Rychlik et al. [314], published after completion of 
our animal trials, describes the complete knock out of all the SPI regions, both together and 
separately, and their effect on S. Enteritidis colonization of 1-day-old chicks.  In addition, at least 
partial deletions of SPI-2 have been produced in S. Typhimurium, as well as full deletions of SPI-
1 [308, 315, 316].  Using the %Red system, developed by Datsenko and Wanner [307], derivative 
strains of WT Sal18 missing either one or both of the entire SPI-1 and SPI-2 regions (Sal18 
$SPI-2::cat and Sal18 $SPI-1$SPI-2::cat) were constructed. 
A previous study testing colonization levels of one-week-old chickens challenged with S. 
Enteritidis strain 1009 on days 7, 14, 28, 35, and 42 PC showed maximal colonization levels of 
spleen and cecum on day 7 [217].  Sadeyen et al. [317] observed similar results when working 
with 30-week-old chickens challenged with the same bacterial strain.  Another study testing layer 
hens challenged with S. Enteritidis Y-24 PT4 showed that the highest colonization in cecum was 
achieved on days 3 and 4 PC [318].  As the maximum colonization in these studies happened 
within the first week, we believed that it was important to monitor the window between days 1 
and 7 PC.  In preliminary trials (data not shown), it was found that by days 3 and 4 PC the WT 
strain Sal18 was beginning to clear from the liver, spleen, and cecum of the chickens.  Therefore, 
days 1, 2, 3, and 4 PC were chosen for further trials.  The challenge dose used in these studies is 
quite high, at 1010 CFU, compared to similar studies, which tend to range from 104 CFU to 108 
CFU [213, 217, 317, 319].  However, preliminary experiments done by our group (data not 
shown) involving the challenge of 21-day-old Broiler chickens and challenge of 1-day-old SPF 
chicks with 106, 108, and 1010 CFU of WT S. Enteritidis strain Sal18 indicated that oral challenge 
with 1010 CFU of our strain yields the best colonization levels of liver and spleen, while cecal 
colonization levels remain the same at all doses. 
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The results of the co-challenge trial show that when 35-day-old SPF chickens are 
challenged with both a WT strain and a strain impaired in both the SPI-1 and SPI-2 T3SSs, the 
WT strain begins to out-compete the mutant strain in the liver and spleen by day 2 PC (Figure 
3.3, panels B and C).  However, there is no detectable difference in the level of WT versus 
mutant strain in the cecal contents (Figure 3.3, panels B and C).  Dieye et al. [315] used a similar 
experimental design in a recent study comparing colonization levels of WT S. Typhimurium UK-
1 and either a !SPI-1 strain missing the entire SPI-1 region, a !SPI-2 strain missing a portion of 
the SPI-2 region encoding structural genes, or a combination !SPI-1!SPI-2 strain.  In this study, 
1-week-old SPF chickens were co-challenged with different combinations of the above strains, 
and chickens were euthanized at days 3, 7, and 14 PC to test colonization levels in the spleen and 
cecum.  Similar to our findings, this group recovered a greater amount of the WT S. 
Typhimurium strain from the spleen than the !SPI-2 and !SPI-1!SPI-2 strains.  They also 
observed that colonization levels of the WT versus the mutant strains in the cecum were not 
different, again supporting our results. 
The spaS and ssaU genes encode structural proteins of the SPI-1 and SPI-2 T3SSs, 
respectively. The spaS gene is last in the inv-spa operon of the SPI-1 while the ssaU gene is 
likewise positioned at the end of the ssaK-U operon of SPI-2.  Deletion of the spaS and ssaU 
genes should stop the secretion of both SPI-1 and SPI-2 secreted proteins, but should not affect 
transcription of other genes in the SPI-1 or SPI-2 regions, or elsewhere in the chromosome [1, 52, 
70, 303, 304].  Our study comparing the !spaS!ssaU mutant strain with the !SPI-1!SPI-2 strain 
in vivo shows that the strain with only the two genes deleted behaves similarly to the strain 
missing the entirety of both islands when given as a co-challenge with a WT strain. 
The results of the single-challenge trial indicate that strains missing either the SPI-2 or 
both the SPI-1 and SPI-2 regions are impaired in their ability to infect the liver and spleen of SPF 
chickens.  On day 1 PC, both the WT and mutant strains begin to spread systemically to organs 
(liver and spleen), but while the WT strain reaches peak colonization of the liver and spleen by 
day 2 PC, and is beginning to clear by day 3 PC, the mutant strains do not reach their peak until 
day 3 PC.  By day 4, both the WT and mutant strains are clearing from the birds (Figures 4.5 and 
4.6).  Bohez et al. [319] observed that peak presence of Salmonella in liver and spleen of SPF 
birds challenged with 108 CFU S. Enteritidis on the day of hatching occurred on day 2, 
supporting our observations.  A further study by Jones et al. [304] found that when SPF chickens 
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were challenged at 1 week of age with S. Typhimurium F98, there was a peak colonization of the 
liver and cecum at 3 days PC.  When challenged with a derivative strain of S. Typhimurium F98, 
impaired in the SPI-1 region ($spaS), peak colonization was again observed 3 days PC, but 
seemed to have cleared faster in the liver and spleen.  In chickens receiving a strain impaired in 
the SPI-2 region ($ssaU), systemic infection was not observed and clearance of the strain from 
the cecum was evident by day 7 PC.  This is partly in accordance with our results presented here.  
Our observations indicate that mutant strains are cleared faster from the liver and spleen than the 
WT strain.  However, we did not see the difference in cecal colonization between WT and mutant 
strains that was observed by Jones et al. [304].  This may be attributed to differences in strain, as 
their studies used an isolate of S. Typhimurium while our studies used S. Enteritidis, or 
differences in challenge dose. 
As mentioned, we have indicated that the SPI-2 T3SS is not important for cecal 
colonization, and while the SPI-2 T3SS does appear to be important for efficient systemic 
infection, it is obviously not the only factor involved.   These observations are in line with the 
results of another group that found that neither the SPI-1 nor the SPI-2 T3SS of a S. 
Typhimurium strain were essential to the invasion of M cells in vitro.  Their studies used an in 
vitro model involving the co-culture of Caco-2 cells with Raji B cells (which causes the Caco-2 
cells to exhibit traits of M cells), in order to better mimic the intestinal environment that 
Salmonella encounters in the human host [320].  Another group using an in vitro model found 
that while the SPI-2 T3SS was expressed at all times within the SCV of mouse macrophage cells, 
the expression level in the SCV of human epithelial cells were reduced compared to those in the 
macrophages [300].  This further supports our conclusion that SPI-2 is important for systemic 
infection in chickens, but not essential for cecal colonization. 
A recent study by Rychlik et al. [314] used S. Enteritidis strain 147 SPI mutants missing 
one of the islands (SPI-1, 2, 3, 4, or 5), missing both SPI-1 and SPI-2, missing all islands (SPI-1 
to 5), retaining one of the islands only (SPI-1, 2, 3, 4, or 5) or retaining both SPI-1 and SPI-2 
only, to test the ability of these mutants, in comparison to the WT strain, to colonize the liver and 
spleen of 1-day-old chicks.  They found that after oral challenge with 5 X 107 CFU, the strains 
missing either SPI-1 or SPI-2 and the strains containing only SPI-1 or SPI-2 maintained a 
medium level of virulence and were still found in the liver and spleen of challenged chicks both 5 
and 7 days PC, although in less abundance than the WT strain.  However, the strain missing all of 
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the pathogenicity islands (SPI-1 to 5) and those containing only one of SPI-3, SPI-4, or SPI-5 
were avirulent and only very small amounts were isolated from the liver and spleen.  Those 
strains missing SPI-3, SPI-4, or SPI-5 were isolated from the liver and spleen at the same levels 
as the WT strain.  They also found that the strain missing both SPI-1 and SPI-2 was isolated from 
the liver and spleen at lower levels than the WT strain, or the strain containing only the SPI-1 and 
SPI-2 regions.  Their study not only demonstrates the importance of both SPI-1 and SPI-2 in 
colonization of the liver and spleen, but also shows that mutants missing one of or both SPI-1 and 
SPI-2 can still be isolated from the liver and spleen, although at much lower levels than WT, 
further confirming our results.  They found no difference in cecal colonization by any of their 
strains, also in accordance with our results. 
A study by Morgan et al. in 2004 [42] involved screening a large number of S. 
Typhimurium mutants, including several single gene knockouts in the SPI-1 and SPI-2 regions.  
They found that their SPI-1 and SPI-2 mutants were not effective colonizers of bovine ileum 
between 3 and 5 days PC.  At first glance, these results seem contrary to our findings.  However, 
this group also found that the majority of the SPI-1 and SPI-2 mutants tested were able to 
successfully colonize the cecum of 14-day-old chickens.  They also tested a number of other 
mutants including single-gene knockouts of certain surface structures and found that while many 
of these mutants were equivalent to the WT strain in their ability to colonize cattle, they were 
attenuated in chickens.  In addition, they observed that mutations of the SPI-4 region caused 
attenuation in cattle, but not in chickens, further demonstrating that Salmonella must use different 
approaches for colonization or infection of different hosts.  This is not surprising as S. 
Typhimurium causes systemic disease in cattle, but does not cause disease in chickens older than 
1 week of age.  Although S. Typhimurium and S. Enteritidis are considered to be distinct 
serovars, they are very close genetically and can cause similar disease in humans.  The fact that 
Morgan’s group found no difference in the ability of their WT strain and their SPI-1 and SPI-2 
mutant strains to colonize chicken ceca corresponds to our results with S. Enteritidis in both 7-
day-old and 35-day-old chickens, and validates our finding that the SPI-2 T3SS is not essential 
for colonization of chickens.  As well, their observations that deletions of certain fimbrial and 
other structural genes caused attenuation of their S. Typhimurium strain in chickens may be the 
answer to how S. Typhimurium and S. Enteritidis colonize chickens without the use of the SPI-1 
and SPI-2 T3SSs.  Further work must be done in this area to determine the exact mechanisms by 
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which S. Typhimurium and S. Enteritidis colonize the chicken cecum and spread systemically in 
these animals. 
In summary, the results of our studies indicate that in a co-challenge situation in 35-day-
old chickens, the WT strains of S. Enteritidis are more competitive than strains impaired in the 
SPI-1 and SPI-2 regions.  As well, we have shown that in a single-challenge model in 1-week-old 
chicks, mutants missing either the SPI-2 region or both the SPI-1 and SPI-2 regions are initially 
impaired in their ability to invade the liver and spleen compared to the WT strain, but remain 
present in the cecum at similar levels to the WT strain.  
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4.0 IMMUNIZATION OF CHICKENS WITH S. ENTERITIDIS PATHOGENICITY 
ISLAND 2 TYPE III SECRETION SYSTEM STRUCTURAL AND EFFECTOR 
COMPONENTS 
 
The information presented in this chapter is currently ‘in press’ for publication in 
Veterinary Microbiology [321]. 
 
4.1 Introduction 
Infections by Salmonella are one of the leading causes of food poisoning in humans [21].  
Salmonella is transmitted to humans via consumption of contaminated poultry meat, water or 
eggs.  Salmonella enterica subspecies enterica serovar Enteritidis (S. Enteritidis) is the most 
commonly isolated serovar in the European Union (EU), and second most common in North 
America.  S. Enteritidis consequently places a significant burden on the health care system and 
the poultry industry [18, 19, 27-29]. 
Because chickens do not generally exhibit symptoms of disease, flocks can become 
colonized quickly, resulting in bacteria being shed in their feces for extended periods of time [23, 
25, 26].  Thus, the demand for a vaccine protecting poultry against S. Enteritidis and S. 
Typhimurium is high.  Although there have been previous successes in this area using live 
attenuated strains of host-adapted Salmonella, there has been far less success in achieving a 
protective vaccine against the non host-adapted strains of Salmonella, such as S. Enteritidis and 
serovar Typhimurium (S. Typhimurium) [15, 16, 25].  The use of probiotics and competitive 
exclusion to reduce initial colonization of chicks by S. Enteritidis and S. Typhimurium has also 
had limited success [322, 323].   To date, only a small number of studies have investigated the 
suitability of subunit vaccines for protection of poultry against Salmonella [265, 266, 269]. 
The focus of this study was to determine if vaccination of chickens with Salmonella 
pathogenicity island 2 (SPI-2) type III secretion system (T3SS) components could elicit a 
humoral immune response while conferring protection against experimental challenge with S. 
Enteritidis [285].  The SPI-2 T3SS is one of two T3SSs that Salmonella uses to invade and 
survive within the host.  Both T3SSs are expressed prior to entry into the host cell, although the 
SPI-1 T3SS is expressed in greater amounts [284], and, as they are exposed to the hosts immune 
system, are potential vaccine candidates.  This study also sought to determine whether vaccinated 
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hens could transfer protective antibodies to progeny.  The ability of SPI-2 T3SS components to 
elicit a strong humoral response in chickens that can be transferred to progeny, as well as their 
ability to slightly lower overall bacterial loads per bird in certain situations, may make these 
components a valuable addition to a combination subunit vaccine. 
 
4.2 Materials and methods 
 
4.2.1 Bacterial strains 
Bacterial strains used in this study were !"!/0123"1"4"5 strains Sal18 and Sal8 (Table 3.1).  
Sal18 was chosen as the challenge strain in vaccine trial 1 as it has been shown to be virulent for 
birds, and invades the liver and spleen as well as colonizes the gut.  Sal8 was chosen for the 
subsequent vaccine trials (2a, 2b, 2c, and 3) as our group found that Sal8 reaches the liver and 
spleen of more birds than Sal18 (100% of birds positive for Sal8 in the liver and/or spleen 
compared to 60% positive with Sal18) (unpublished data). 
With respect to culturing bacteria, standard procedures were followed using Luria-Bertani 
(LB) broth and agar, and Brilliant Green (BG) agar at 37°C.  Media was supplemented with 100 
or 50 µg/ml ampicillin, 10 or 5 µg/ml tetracycline, or 30 or 9 µg/ml chloramphenicol when called 
for.  All antibiotics were obtained from Sigma-Aldritch. 
 
4.2.2 Passage of Salmonella strains 
Strains of interest were passaged in chickens as previously described in section 4.2.10. 
 
4.2.3 Recovery of Salmonella on Brilliant Green agar 
All strains used in the trials below were first subjected to plating on BG agar, as well as 
LB agar with and without antibiotics to determine plating efficiency and strain fitness as 
described in section 4.2.11. 
 
4.2.4 Protein expression and purification 
Genes of potential vaccine candidates were cloned according to standard procedures.  
Proteins were expressed and purified as described previously [312].  Bacterial strains, plasmids, 
and primers used for this purpose are listed in Tables 3.1, 3.2, and 3.3, respectively.  
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4.2.5 Animal handling and treatment 
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use. 
 
4.2.6 Vaccination of chickens 
Specific pathogen free (SPF) chicken eggs were obtained from Charles River 
Laboratories, Inc (US).  Eggs were incubated for 21 days until hatch at the Department of Poultry 
Science (University of Saskatchewan).  After hatching, the chicks remained at the Department of 
Poultry Science, but were transferred to off-the-ground wire cages.  Swabs were taken from the 
birds and around their environment throughout the trial and were plated on BG agar to test for the 
presence of Salmonella.  Shortly before challenge, the birds were transferred to an isolation room 
at the Vaccine and Infectious Disease Organization (VIDO).  These chickens were used for 
vaccine trial 1. 
 
4.2.6.1 Vaccine trial 1 
Chickens were separated into three groups of 30 birds each, and injected with phosphate 
buffered saline (PBS), SPI-1 proteins (PrgI and SipD), or SPI-2 proteins (SseB and SseD).  
Components used for vaccination were formulated to be 100 µg total protein in 0.5 ml PBS with 
30% emulsigen D, and delivered subcutaneously.  Groups were vaccinated on days 14 (primary 
vaccination) and 27 (secondary vaccination/boost) of age, and challenged orally with 1010 wild-
type (WT) S. Enteritidis strain Sal18 containing a tetracycline resistance cassette [282] on day 34 
of age.  One third of each group was sacrificed on days 1, 2, and 4 post-challenge (PC). Colony 
forming units (CFU)/g were calculated for the cecum, liver and spleen of all groups, and portions 
of the liver and spleen were enriched in order to determine the total number of birds positive for 
Salmonella.  Enzyme-linked immunosorbant assay (ELISA) was used to test sera from chickens 
at trial day 27 and on days of euthanization for IgY antibody titres against vaccine components. 
Only the data from the control group and SPI-2 group will be presented here.  Data concerning 
the SPI-1 vaccinates was included in the statistical analyses, and has recently been reported 
[324]. 
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4.2.6.2 Vaccine trial 2 
Leghorn layer hens were obtained from, and housed at, the Department of Poultry Science 
(University of Saskatchewan).  Groups of ten hens were divided into five groups and received 
one of five vaccines: the negative control (PBS), the positive control vaccine (AviPro® – 
Lohmann Animal Health International), SPI-1 protein vaccine (PrgI, InvG, SopB, SipC, and 
SipD), SPI-2 structural protein vaccine (SsaC, SsaG, SseB, SseD, and SipD), or SPI-2 effector 
protein vaccine (SseI, SseL, SifA, SifB, and SipD).  A list of SPI-2 proteins and their function 
can be found in Table 1.3.  The SPI-1 T3SS translocon protein SipD was added to each of the 
multi-protein vaccines.  As previously reported by our group, serum containing SipD specific 
antibodies inhibits the invasion of Salmonella into Caco-2 cells, making it a promising vaccine 
candidate [325].  Three vaccine doses were given subcutaneously at three-week intervals.  Each 
protein component vaccination dose consisted of 100 µg total protein in 0.5 ml of PBS containing 
30% emulsigen D.  The negative control group received 0.5 ml PBS with 30% emulsigen D per 
dose, while the positive control group only received 0.25 ml per dose as suggested by the 
manufacturer.  Blood was collected at the time of each vaccination (days 0, 21, and 42), and three 
weeks after the third vaccination (day 63).  In addition, one to three eggs were collected from 
each bird on days 64, 65, and 71.  Serum was also collected at days 105, 116, and 121 of the trial.  
ELISAs were used to measure serum and egg yolk IgY antibody titres against the vaccine 
components.  Throughout the trial, swabs were taken from the hens and their environment and 
plated on BG agar to test for the presence of Salmonella.  Eggs from these hens were used in 
vaccine trials 2a, 2b, and 2c, while the hens themselves were used in vaccine trial 3.  For the 
second set of trials, 2a, 2b, and 2c, a seeder model of infection was utilized in order to better 
emulate a natural infection process in a poultry flock.  This method has been well established by 
other groups [326, 327].  Only data pertaining to the negative and positive controls, as well as the 
SPI-2 structural and effector protein vaccines will be presented here.  See figure 4.1 for a timeline 
of vaccine trials 2 and 3. 
 
4.2.6.2.1 Vaccine trial 2a 
A total number of 165 eggs set on day 71 of the trial were hatched at the Department of 
Poultry Science (University of Saskatchewan), tagged, and placed in an isolation room at VIDO.  
A total of 75% of the chicks were orally challenged (seeder chicks) with 108 CFU of WT S.   
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Figure 4.1  Timeline for vaccine trials 2 and 3 
 
The column on the left represents the trial day, the middle column shows the days hens were 
vaccinated, when eggs from vaccinated hens were set for the seeder-contact model chick trials 
(trials 2a, 2b, and 2c), and finally the vaccinated hen trial (trial 3).  See materials and methods 
section 4.2.6.2 and 4.2.6.3 for specific details pertaining to vaccine trials 2 and 3.  
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Enteritidis strain Sal8 in 0.5 ml PBS.  The remaining 25% of chicks were not challenged (contact 
chicks), but allowed to commingle with the challenged chicks.  Half of the chicks were 
euthanized  on day  2 PC  and their  livers,  spleens,  and ceca  processed to  assess the  amount of 
challenge strain present.  The remaining chicks were euthanized on day 3 PC, and processed 
identically. 
 
4.2.6.2.2 Vaccine trial 2b 
A total of 213 eggs set on trial day 84 were hatched, tagged, and placed in a VIDO 
isolation room.  This time, 60% of the chicks were seeders, while 40% were contact birds.   
Seeder chicks were orally challenged with 108 CFU of WT !"!/0123"1"4"5 strain Sal8 in 0.5 ml 
PBS.  Half of the chicks were euthanized on day 2 PC in order to process the liver, spleen, and 
cecum to assess the amount of challenge strain present.  The remaining chicks were euthanized 
on day 3 PC, and, again, the liver, spleen, and cecum were processed. 
 
4.2.6.2.3 Vaccine trial 2c 
A total of 219 eggs set on day 113 were hatched, tagged, and placed in a VIDO isolation 
room.  Only 10% of the chicks were assigned to be seeder chicks and orally challenged with 108 
CFU of WT S. Enteritidis strain Sal8 in 0.5 ml PBS, while the remaining 90% of chicks were 
contact chicks.  Again, half of the chicks were euthanized on day 2 PC and half euthanized on 
day 3 PC in order to process the liver, spleen, and cecum to assess the amount of challenge strain 
present. 
 
4.2.6.3 Vaccine trial 3 
Six hens from each vaccine group in vaccine trial 2 were chosen for this trial.  All hens 
were challenged orally with 5 X 108 CFU of WT S. Enteritidis strain Sal8 in 0.5 ml PBS.  The 
hens were euthanized on day 2 PC and liver, spleen, ovaries, blood, and cecum were processed to 
assess the amount of challenge strain present. 
 
4.2.7 Antibody isolation from egg yolks 
Egg yolk (1 ml) was diluted one in four with acidified water (pH 2.5).  The yolk and 
water mixture was mixed via nutator at room temperature for 15 minutes and frozen at -20°C. 
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After 48 hours, the mixture was thawed at room temperature and subjected to centrifugation at 
3500 x g for 30 minutes at 4°C.  The resulting supernatant was used in ELISAs to test IgY 
antibody titres. 
 
4.2.8 Enzyme–linked immunosorbant assay 
Immulon® 2HB plates (Nunc) were coated with 100 ng total of SPI-1 or SPI-2 vaccine 
components (equal parts per protein), or 100 µg of previously prepared Sal 8 bacterin for the 
AviPro group ELISAs, in 100 µl of coating buffer per well (12.5 mM Na2CO3 and 37.5 mM 
NaHCO3) and incubated overnight at 4°C.  The next day, plates were washed 6 times with double 
distilled water (ddH2O) using a mechanical plate washer.  Plates were then blocked with borate 
buffered saline containing Tween 20 and bovine serum albumin (BSA) (BBS-TB) (0.17 M 
H3BO3, 0.12 M NaCl, 1 mM EDTA, 0.05% Tween 20, 0.25% BSA) for 30 minutes at room 
temperature.  The plates were washed as previously, and BBS-TB was added at 100 µl per well, 
except for the first set of wells, which received serum samples in BBS-TB at a dilution of 1/40 in 
130 µl total.  An amount of 33.3 µl from the first set of wells was transferred to the next set of 
wells, mixed, and four fold dilutions performed similarly in subsequent wells.  Plates were 
incubated for 30 minutes at room temperature, washed, and blocked with BBS-TB (50 µl per 
well) for 10 minutes at room temperature prior to another wash step and addition of secondary 
antibody (horse radish peroxidase labeled goat anti-chicken IgG supplied by KPL) at a dilution of 
1/1000, at 50 µl per well.  Plates were incubated with the secondary antibody for 30 minutes at 
room temperature, washed as previous, and blocked again with BBS-TB at 50 µl per well for 30 
minutes at room temperature.  Plates were washed, and substrate was added at 75 µl per well 
(ABTS [2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)] peroxidase substrate – KPL), 
following a final wash step.  After a 15 minute incubation at room temperature, the reaction was 
stopped by adding 75 µl per well of ABTS peroxidase stop solution (KPL) diluted one in five in 
ddH2O and absorbance was read using a plate reader (Bio-Rad) at a wavelength of 405 nm (with 
a reference wavelength of 490 nm). 
 
4.2.9 Statistical analysis 
All statistical analyses were performed using GraphPad Prism® 5.0 for Mac OS X.  For 
vaccine trial 1, a one-way ANOVA Kruskal-Wallis test was performed on the ELISA data, as 
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well as the CFU/g data obtained from liver, spleen, and cecum of birds, followed by Dunn’s 
multiple comparison test if significance was observed.  Enrichment data was subject to the chi-
square test.  For vaccine trial 2, ELISA data were ranked (using Microsoft® ExcelTM) within day 
of sample procurement, and two-tailed t-tests were performed.  The CFU/g data was also ranked 
within day of sample acquisition.  Ranked data was then subject to one-way ANOVA (including 
Bartlett’s test for equal variance), and followed with Dunnett’s multiple comparison test if 
significance was found.  Enrichment data was subject to the chi-square test.  A p-value < 0.05 
was considered significant. 
 
4.3 Results 
 
4.3.1 Vaccine trial 1 
Sera from control animals vaccinated with PBS, and those vaccinated with the SPI-2 
protein vaccine (SseB and SseD), were tested on ELISA plates coated with the vaccine 
components (SseB and SseD).  Birds in the SPI-2 vaccine group had significantly higher IgY 
antibody serum titres than those of the control group on days 1, 2, and 4 PC (p-values < 0.05, 
0.001, and 0.01, respectively) (Figure 4.1).  Those birds vaccinated with the SPI-2 proteins were 
found to have less recoverable CFU/g of the challenge strain in their livers than those that 
received PBS on days 2 and 4 PC; however, a statistically significant difference was only 
observed on day 4 PC (p-value < 0.01) (Figure 4.2, panel A).  No statistically significant 
difference was found in the spleens and ceca of these birds (Figure 4.2, panels B and C).  After 
enrichment of samples from the liver and spleen, there was no significant difference observed 
between the numbers of birds positive for presence of the challenge strain; and by day 2 PC 
nearly 100% of the birds were positive for the challenge strain in their liver and/or spleen (Figure 
4.3). 
 
4.3.2 Vaccine trial 2 
 
4.3.2.1 Vaccination of hens 
Sera from hens that received PBS, and those vaccinated with the SPI-2 structural protein 
vaccines were tested by ELISA for SPI-2 structural component specific IgY.  Birds in the SPI-2   
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Figure 4.2  Vaccine trial 1:  Serum antibody titres specific for vaccine components 
 
IgY titres specific for SseB and SseD in sera from chickens vaccinated with SseB and SseD (") 
and control chickens that received PBS (#).  Sera were obtained before the secondary 
vaccination, and on day of euthanization (days 1, 2, and 4 PC).  *, p-value < 0.05; **, p-value < 
0.01; ***, p-value < 0.001; ****, p-value < 0.0001.  
! -*!
 
 
 
 
Figure 4.3  Vaccine trial 1:  Recovery of Salmonella from liver, spleen, and cecum 
 
Panel A shows the calculated CFU/g for recovered bacteria in the liver of chickens vaccinated 
with SseB and SseD (") and control chickens that received PBS (#) on days 1, 2, and 4 PC.  
Panels B and C show the same for spleen and cecum.  S. Enteritidis counts below 101 CFU/g 
cannot be detected by direct plating using the sampling method described here.  A dotted line 
($$$$$$) has been placed marking this detection level, and birds negative for countable CFU after 
direct plating on BG agar were assigned a value of 1 for graphical purposes.  *, p-value < 0.05; 
**, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 0.0001.  
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Figure 4.4  Vaccine trial 1:  Colonization levels after enrichment 
 
As colonization levels of the liver and spleen can often be quite low, portions of these organs 
were enriched in selenite broth to increase detection sensitivity.  The number of birds vaccinated 
with SseB and SseD that were found to be positive for presence of the challenge strain after 
enrichment are represented by black bars.  Grey bars represent those positive that received PBS.  
White bars represent birds that were negative for presence of Salmonella in both their liver and 
spleen after enrichment.  
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Figure 4.5  Vaccine trial 2:  Serum antibody titres of hens specific for vaccine components 
 
Sera were collected before vaccination (day 0), on the days of secondary and tertiary vaccination 
(days 21 and 42, respectively) and 3 weeks after the tertiary vaccination (day 63).  Panel A 
shows the IgY titres specific for vaccine components in sera from chickens vaccinated with SPI-2 
T3SS structural proteins ($) compared to control chickens vaccinated with PBS (#).  Panels B 
and C depict the same, but for birds vaccinated with SPI-2 T3SS effector proteins (') or the 
AviPro® vaccine (!) compared to control chickens vaccinated with PBS (#).  *, p-value < 0.05; 
**, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 0.0001.  
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structural vaccine group had significantly higher IgY antibody serum titres than those of the 
control group after vaccination on day 21 (secondary vaccination), day 42 (tertiary vaccination), 
and day 63 (3 weeks after tertiary vaccination) (p-values < 0.0001) (Figure 4.4, panel A).  The 
same  was   observed  for  hens   vaccinated  with   SPI-2  effector   proteins   compared  to  those 
vaccinated with PBS (p-values < 0.0001 on days 21, 42, and 63) (Figure 4.4, panel B).  Those 
receiving the AviPro® vaccine also had higher serum IgY antibody titres than control birds (p-
values < 0.0001 on days 21, 42, and 63) (Figure 4.4, panel C).  On day 0 (day of first vaccination 
and start of the trial), all vaccinate groups had similar serum IgY levels to the control group 
(PBS), however the group that received the SPI-2 structural vaccine had slightly lower serum IgY 
levels than the control group (p-value = 0.0403) (Figure 4.4). 
 
4.3.2.2 Maternal transfer of antibodies to eggs 
Serum in sufficient quantity for analysis by ELISA is quite difficult to obtain from chicks 
as the process places an extreme amount of stress on them, causing increased mortality.  In order 
to determine whether IgY antibodies specific to the vaccines given to the hens were transferred to 
the progeny, eggs were collected on trial days 64, 65, and 71.  Egg yolks were processed and 
analyzed for IgY antibodies specific to the vaccine the hen had received.  All eggs collected from 
hens that received the SPI-2 structural protein vaccine had significantly higher egg yolk IgY 
antibody titres than those from hens that received PBS (p-values < 0.0001 for eggs collected on 
days 64, 65, and 71) (Figure 4.5, panel A).  Similarly, eggs collected from hens vaccinated with 
the SPI-2 effector vaccine had IgY antibody titres significantly higher than those from hens 
vaccinated with PBS (p-values < 0.0001 on days 64, 65, and 71) (Figure 4.5, panel B).  Eggs 
collected from hens that had received the AviPro® vaccine had higher IgY antibody titres than 
the control group on all days as well (p-values < 0.0001 for eggs collected on days 64, 65, and 
71) (Figure 4.5, panel C). 
 
4.3.2.3 Vaccine trial 2a 
In vaccine trial 2a, 75% of the progeny were orally challenged with Sal8 (seeder birds) 
while the 25% that were unchallenged remained in contact with the seeder birds (contact birds).  
Seeder birds whose mothers had been administered the SPI-2 structural or SPI-2 effector vaccine 
had significantly higher recoverable CFU/g of the challenge strain in their liver on day 3 PC (p-   
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Figure 4.6  Vaccine trial 2:  Egg yolk antibody titres specific for vaccine components 
 
Eggs from vaccinated hens were collected on days 64, 65, and 71.  Panel A shows the IgY titres 
specific for vaccine components in egg yolks from eggs collected from hens vaccinated with SPI-
2 T3SS structural proteins ($) compared to control chickens that received PBS (#).  Panels B 
and C depict the same, but for eggs from birds vaccinated with SPI-2 T3SS effector proteins (') 
or the AviPro® vaccine (!) compared to control chickens that received PBS (#).  *, p-value < 
0.05; **, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 0.0001.  
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Figure 4.7  Vaccine trial 2a:  Recovery of Salmonella from liver, spleen, and cecum of 
progeny 
 
In vaccine trial 2a, 75% of progeny were challenged on the day after hatch (seeder birds) while 
25% of progeny remained unchallenged (contact birds), but were allowed to commingle with the 
seeder birds.  Panel A shows the calculated CFU/g for recovered bacteria in the liver, spleen, and 
cecum of seeder birds on days 2 and 3 PC.  #, chicks whose mothers received with PBS; $, 
chicks whose mothers were vaccinated with SPI-2 T3SS structural proteins; ', chicks whose 
mothers were vaccinated with SPI-2 T3SS effector proteins; !, chicks whose mothers were 
vaccinated with the AviPro® vaccine. Panel B shows the same for contact birds.  S. Enteritidis 
counts below 101 CFU/g cannot be detected by direct plating using the sampling method 
described here.  A dotted line ($$$$$$) has been placed marking this detection level, and birds 
negative for countable CFU after direct plating on BG agar were assigned a value of 1 for 
graphical purposes.  *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 
0.0001.  
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values < 0.01 and < 0.001 respectively) (Figure 4.6, panel A).  A similar trend was also observed 
in the spleens of these birds (p-value < 0.001 for both groups on both days 2 and 3 PC).  There 
was,  however, no  difference in  bacterial cecal  load in any of the seeder  birds from  these  same 
groups.  Seeder birds whose mothers had received the AviPro® vaccine had similar bacterial 
loads in the liver to the control group, but significantly lower levels in the spleen on day 2 and 3  
PC (p-values < 0.01), as well as lower loads in the cecum on day 3 PC (p-value < 0.01) (Figure 
4.6, panel A).  Birds in the AviPro® group were the only ones who had members of the group 
negative for recovery of challenge strain in the spleen; however, upon enrichment, all birds were 
found to be positive for the challenge strain in their liver and/or spleen (data not shown). 
Contact birds had similar bacterial loads across all groups in the liver and cecum, but the 
trend in the spleen was similar to those of the seeder birds (Figure 4.6, panel B).  Contact birds 
whose mothers had received either the SPI-2 structural or SPI-2 effector vaccine had higher 
levels of challenge strain in their spleens on both days 2 and 3 PC, although the results were only 
statistically significant for the SPI-2 effector group (p-values < 0.001).  Contact birds whose 
mothers had been given the AviPro® vaccine had similar bacterial loads to the control group in 
the liver and cecum, but lower loads in the spleen on day 2 PC (p-value < 0.05) (Figure 4.6, panel 
B).  Again, this group was the only one that had birds negative for recovery of the challenge 
strain.  However, upon enrichment of samples, all birds were found to be positive for Salmonella 
in their liver and/or spleen (data not shown). 
 
4.3.2.4 Vaccine trial 2b 
For vaccine trial 2b, 60% of the progeny were challenged with Sal8 (seeder birds) while 
40% remained unchallenged, but in contact with the seeder birds (contact birds).  This time, 
seeder birds whose mothers had been administered the SPI-2 structural or SPI-2 effector vaccine 
had significantly lower recoverable CFU/g of the challenge strain in their liver on day 2 PC (p-
values < 0.01 and < 0.05 respectively) and day 3 PC (p-values < 0.001 and < 0.01 respectively) 
(Figure 4.7, panel A).  There was no difference between levels of bacteria in the liver between the 
AviPro® group and the control group.  Spleens of the seeder birds in the SPI-2 vaccinate groups 
showed a similar trend (p-value < 0.001 for the SPI-2 structural group on both days 2 and 3 PC, 
and p-values of < 0.01 on day 2 PC and < 0.001 on day 3 PC for the SPI-2 effector group).  A 
difference between the levels of bacteria recovered from the spleens of the AviPro® group and  
! %.'!
 
 
 
 
Figure 4.8  Vaccine trial 2b:  Recovery of Salmonella from liver, spleen, and cecum of 
progeny 
 
In vaccine trial 2b, 60% of progeny were challenged on the day after hatch (seeder birds) while 
40% of progeny remained unchallenged (contact birds), but were allowed to commingle with the 
seeder birds.  Panel A shows the calculated CFU/g for recovered bacteria in the liver, spleen, and 
cecum of seeder birds on days 2 and 3 PC.  #, chicks whose mothers received PBS; $, chicks 
whose mothers were vaccinated with SPI-2 T3SS structural proteins; ', chicks whose mothers 
were vaccinated with SPI-2 T3SS effector proteins; !, chicks whose mothers were vaccinated 
with the AviPro® vaccine. Panel B shows the same for contact birds.  S. Enteritidis counts below 
101 CFU/g cannot be detected by direct plating using the sampling method described here.  A 
dotted line ($$$$$$) has been placed marking this detection level, and birds negative for countable 
CFU after direct plating on BG agar were assigned a value of 1 for graphical purposes.  *, p-
value < 0.05; **, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 0.0001.  
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the control group was also observed, with bacterial loads being lower in the AviPro® group on 
days 2 (p-value < 0.001) and 3 PC (p-value < 0.05).  Although there was no difference in 
bacterial cecal load in any of the seeder birds from the SPI-2 structural or effector groups, those  
in the AviPro® group had slightly lower cecal loads on day 3 PC (p-value < 0.05) (Figure 4.7, 
panel A).  Upon enrichment, all birds were found to be positive for the challenge strain in their 
liver and/or spleen (data not shown). 
When the contact birds were examined, those whose mothers had received either the SPI-
2 structural or AviPro® vaccine had lower levels of challenge strain in their liver on day 2 PC (p-
value < 0.01 and < 0.001, respectively) (Figure 4.7, panel B).  Results for the spleens match those 
of the livers.  All groups had a statistically significant reduction in bacterial loads on days 2 and 3 
PC (SPI-2 structural p-values < 0.001 on both days PC, SPI-2 effector p-values < 0.01 on day 2 
PC and < 0.001 on day 3 PC, and AviPro® p-values < 0.001 on both days PC).  On day 2 PC, all 
contact birds had similar bacterial loads in their ceca, while one day 3 PC, birds whose mothers 
had been given the SPI-2 effector or AviPro® vaccine had lower loads in their ceca than the 
control group (p-values < 0.01) (Figure 4.7, panel B).  Only contact birds whose mothers had 
received AviPro® were found to be negative for recovery of the challenge strain in the spleen.  
However, upon enrichment of samples, all birds were again found to be positive for Salmonella 
in their liver and/or spleen (data not shown). 
 
4.3.2.5 Vaccine trial 2c 
In order to better simulate the infection situation in the field, in vaccine trial 2c only 10% 
of the progeny were challenged with Sal8 (seeder birds) while 90% remained unchallenged, but 
in contact with the seeder birds (contact birds).  As such a low number (two per group) of birds 
were challenged, statistics could not be performed on the seeder group.  However, it appears that 
seeder birds whose mothers had been vaccinated with SPI-2 effector proteins had higher levels of 
challenge strain in their livers on day 3 PC, while all other groups appeared to have similar loads 
to the control group on both days 2 and 3 PC (Figure 4.8, panel A).  Those whose mothers had 
been vaccinated with AviPro® were observed to have lower levels in the spleen on both days 2 
and 3 PC, while the other two groups appeared to match the control group.  There was no 
difference between any of the groups on either day in cecal bacterial loads (Figure 4.8, panel A).  
After enrichment, all birds were found to be positive for the challenge strain in their liver and/or  
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Figure 4.9  Vaccine trial 2c:  Recovery of Salmonella from liver, spleen, and cecum of 
progeny 
 
In vaccine trial 2c, only 10% of progeny were challenged on the day after hatch (seeder birds) 
while 90% of progeny remained un-challenged (contact birds), but were allowed to comingle 
with the seeder birds.  Panel A shows the calculated CFU/g for recovered bacteria in the liver, 
spleen, and cecum of seeder birds on days 2 and 3 PC.  #, chicks whose mothers received PBS; 
$, chicks whose mothers were vaccinated with SPI-2 T3SS structural proteins; ', chicks whose 
mothers were vaccinated with SPI-2 T3SS effector proteins; !, chicks whose mothers were 
vaccinated with the AviPro® vaccine. Panel B shows the same for contact birds.  S. Enteritidis 
counts below 101 CFU/g cannot be detected by direct plating using the sampling method 
described here.  A dotted line ($$$$$$) has been placed marking this detection level, and birds 
negative for countable CFU after direct plating on BG agar were assigned a value of 1 for 
graphical purposes.  *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 
0.0001.  
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spleen (data not shown). 
Contact birds whose mothers had received either the SPI-2 structural or AviPro® vaccine 
had lower levels of challenge strain in their liver than the control group on day 2 PC (p-values <  
0.05), while those in the SPI-2 structural group were similar to the control group (Figure 4.8, 
panel B).  All groups had similar levels in their livers on day 3 PC.  When the spleens of contact 
birds were examined, no difference in bacterial load between any groups was observed on day 2 
PC, while those in the AviPro® group had lower levels of challenge strain present on day 3 PC 
(p-value < 0.001).  There was no difference between any of the groups on either day in cecal 
loads (Figure 4.8, panel B).  Again, upon enrichment of samples, all birds were found to be 
positive for Salmonella in their liver and/or spleen (data not shown). 
 
4.3.3 Vaccine trial 3 
Vaccine trial 3 involved challenge of 30 of the hens from vaccine trial 2.  Vaccinated hens 
were found to have maintained higher serum IgY antibody titres specific to vaccine components 
than those of the hens that received PBS (Figure 4.9).  Those that had received the SPI-2 
structural vaccine had high titres against those components on days 105, 116, and 121 compared 
to those that received PBS (p-values = 0.0461, < 0.0001, and = 0.0002 respectively) (Figure 4.9, 
panel A).  Hens in the SPI-2 effector group had significantly higher IgY titres than those of the 
control on days 105 and 116 (p-values < 0.0001), and day 121 (p-value = 0.0077) (Figure 4.9, 
panel B).  Those hens which received the AviPro® vaccine followed the same trend as the SPI-2 
effector vaccine with statistically higher serum IgY titres observed on days 105 and 116 (p-values 
< 0.0001), and day 121 (p-value = 0.0032) (Figure 4.9, panel C).  When the levels of bacteria in 
the hens were examined, no bacteria could be isolated via direct plating from the ovaries or 
blood, while only one hen had countable levels of bacteria within its liver and spleen (Figure 
4.10, panels A and B, respectively).  Within the ceca, only those hens that had been vaccinated 
with the AviPro® vaccine had significantly lower bacterial loads (p-value < 0.001) (Figure 4.10, 
panel C).  After enrichment of liver, spleen, ovaries, and blood, three (out of six) of the hens in 
the PBS group were positive for the challenge strain, four of the hens in the SPI-2 structural 
group, two of the hens in the SPI-2 effector group, and only one of the hens in the AviPro® 
group were positive for the challenge strain in their liver and/or spleen (Figure 4.11).  There was, 
however, no statistical significance between these groups. 
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Figure 4.10  Vaccine trial 3:  Serum antibody titres of Hens specific for vaccine components 
 
Sera were collected on day 105 (9 weeks after tertiary vaccination), 116, and 121 in order 
determine if serum IgY titres specific for vaccine components remained high in vaccinated hens.  
Panel A shows the IgY titres specific for vaccine components in sera from chickens vaccinated 
with SPI-2 T3SS structural proteins ($) compared to control chickens that received PBS (#).  
Panels B and C depict the same, but for birds vaccinated with SPI-2 T3SS effector proteins (') 
or the AviPro® vaccine (!) compared to control chickens that received PBS (#).  *, p-value < 
0.05; **, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 0.0001.  
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Figure 4.11  Vaccine trial 3:  Recovery of Salmonella from liver, spleen, and cecum of hens 
 
In vaccine trial 3, hens were challenged with S. Enteritidis 11 weeks after tertiary vaccination.  
Panel A shows the calculated CFU/g for recovered bacteria in the liver on day 2 PC, while 
panels B and C show the calculated CFU/g in spleen and cecum on day 2 PC.  #, hens that 
received PBS; $, hens vaccinated with SPI-2 T3SS structural proteins; ', hens vaccinated with 
SPI-2 T3SS effector proteins; !, hens vaccinated with the AviPro® vaccine.  S. Enteritidis 
counts below 101 CFU/g cannot be detected by direct plating using the sampling method 
described here.  A dotted line ($$$$$$) has been placed marking this detection level, and birds 
negative for countable CFU after direct plating on BG agar were assigned a value of 1 for 
graphical purposes.  *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001; ****, p-value < 
0.0001.  
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Figure 4.12  Vaccine trial 3:  Colonization levels after enrichment of liver, spleen, ovaries, 
and blood 
 
As colonization levels of the liver, spleen, ovaries, and blood can often be quite low, portions of 
these samples were enriched in selenite broth to increase detection sensitivity.  The number of 
birds that had received PBS found to be positive for the presence of S. Enteritidis on day 2 PC 
after enrichment is represented by a black bar.  A checkered bar represents those positive that 
were vaccinated with SPI-2 T3SS structural proteins, a diagonally lined bar represents the 
number of positive hens that had been vaccinated with SPI-2 T3SS effector proteins, and a 
horizontally lined bar represents those positive who were vaccinated with the AviPro® vaccine.  
White bars represent birds that were negative for presence of Salmonella in their liver, spleen, 
ovaries, and blood after enrichment. 
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4.4 Discussion 
There is currently a need for a safe and efficacious vaccine that will protect poultry 
against colonization by S. Enteritidis, and thus protect humans against salmonellosis caused by S. 
Enteritidis associated with poultry meat and eggs.  This is the first study, to our knowledge, that 
has examined the potential of a vaccine containing proteins of the SPI-2 T3SS.  The focus of the 
first and third trials was to gauge whether a vaccine containing SPI-2 T3SS components could 
induce a humoral response in chickens, and confer protection against colonization of those 
chickens by S. Enteritidis.  The focus of the second set of trials was to determine if hens 
immunized with SPI-2 T3SS components could transfer a significant quantity of maternal 
antibodies to progeny, and to determine whether these transferred antibodies would have a 
protective effect on the progeny against challenge with S. Enteritidis. 
Ideally, a good vaccine should confer strong protection against both intestinal and 
systemic colonization of poultry, while not causing disease symptoms in either poultry or humans 
[14].  It is generally accepted, based mainly on evidence obtained using the mouse typhoid 
model, that a strong cell-mediated immune response is more important in clearance of Salmonella 
than a humoral immune response, although some studies have shown that the humoral immune 
response is still important.  Therefore, a good vaccine should induce both a strong cell-mediated 
and humoral immune response, both systemically and mucosally [15, 26, 206, 209].  Killed 
bacteria and subunit-based vaccines tend to elicit a good humoral immune response, but lack in 
their ability to induce a strong cell-mediated immune response.  Although live bacterial vaccines 
have an advantage in this area, as they are able to induce both strong humoral and cell-mediated 
immune responses, killed bacteria and subunit vaccines tend to be more accepted by the public, 
and have fewer human and animal health risks associated with them.  There is the possibility of 
live attenuated bacterial vaccine strains spreading from animal to animal, and even to humans, as 
well as a chance of these strains reacquiring virulence [25, 271, 328].  Therefore, the 
development of an effective killed bacteria or subunit vaccine that elicits both a strong humoral 
and cell-mediated immune response is important for reducing the spread of S. Enteritidis and S. 
Typhimurium to humans. 
While it has been stated that cell-mediated immune response is more important for 
clearance of Salmonella than a humoral immune response, most of these studies have been done 
in mice [15, 26, 329].  However, recent work has shown that passive immunization with S. 
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Typhimurium-specific antibodies can partially protect mice against virulent challenge, illustrating 
that humoral immunity can play an important role in protection from Salmonella [211].  This 
group showed that a humoral immune response cooperated with a cell-mediated immune 
response in mice infected with S. Typhimurium, inducing protective immunity against S. 
Typhimurium.  Mouse macrophages infected with S. Typhimurium that had been treated with S. 
Typhimurium-specific antibodies had similar bacterial loads as those that were not treated with S. 
Typhimurium-specific antibodies, however, mice given S. Typhimurium-specific antibodies and 
then challenged with S. Typhimurium had much lower mortality rates than those that were not 
given S. Typhimurium-specific antibodies.  This indicates the importance of both humoral and 
cell-mediated immunity in protecting against fatal infection by S. Typhimurium, even though 
actual bacterial loads may remain similar [211]. 
To date, very little work has focused on developing a protein subunit vaccine against 
Salmonella for use in poultry, although a few studies involving siderophore protein vaccines, and 
one involving fimbria have been carried out.  In one study by Kaneshige et al. [268], 30-day-old 
SPF chickens were immunized with the siderophore receptor IroN and subsequently challenged 
with S. Enteritidis.  Vaccinated chickens showed a strong serum IgY antibody response to the 
vaccine, and vaccinates had a 10% mortality rate compared to the 80% mortality rate of non-
vaccinates.  A study by Meenakshi et al. [265] in 1999 demonstrated that chickens vaccinated 
either parenterally or orally with S. Enteritidis outer membrane proteins had high serum antibody 
titres compared to non-vaccinates (similar to our results), and, upon challenge with S. Enteritidis, 
shed significantly less S. Enteritidis in their feces.  Similarly, when 9-week-old SPF chickens 
were vaccinated subcutaneously with two S. Enteritidis outer membrane proteins and challenged 
with S. Enteritidis, vaccinates had significantly lower numbers of S. Enteritidis attached to their 
intestinal mucosa [266]. Unfortunately, we did not see this decreased shedding effect with our 
protein subunit vaccines. 
To our knowledge, there has been no attempt at developing a protein subunit vaccine 
based on SPI-2 T3SS components for use in chickens.  One group has studied the potential of a 
SPI-1 T3SS effector-based vaccine in pigs challenged with S. Typhimurium [330].  This group 
found that while vaccinates had lower levels of S. Typhimurium in their ileum and colon, 
bacterial levels in the intestinal lymph nodes and mucosa were similar to non-vaccinates.  They 
also found that the lower levels of S. Typhimurium found in vaccinates was not SPI-1 specific, 
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indicating that a SPI-1 T3SS effector-based vaccine is not a viable option for protecting pigs 
against colonization by S. Typhimurium.  There has, however, been some success using T3SS 
protein based vaccines and passive immunization for protection against other species of 
pathogenic bacteria including Chlamydia, Shigella, Yersinia, Pseudomonas, and E. coli [195].  Of 
note is the first licensed vaccine based on the strategy of using T3SS components in a vaccine – 
Econiche™.  Econiche™ is protective against colonization of cattle by E. coli O157:H7 [331, 
332]. 
Taken together, the results of these studies suggest that the use of certain SPI-2 T3SS 
protein components in a subunit vaccine, in combination with other components, may be a viable 
option.  While showing mild protective effects on their own, in certain situations, these proteins 
elicit a strong humoral immune response in chickens that can be transferred maternally to 
progeny.  These results may be useful to further vaccine development for a protein subunit 
vaccine that will elicit both cell-mediated and humoral immune responses and induce protection 
of chickens against colonization by S. Enteritidis.  
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5.0 EFFECT OF THE SALMOENLLA PATHOGENICITY ISLAND 2 TYPE III 
SECRETION SYSTEM ON SALMONELLA SURVIVAL IN ACTIVATED CHICKEN 
MACROPHAGE-LIKE HD11 CELLS 
 
5.1 Introduction 
Infections by Salmonella enterica subspecies enterica are one of the leading causes of 
food borne gastroenteritis in humans [21].  Among those serovars responsible for food poisoning 
in humans, serovars Typhimurium (S. Typhimurium) and Enteritidis (S. Enteritidis) are most 
commonly isolated serovars from both humans (Figure 1.1) and animals (Figure 1.2) in many 
regions.  In North America, S. Typhimurium is the primary serovar isolated from both humans 
and animals, while S. Enteritidis is the second most common serovar isolated from humans.  The 
opposite is true for most of the European Union, with S. Enteritidis being the number one isolate 
from both humans and animals and S. Typhimurium being number two [27].  Both S. 
Typhimurium and S. Enteritidis are capable of causing systemic disease in humans, although this 
is not the normal course of infection and only occurs in very young, very old and/or 
immunocompromised individuals [184]. 
Salmonella uses two specialized type III secretion systems (T3SS) that facilitate invasion 
and survival within the host cell.  These two T3SSs are encoded within Salmonella pathogenicity 
islands 1 and 2 (SPI-1 and SPI-2) and secrete effectors into the host cell, triggering a number of 
events in the infected cell.  These events ultimately lead to the symptoms of disease.  It is the 
current view that the SPI-1 T3SS is mainly involved in invasion of the host cell, while the SPI-2 
T3SS plays a role in survival within the host cell and maintenance of the Salmonella containing 
vesicle (SCV) [59, 284, 285].  SPI-2 is a region of approximately 40 kb located at centisome 31 
in Salmonella species, and has been reported to be necessary for systemic infection, intracellular 
proliferation and survival, and maintenance of the SCV.  However, the majority of these studies 
have been performed in mice, where S. Typhimurium and S. Enteritidis produce a typhoid-like 
infection rather than gastroenteritis, and therefore may not be indicative of the course of infection 
in healthy adult humans and chickens  [55, 286-288]. 
The preferred site of invasion for Salmonella is through microfold (M) cells of the 
intestine.  M cells reside within the follicular associated epithelium that overlays the Peyer’s 
patches, have a less pronounced brush boarder, and are associated with mucous in less abundance 
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than other intestinal epithelial cells.  Once through the epithelial barrier, Salmonella are taken up 
by resident or recruited macrophages and dendritic cells [183, 189, 190, 194, 196].  An effective 
innate immune response is necessary to clear Salmonella and prevent systemic spread; recruited 
macrophages, natural killer (NK) cells and dendritic cells are paramount in this process, but in 
some cases Salmonella is able to manipulate and invade the host immune response and spread 
systemically [184, 185, 194, 333].  However, within phagocytic cells, SPI-2 effectors are secreted 
across the SCV membrane and stop the fusion of lysosomes with the SCV, thereby avoiding 
bacterial killing by defensins, cathelicidins, lysozymes, lipases, proteases, and reactive oxygen 
and nitrogen species (ROS and RNS) [178, 289, 290, 334].  T3SS effectors facilitate the 
maturation of the SCV, and can act as pro- or anti-inflammatory factors [291, 292]. 
Previously, our group found that while S. Enteritidis SPI-2 mutants were slower to 
colonize the spleens and livers of chickens, the levels of the mutant and WT were similar by day 
4 post-challenge (PC) [282].  A major mode of transport for Salmonella to systemic sites like the 
liver and spleen is likely within macrophages [335].  There is a vast array of conflicting evidence 
in the literature about the importance of the SPI-2 T3SS to the survival of S. Typhimurium and S. 
Enteritidis within macrophages. In this study, we demonstrate that in activated HD11 chicken 
macrophage-like cell line, the SPI-2 T3SS does not contribute to survival of S. Typhimurium and 
S. Enteritidis. 
 
5.2 Materials and methods 
 
5.2.1 Cloning and production of Salmonella pathogenicity island 2 mutants 
Construction of SPI-2 mutants and cloning are have been described previously in chapter 
3 [282]. 
 
5.2.2 Bacterial strains and growth conditions 
Bacterial strains used in this study are described in Table 3.1.  Standard growth 
procedures were followed using Luria-Bertani (LB) broth and agar at 37°C. 
 
5.2.3 HD11 cell line and growth conditions 
HD11 cells were kindly provided to VIDO by Dr. Kirk C. Klasing (currently Department 
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of Animal Science, University of California – Davis, Davis, CA, USA).  HD11 cells are a 
macrophage-like immortalized cell line derived from chicken bone marrow and transformed with 
the avian myelocytomatosis type MC29 virus [336].  HD11 cells were maintained at 42°C, in a 
humidified incubator (5% CO2), in RPMI 1640 media (Gibco) supplemented with 10% fetal 
bovine serum (FBS), 2 mM L-glutamine (Gibco), and 10 mM HEPES.  For all assays involving 
bacteria the was changed to RPMI 1640 containing 10% heat-inactivated FBS, 2 mM L-
glutamine, and 10 mM HEPES before cells were seeded into 24-well plates.  HD11 cells were 
used for all assays between passages 15 and 25. 
 
5.2.4 Gentamicin protection assay 
Approximately 12 hours before infection, HD11 cells were placed in RPMI 1640 (10% 
heat-inactivated FBS, 2 mM L-glutamine and 10 mM HEPES), treated with 100 ng/ml phorbol 
12-myristate 13-acetate (PMA) (Sigma-Aldrich), and seeded into 24-well cell-bind plates 
(Corning) at a concentration of 5 x 105 cells per well.  At this time growth of bacterial strains 
were started.  12 hours post-activation, HD11 cells were checked to ensure that differentiation 
was induced by PMA (Figure 5.1) and bacterial overnight cultures were sub-cultured and grown 
to an OD600 corresponding to 1 x 108 CFU/ml.  The number of viable HD11 cells was determined 
from three wells via trypan blue exclusion.  Media was removed from the cells, and bacteria (in 
pre-warmed RPMI 1640) were added to each well at a multiplicity of infection (MOI) of 25 (time 
0 h).  Serial dilutions of the bacteria were made and plated in order to confirm that each strain 
was added to the HD11 cells at a multiplicity of infection (MOI) of approximately 25.  Plates 
containing HD11 cells and bacteria were subject to centrifugation at 200 x g in a Sorvall 
benchtop centrifuge for 5 minutes at room temperature, and then placed at 42°C.  After 0.5 h, 
media containing bacteria was carefully removed from the HD11 cells, and the cells were washed 
once with PBS containing 500 µg/ml gentamicin.  RPMI 1640 containing 250 µg/ml gentamicin 
was then added to each well, and the plates were placed back at 42°C.  At each time point (0.5, 3, 
6, 12 and 24 hours post-infection [PI]), media was removed from three wells per bacterial strain 
and centrifuged at 20,800 x g in an Eppendorf benchtop microfuge for 10 minutes at 4°C.  
Sediments from this media fraction were resuspended in 0.5 ml 1% Triton X-100, and 100 µl 
portions from each sample were plated on LB-agar using 3 mm borosilicate glass beads.  Cells 
from three wells per bacterial strain were washed once with PBS, and lysed in 0.5 ml 1% Triton  
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Figure 5.1  HD11 chicken macrophage-like cells 
 
Panel A depicts HD11 cells that have not been stimulated with PMA, while Panel B shows 
HD11 cells 12 hours after stimulation with PMA.  Photographs were taken under 10X 
magnification. !  
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X-100 in PBS.  Dilution series of the cell monolayer fractions were made and 100 µl of each 
dilution (10-4, 10-3, 10-2, 10-1, 100) was plated on LB agar.  In order to confirm the effectiveness 
of the gentamicin, at the 0 h time point bacteria were also added to a culture tube containing 5 ml 
of RPMI and 5 ml of RPMI with 250 µg/ml gentamicin added.  100 µl from each tube was plated 
on LB agar at each time point.  This experiment was repeated three times, and data pooled for 
statistical analysis. 
 
5.2.5 Location of Salmonella in the media fraction 
To determine if the bacteria in the media fraction were free, or contained within detached 
HD11 cells or cell portions, 100 µl of the media fraction from the 3 h PI time point, from HD11 
cells infected with S. Typhimurium strain SL1344, were plated on LB agar for initial CFU/ml 
values.  The media fraction was then divided into two 5 ml portions in 14 ml culture tubes.  To 
one tube, 1% Triton X-100 was added in order to lyse any eukaryotic cell membranes, and the 
tubes were placed in a shaker at 37°C for 3 hours, following which a further 100 µl from each 
tube was plated on LB agar.  A portion of the initial media fraction was also subject to staining 
with Giemsa or PKH26 (Sigma-Aldrich) and viewed using a fluorescence microscope (Zeiss 
Axiovert 200M).  PKH26 is a red fluorescent dye linked to long aliphatic tails that can insert into 
lipid regions of cell membranes.  PKH26 and Giemsa staining were carried out as indicated by 
the manufacturer. 
 
5.2.6 Immunofluorescence 
Survival assays were performed in 8 well chamber slides as above; however, bacterial 
numbers were not enumerated by plating.  Instead, at each time point (0, 0.5, 3, 6, 12, and 24 
hours PI), the media fraction was collected, sedimented, and resuspended in 100 µl 0.1% EDTA 
in PBS.  The samples from the media fraction were then placed on slides using a CytoSpin 4 
centrifuge (Thermo Scientific).  Briefly, slides were placed in the CytoSpin centrifuge, and 100 
µl of FBS was added and centrifuged onto the slides at 400 x g for 3 minutes, followed by the 
addition of 100 µl of sample under the same conditions.  Slides were allowed to dry overnight, 
and fixed in ice-cold acetone for 10 minutes. After fixation, slides were washed 3 times with 
PBS, and then incubated for 0.5 hour with fluorescein-conjugated mouse anti-Salmonella IgG or 
fluorescein-conjugated rabbit anti-E. coli IgG (1/50 in PBS).  Samples were washed as before, 
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and then treated with rhodamine-conjugated goat anti-mouse IgG or rhodamine-conjugated goat 
anti-rabbit IgG (1/50 in PBS).  Samples were washed, and then treated with 0.5% Triton X-100 
for 5 minutes to permeabilize HD11 cell membranes.  Following an additional wash, goat anti-
Salmonella IgG conjugated with fluorescein or rabbit anti-E. coli IgG conjugated with 
fluorescein (1/50 in PBS) were added to the samples.  All antibodies were purchased from AbD 
Serotec.  Samples were washed, and then stained with DAPI (10 µg/ml) (Sigma-Aldrich) for 15 
minutes at room temperature.  Coverslips were added to the slides using FluorSave™ mounting 
medium (EMD chemicals INC), and all samples were viewed using the Zeiss Axiovert 200M 
microscope with a mercury vapour short-arc lamp for fluorescence.  Photographs were taken 
using the Zeiss Axiocam and were processed using Adobe© Photoshop© CS 5 for Mac OS X.  
Manipulations included cropping for space and level adjustment to reduce background noise. 
 
5.2.7 Superoxide assay 
The assay to measure superoxide production via luminometry was adapted from Thrasher 
et al. [337].  Briefly, 12 hours before the experiment, 2 x 107 HD11 cells were seeded into two 75 
cm2 tissue culture flasks.  PMA was added to one of the flasks at a concentration of 100 ng/ml.  
The next day cells were washed once with PBS and harvested by the addition of 0.5% trypsin.  
Cells were counted and amounts corresponding to 5.0 x 105 cells were added to individual 
eppendorf tubes prior to being centrifuged at 2700 x g for 5 min at 4°C, and resuspended in 100 
µl Hanks’ buffered saline (HBS) with calcium and magnesium (137 mM NaCl, 5.4 mM KCl, 358 
mM NaHCO3, 0.44 mM KH2PO4, 0.34 mM Na2HPO4, 0.5 mM CaCl2, 1 mM MgCl2).  Directly 
before reading luminescence, 100 µl of 10 µM luminol (Sigma-Aldrich) in HBS and 10 U of 
horseradish peroxidase (HRP) (Sigma-Aldrich) in 50 µl HBS were added to the cells.  Samples 
were read for 5 seconds at 3 – 5 minute intervals using a GloMax 20/20 luminometer (Promega 
Biosciences). 
 
5.2.8 Statistical analysis 
Data from each survival assay were pooled and ranked using Microsoft® ExcelTM for 
Mac OS X.  All statistical analyses were performed using GraphPad Prism® 5.0 for Mac OS X.  
One-way ANOVAs were performed on each time point.  If significance between groups was 
found, the data was further analyzed using the post-hoc Tukey test.  p-values ( 0.05 were 
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considered significant.  Data from two superoxide assays were ranked and a two-way ANOVA 
was performed, followed by the post-hoc Bonferroni multiple comparisons test. 
 
5.3 Results 
 
5.3.1 Activation of HD11 cells 
HD11 cells are normally loosely adherent to plastic and have an ovoid shape; but can be 
activated to become more macrophage-like after stimulation with PMA (Figure 5.1, panel A).  
Twelve hours after exposure to 100 ng/ml PMA, the HD11 cells become more adherent and the 
morphology becomes further macrophage-like, with a spindle shape (Figure 5.1, panel B).  In 
addition, stimulated cells were found to produce more reactive oxygen species than unstimulated 
cells, as measured by production of hydrogen peroxide (p-value < 0.0001) (Figure 5.2). 
 
5.3.2 Survival of Salmonella pathogenicity island 2 mutants within HD11 cells 
At 0.5 hours PI, the non-pathogenic E. coli DH5& strain was recovered from the cell 
monolayer fraction at much higher levels than were any of the Salmonella strains (SL1344, 
Sal18, !SPI-2 p-value < 0.001 and !ssaR p-value < 0.01) (Figure 5.3, panel A).  At 3, 6, 12, and 
24 h PI, viable E. coli DH5& were no longer recoverable from the cell monolayer fraction (all p-
value < 0.001, except !ssaR at 24 h PI: p-value < 0.01) (Figure 5.3, panels B-E).  This 
observation indicates that even though more viable E. coli DH5& bacteria were recovered 0.5 h 
PI compared to the Salmonella strains, it is clear that the HD11 cells are able to effectively kill 
the E. coli strain after the initial infection process.  Non-viable (or non-recoverable) E. coli DH5& 
are still visible by immunofluorescence at all time points, although in less abundant amounts than 
the Salmonella strains (Figures 5.5 – 5.9, panel E).  When the Salmonella strains were examined 
it was found that more of the S. Typhimurium wild-type (WT) strain (SL1344) was recovered 
from the cell monolayer fraction than the WT S. Enteritidis strain (Sal18) at all time points, with 
statistical significance observed at 0.5, 3, 6 and 12 h PI (p-value < 0.001) (Figure 5.3).  There was 
no difference in recovery between the WT S. Typhimurium and SPI-2 mutant (!ssaR) S. 
Typhimurium strains, while greater amounts of the S. Enteritidis SPI-2 (!SPI-2) mutant were 
recovered than the WT S. Enteritidis strain at 3, 6 (p-values < 0.001) and 12 h PI (p-value < 0.05) 
(figure 5.3).  
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Figure 5.2  Hydrogen peroxide production by activated HD11 cells 
 
Fold difference in hydrogen peroxide production in HD11 cells 12 hours after stimulation with 
PMA compared to that of unstimulated cells, as measured by luminescence produced by the 
reaction between hydrogen peroxide, luminol and horseradish peroxidase (HRP).  
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Figure 5.3  Recovery of Salmonella from the cell monolayer fraction of HD11 cells over time 
 
The ability of SPI-2 mutants (ST !ssaR and SE !SPI-2) to survive in the chicken macrophage 
HD11 cell line was compared to their parent WT strains (ST SL1344 and SE Sal18) as well as to 
the non-pathogenic E. coli strain E. coli DH5&.  Panel A shows the recovered CFU/ml from the 
cell monolayer fraction at 0.5 h post-infection (PI), prior to addition of gentamicin.  Panels B, C, 
D and E show the recovered CFU/ml from the cell monolayer fraction after the addition of 
gentamicin at 3, 6, 12 and 24 h PI respectively.  *, p-value < 0.05; **, p-value < 0.01; ***, p-
value < 0.001.  Note that the scale of the Y-axis is linear, and differs between time points.  
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5.3.3 Bacteria in the media fraction 
At 3, 6, 12 and 24 h PI (after the addition of gentamicin), Salmonella could be recovered 
from the media taken off the cell monolayer.  When the media fraction was separated into two 
tubes (one containing 1% Triton X-100) and grown for 3 hours, bacteria was only recoverable 
from the media fraction to which no Triton X-100 had been added.  As 1% Triton X-100 is 
capable of disrupting eukaryotic, but not bacterial, cell membranes, this indicates that the bacteria 
are contained within eukaryotic cell membranes.  Furthermore, PKH and Giemsa staining of the 
media fraction showed both whole cell and smaller membrane fragments in the media fraction 
(data not shown) and Immunofluorescence at 0.5, 3, 6, 12 and 24 h PI showed that most 
Salmonella were associated with whole HD11 cells that have detached from the monolayer 
(Figure 3.10 panels A, B and C), or fragmented cells (Figure 3.10 panels D and E). At 3 and 6 h 
PI, more of the WT S. Typhimurium strain SL1344 was recovered from the media fraction than 
the WT S. Enteritidis strain Sal18 (p-value < 0.05 and < 0.001 respectively) (Figure 5.4, panels A 
and B).  At 6 h PI, both mutant strains (!ssaR and !SPI-2) were recovered in greater amounts 
than their respective parent strains (SL1344 and Sal18) (Figure 5.4, panel B).  Finally, E. coli 
strain DH5& was not recoverable from the media fraction at any time point (Figure 5.4). 
 
5.4 Discussion 
Chicken macrophage-like HD11 cells can be induced to be more macrophage-like by 
stimulation with PMA, as evidenced by morphology and production of reactive oxygen species 
(Figures 2.1 and 2.2, respectively).  At 0.5 h PI, prior to addition of gentamicin, more E. coli 
DH5& were recovered from the cell monolayer fraction than the Salmonella strains.  It is unclear 
why this may be, as similar numbers of intracellular and extracellular bacteria were present in all 
samples when visualized by immunofluorescence microscopy (Figure 2.5).  However, this 
microscopy does not differentiate viable from killed bacteria and it is possible that more live E. 
coli DH5& bacteria are initially phagocytosed by the macrophages, or that more E. coli DH5& 
remain associated with (but not phagocytosed) by the cells after the washing process.  Following 
the addition of gentamicin, activated HD11 cells effectively killed E. coli DH5&, as viable E. coli 
DH5& were not recoverable from either the cell monolayer fraction or media fraction at any time 
point past 0.5 h.  In comparison, all Salmonella strains were recoverable up to 24 h PI from 
HD11 cells.  At most time points, the S. Typhimurium strain appeared to survive better within the  
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Figure 5.4  Recovery of Salmonella from the media fraction of HD11 cells over time 
 
The ability of SPI-2 mutants (ST !ssaR and SE !SPI-2) to survive in the chicken macrophage 
HD11 cell line was compared to their parent WT strains (ST SL1344 and SE Sal18) as well as to 
the lab E. coli strain E. coli DH5&.  Surprisingly, Salmonella, but not E. coli, was recovered from 
the media at all time points PI following the addition of gentamicin.  Panel A shows the CFU/ml 
recovered from the media fraction at 3 h post-infection (PI) while Panels B, C and D show the 
CFU/ml recovered from the media fraction at 6, 12 and 24 h PI respectively.  *, p-value < 0.05; 
**, p-value < 0.01; ***, p-value < 0.001.  Note that the scale of the Y-axis is linear, and differs 
between time points.  
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Figure 5.5  Salmonella associated with the cell monolayer fraction at 0.5 h PI 
 
HD11 cell nuclei are stained blue, both intra- and extracellular bacteria are green, and 
extracellular bacteria appear red or yellow.  Panel A shows HD11 cells infected with WT ST 
strain SL1344, Panel B shows HD11 cells infected with ST SPI-2 mutant !ssaR.  Panels C and 
D show HD11 cells infected with WT SE strain Sal18 and SE SPI-2 mutant !SPI-2, respectively.  
Panel E shows HD11 cells infected with lab E. coli strain E. coli DH5&.  
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Figure 5.6  Salmonella associated with the cell monolayer fraction at 3 h PI 
 
HD11 cell nuclei are stained blue, both intra- and extracellular bacteria are green, and 
extracellular bacteria appear red or yellow.  Panel A shows HD11 cells infected with WT ST 
strain SL1344, Panel B shows HD11 cells infected with ST SPI-2 mutant !ssaR.  Panels C and 
D show HD11 cells infected with WT SE strain Sal18 and SE SPI-2 mutant !SPI-2, respectively.  
Panel E shows HD11 cells infected with lab E. coli strain E. coli DH5&.  
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Figure 5.7  Salmonella associated with the cell monolayer fraction at 6 h PI 
 
HD11 cell nuclei are stained blue, both intra- and extracellular bacteria are green, and 
extracellular bacteria appear red or yellow.  Panel A shows HD11 cells infected with WT ST 
strain SL1344, Panel B shows HD11 cells infected with ST SPI-2 mutant !ssaR.  Panels C and 
D show HD11 cells infected with WT SE strain Sal18 and SE SPI-2 mutant !SPI-2, respectively.  
Panel E shows HD11 cells infected with lab E. coli strain E. coli DH5&.  
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Figure 5.8  Salmonella associated with the cell monolayer fraction at 12 h PI 
 
HD11 cell nuclei are stained blue, both intra- and extracellular bacteria are green, and 
extracellular bacteria appear red or yellow.  Panel A shows HD11 cells infected with WT ST 
strain SL1344, Panel B shows HD11 cells infected with ST SPI-2 mutant !ssaR.  Panels C and 
D show HD11 cells infected with WT SE strain Sal18 and SE SPI-2 mutant !SPI-2, respectively.  
Panel E shows HD11 cells infected with lab E. coli strain E. coli DH5&.  
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Figure 5.9  Salmonella associated with the cell monolayer fraction at 24 h PI 
 
HD11 cell nuclei are stained blue, both intra- and extracellular bacteria are green, and 
extracellular bacteria appear red or yellow.  Panel A shows HD11 cells infected with WT ST 
strain SL1344, Panel B shows HD11 cells infected with ST SPI-2 mutant !ssaR.  Panels C and 
D show HD11 cells infected with WT SE strain Sal18 and SE SPI-2 mutant !SPI-2, respectively.  
Panel E shows HD11 cells infected with lab E. coli strain E. coli DH5&.  
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Figure 5.10  WT ST strain SL1344 in the media fraction over time 
 
HD11 cell nuclei are stained blue, both intra- and extracellular bacteria are green, and 
extracellular bacteria appear red or yellow.  Panel A shows an HD11 cell loaded with WT ST 
strain SL1344 at 0.5 h PI, just prior to addition of gentamicin.  Panels B and C show whole 
HD11 cells containing SL1344 at 3 and 6 h PI, respectively, after addition of gentamicin.  Panels 
D and E show fragmented HD11 cells containing SL1344 at 12 and 24 h PI, respectively, after 
the addition of gentamicin.  Whole and fragmented cells containing SL1344 were visible at all 
time points in the media fraction.  
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HD11 cells than the S. Enteritidis strain.  Importantly, at no time did the WT S. Typhimurium or 
S. Enteritidis strains survive better than their respective SPI-2 mutant strains, and, at 3, 6, and 12 
h PI, the S. Enteritidis SPI-2 mutant (!SPI-2) out-performed the WT strain.  All strains, including 
non-recoverable E. coli DH5&, were visible within macrophages at all time points PI by 
immunofluorescence, but it is likely that the immunofluorescence was detecting killed, as well as 
viable, bacteria (Figures 2.5 – 2.9).  There were usually only one or two bacteria were seen within 
an individual cell, although a few instances of large bacterial load were also observed.  After the 
addition of gentamicin, fewer macrophages containing E. coli were visible, when compared to 
those infected with Salmonella strains. 
In a mouse model of infection, multiple groups have shown that various SPI-2 mutants 
are highly attenuated in virulence (measured by LD50) [59, 61, 149, 338].  Initially, Hensel et al. 
showed that S. Typhimurium SPI-2 mutants replicated at similar levels to WT S. Typhimurium in 
the mouse macrophage-like RAW264.7 cell line [1].  However, later work by the same group 
(and others) indicated that SPI-2 mutants failed to replicate as well in mouse macrophages than 
WT strains if they were first grown to stationary phase and then opsonized before infection to 
enhance uptake of bacteria by macrophages [59, 61, 338].  In our experiments, bacteria were 
grown to mid-log phase before infection, and were not opsonized, because these conditions do 
not mimic the initial stages of infection.  Many groups have recently published results in 
accordance with our findings.  Forest et al. [339] determined that the absence of a functional SPI-
2 T3SS in serovar Typhi (S. Typhi) did not affect survival in human macrophages.  Aussel et al. 
[340] demonstrated that S. Typhimurium containing a non-functional SPI-2 or SPI-1 T3SS was 
able to survive similarly to WT S. Typhimurium in both mouse bone marrow-derived 
macrophages and RAW264.7 macrophages, but that the same mutants did not replicate to similar 
levels of the WT strain in vivo.  A study by Helaine et al. [341] determined that while SPI-2 was 
important for replication of S. Typhimurium in macrophages, it does not affect the survival of 
phagocytosed bacteria within the SCV.  Furthermore, it was shown in this study that most WT S. 
Typhimurium that are taken up by macrophages do not undergo replication at all, but rather enter 
a dormant state within the SCV.  The number of bacteria in stasis did not differ between WT 
macrophages, phox-/- macrophages, or macrophages stimulated with IFN#.  Thus, Salmonella may 
be able to survive within macrophages without replication and disseminate to systemic sites, 
regardless of the presence of SPI-2.  In fact, it has been shown that SPI-2 mutants are able to 
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reach the livers and spleens of mice, that similar numbers of spleen cells are infected, but mice 
infected with SPI-2 mutants have a reduced bacterial load in these organs [149, 341].  Previous 
work by our group showed that although S. Enteritidis SPI-1 and SPI-2 mutants were recovered 
in the livers and spleens of infected chickens in less abundance than the WT S. Enteritidis strain 
initially, the mutant strains reached comparable levels to the WT strain by day 4 PC [282, 312]. 
It is well known that the production of reactive oxygen species (ROS) by phagocytes is 
important for control of intracellular pathogens.  Humans, or animals, with mutations in NADPH 
oxidase (Phox) are prone to severe recurrent infections by fungi and intracellular bacteria, 
including Salmonella [334, 342].  Phox assembles on phagosomes that contain intracellular 
pathogens, and is responsible for the production of superoxide (O2-).  Superoxide is not readily 
able to cross the membranes of bacteria, but can spontaneously dismutate, or be dismutated by 
superoxide dismutases, into hydrogen peroxide (H2O2).  Hydrogen peroxide can easily diffuse 
across bacterial membranes and can form highly reactive hydroxyl (HO) radicals in the presence 
of iron (Fe2+) that damage bacterial DNA, proteins and lipids [334, 340].  Salmonella has 
developed multiple defenses to this process.  Salmonella has two periplasmic superoxide 
dismutases (SodCI and SodCII) that combat exogenous superoxide.  It also expresses three 
known cytosolic catalases (KatG, KatE, and KatN) and three cytosolic peroxidases (SodA, SodB, 
and Tpx) that degrade hydrogen peroxide within the bacterial cytoplasm.  SodCI and SodCII, 
along with the cytoplasmic peroxidase Tpx, have been shown to be important for survival of S. 
Typhimurium in mouse macrophages [340, 342, 343].  It has also been previously shown that 
SPI-2 is important for vesicular trafficking and the association of Phox with the SCV in human 
and mouse macrophages; this observation led researchers to propose that the SPI-2 T3SS was 
essential in avoiding the oxidative burst [342, 344, 345].  However, recent work by Aussel et al. 
[340] indicates that SodCI, SodCII and Tpx are sufficient for Salmonella to overcome ROS, and 
that S. Typhimurium SPI-2 mutants perform similarly to WT S. Typhimurium in vitro.  They 
found that, in vivo, the WT S. Typhimurium had increased replication in relation to the SPI-2 
mutant in both WT and phox-/- mice (although both strains reached higher levels in the phox-/- 
mice), indicating that while SPI-2 is important for replication, it does not play a major role in 
evasion of ROS.  While we showed that HD11 macrophages activated with PMA produced 
greater levels of hydrogen peroxide than non-activated macrophages (Figure 2.2), we did not see 
a major difference in survival or replication of SPI-2 mutants compared to WT in these activated 
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cells.  This indicates that any avoidance of ROS in this case was independent of a functional SPI-
2 T3SS.  Slauch et al. [346] state that ROS in the SCV of infected cells may not be diminished by 
WT Salmonella as previously reported, so the role of SPI-2 in avoidance of ROS, as well as the 
importance of ROS in control of Salmonella infection, remains unclear. 
SPI-2 has been shown to change cytokine and chemokine production by macrophages, 
including the HD11 cell line [333, 347-349].   In HD11 cells, PipB has been shown to be 
important in the down regulation of pro-inflammatory cytokines, indicating a role for SPI-2 in 
repression of the host’s innate immune response [348].  SPI-2 has also been shown to be 
important in limiting the antigen presenting abilities of macrophages and dendritic cells to T cells 
[350, 351].    It may be that SPI-2 is less important for survival of Salmonella within 
macrophages, but more important in modulation of macrophage stimulation of other immune 
cells via cytokine/chemokine production and antigen presentation.  This would better explain 
some of the differences seen between in vitro SPI-2 Salmonella mutant survival and in vivo SPI-2 
Salmonella mutant vulnerability. 
Surprisingly, in our study, Salmonella was recoverable in the media fraction at each time 
point after the addition of gentamicin.  These bacteria were found to be associated with both 
whole detached cells and closed cell fragments.  If the bacteria within the cell fragments are 
viable, this would be a novel way for Salmonella to avoid the host immune system between host 
cell death and uptake by other phagocytic cells. 
Taken together, these results indicate that survival in activated chicken HD11 
macrophage-like cells is likely SPI-2 independent.  It would be interesting to see if similar results 
were found in vivo, looking to see if WT and SPI-2 mutant Salmonella strains could be recovered 
from macrophages of orally infected chickens.  In addition, it would also be useful to include 
profiling of cytokines and chemokines produced by infected macrophages in order to determine 
the importance of ROS and RNS in bacterial clearance from chickens, as the vast majority of 
work has been carried out in mice.  Further characterization of bacteria in the media fraction, in 
particular, whether those within macrophage fragments remain viable to infect naive 
macrophages, would be illuminating. 
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6.0 GENERAL DISCUSSION AND CONCLUSIONS 
 
6.1 General discussion 
Infections by Salmonella enterica subspecies enterica serovars Typhimurium (S. 
Typhimurium) and Enteritidis (S. Enteritidis) are one of the most common causes of bacterial 
food borne gastroenteritis (food poisoning) in humans worldwide [21]. S. Enteritidis and S. 
Typhimurium are passed to humans via consumption of contaminated poultry meat, contaminated 
water, and eggs [22].  Because chickens generally do not show symptoms of disease, Salmonella 
can spread throughout a poultry flock quite quickly and chickens will shed bacteria in their feces 
for extended periods of time [23-26].  Loss of consumer confidence in products because of 
Salmonella contamination can result in substantial economic loss to the poultry industry.  
Additionally, human cases of salmonellosis place a significant burden on the health care system 
[18].  In humans, S. Typhimurium and S. Enteritidis generally produce self-limiting 
gastroenteritis, but in rare occasions can cause typhoid-like systemic disease.  In susceptible 
mice, S. Typhimurium and S. Enteritidis cause a lethal typhoid like disease, while resistant mice 
can develop chronic systemic infection.  In gnotobiotic or streptomycin pre-treated mice, S. 
Typhimurium and S. Enteritidis cause symptoms resembling gastroenteritis.  In most healthy 
adult chickens, infection with S. Typhimurium and S. Enteritidis result in an asymptomatic carrier 
state [13, 181, 204]. 
Salmonella uses two specialized type III secretion systems (T3SS) that facilitate invasion 
and survival within the host cell and are encoded within Salmonella pathogenicity islands 1 and 2 
(SPI-1 and SPI-2).  The SPI-1 and SPI-2 T3SS secrete effectors into the host cell, triggering a 
number of events in the infected cell.  It is the current view that the SPI-1 T3SS is mainly 
involved in invasion of the host cell, while the SPI-2 T3SS plays a role in survival within the host 
cell and maintenance of the Salmonella containing vesicle (SCV) [59, 284, 285].  The SPI-2 
T3SS has been reported to be necessary for systemic infection, intracellular proliferation and 
survival, and maintenance of the SCV.  However, the majority of these studies have been 
performed in mice, where S. Typhimurium and S. Enteritidis produce a typhoid-like infection 
rather than gastroenteritis, and therefore may not be indicative of the course of infection in 
healthy adult humans and the asymptomatic carrier state in chickens  [55, 286-288]. 
In order to determine the importance of the SPI-2 T3SS in cecal colonization and 
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systemic spread in chickens, the ability of S. Enteritidis SPI-2 mutants to colonize chickens was 
examined by us.  When 35-day-old SPF chickens were challenged with both a WT strain and a 
strain impaired in both the SPI-1 and SPI-2 T3SSs, the WT strain began to out-compete the 
mutant strain in the liver and spleen by day 2 PC, but there was no detectable difference in the 
level of WT versus mutant strain in the cecal contents.  Dieye et al. [315] used a similar 
experimental design in a recent study comparing colonization levels of a WT S. Typhimurium 
strain and either a !SPI-1 strain missing the entire SPI-1 region, a !SPI-2 strain missing a 
portion of the SPI-2 region encoding structural genes, or a combination !SPI-1!SPI-2 strain.  
Similar to our findings, this group recovered a greater amount of the WT S. Typhimurium strain 
from the spleen than the !SPI-2 and !SPI-1!SPI-2 strains.  They also observed that colonization 
levels of the WT versus the mutant strains in the cecum were not different, again supporting our 
results.  When one-week-old SPF chickens were challenged with a WT S. Enteritidis strain, a 
strain missing SPI-2, or a strain missing both SPI-1 and SPI-2, we observed that the mutant 
strains were impaired in their ability to infect the liver and spleen, but were recovered from the 
cecum at similar levels as the WT.  On day 1 PC, both the WT and mutant strains had begun to 
spread to the liver and spleen, but while the WT strain reached peak colonization of the liver and 
spleen by day 2 PC, and was beginning to clear by day 3 PC, the mutant strains did not reach 
their peak until day 3 PC.  By day 4 PC, both the WT and mutant strains were beginning to clear 
from the birds.  Bohez et al. [319] observed that maximum presence of Salmonella in liver and 
spleen of SPF birds challenged with 108 CFU S. Enteritidis on the day of hatching occurred on 
day 2, supporting our observations.  Others have also observed that SPI-2 mutant strains, while 
able to reach the liver and spleen of chickens, have a later peak colonization than the WT strain, 
and tended to be cleared faster from systemic sites [304, 314]. 
Live bacterial vaccines often produce long lasting immunity at both systemic and mucosal 
sites, however fear of reversion to virulence and release of genetically engineered organisms into 
the environment are a major concern.  Inactivated bacterial vaccines (also known as bacterins) 
and subunit protein-based vaccines are often capable of inducing a strong humoral immune 
response, but tend not to induce production of mucosal IgA or a potent cell-mediated immune 
response.  They are attractive over live vaccines as there is no chance of reactivated virulence or 
of live genetically modified bacteria entering the environment.  Ideally, a vaccine for use in 
poultry to combat Salmonella should induce both strong humoral and cell-mediated immune 
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responses that confer protection against more than one serovar [15, 206, 220].  In our series of 
vaccine trials we found that vaccination of chickens with SPI-2 structural or effector components 
induced high levels of vaccine specific IgY that were long lasting and transferrable to progeny.  
Groups of chickens vaccinated with SPI-2 proteins, and progeny of vaccinates, exhibited lower 
overall numbers of Salmonella than unvaccinated controls. 
In a mouse model of infection, multiple groups have shown that various SPI-2 mutants 
are highly attenuated in virulence, both in vivo and in vitro.  Most of the in vitro work involved 
first growing Salmonella to stationary phase and then opsonizing it to facilitate uptake by 
macrophages [59, 61, 149, 338].  In our experiments, bacteria were grown to mid-log phase 
before infection, and were not opsonized, because these conditions do not mimic the initial stages 
of infection.  Activated chicken macrophage-like HD11 cells were able to control infection with a 
non-pathogenic E. coli strain, eliminating recoverable bacteria by 3 h PI.  However, both S. 
Typhimurium and S. Enteritidis SPI-2 mutants performed similarly to their parent strains, with 
significant numbers of Salmonella recovered up to 24 h PI.  Similar results were observed by 
Hensel et al. [1] and Aussel et al. [340] using S. Typhimurium and S. Typhimurium SPI-2 
mutants in mouse macrophage-like RAW264.7 cells primary mouse macrophage cells.  Helaine 
et al. [341] observed that while SPI-2 of S. Typhimurium was important for replication of the 
bacterium within the SCV, it was not necessary for survival in mouse macrophages. SPI-2 has 
also been shown to modulate pro- and anti-inflammatory cytokine production in mammalian 
cells, as well as limit antigen presentation by dendritic cells and T cells [333, 347-349, 351]. 
Taking the observations of others into consideration, along with our observations, both in 
vivo and in vitro, it may be that Salmonella can survive within macrophages without replication 
and disseminate to systemic sites regardless of the presence of SPI-2.  It may be that SPI-2 is less 
important for survival of Salmonella within macrophages, but more important in modulation of 
macrophage stimulation of other immune cells via cytokine/chemokine production and antigen 
presentation.  This would better explain some of the differences seen between in vitro SPI-2 
Salmonella mutant survival and in vivo SPI-2 Salmonella mutant vulnerability, as well as the 
differences in infection outcome in different hosts.  Our work has increased knowledge about the 
role of the SPI-2 T3SS of S. Enteritidis in chickens and chicken macrophages. However, further 
research is needed to determine the exact mechanisms of systemic spread by S. Enteritidis and its 
role in immune modulation in chickens.  
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6.2 Future directions 
Further research into the role of the SPI-2 T3SS in systemic spread in chickens is needed.  
Specific experiments involving challenge of chickens with labeled wild-type and Salmonella SPI-
2 mutants would allow real-time observation of how the strains disseminate throughout the 
chicken.  This would also allow for the surveillance of the specific cell types that the two strains 
are residing in within the chickens.  Further, after isolation of infected phagocytic cells from 
challenged chickens, specific cytokine and chemokine profiles of these cells could be undertaken 
to see how SPI-2 effects immune cell function.  Rather than using the available immortalized cell 
lines, isolation of a primary chicken macrophage cell line would be important for time course 
studies.  Observations on how the cytokine and chemokine profiles of these cells change over 
time, when infected with wild-type Salmonella compared to the SPI-2 mutant, as well as whether 
the lack of SPI-2 affects replication of the bacteria within these cells would be helpful.  
Characterization of how Salmonella induces cell death in primary chicken macrophages, and the 
role SPI-2 plays, would be very useful and further study of the media fraction in the gentamicin 
protection assay would be interesting to see if Salmonella is truly contained in small membrane 
vesicles that are able to be taken up by naïve macrophages, and continue the infection process. 
It would be interesting to see if there is any cross-reactivity in antibodies produced by 
hens vaccinated with either of the SPI-2 vaccines compared to the AviPro® vaccine.  As the SPI-
2 vaccines showed some promise, it would be worthwhile to try various vaccine formulations 
using some of the proteins, especially SseB.  An oral vaccine would be the most desirable for use 
in poultry, and use in a situation more reminiscent to what they would see in the field, using the 
seeder-contact model, lower challenge doses, and a longer surveillance period, would be 
extremely useful. 
 
6.3 General conclusions 
o In a co-challenge situation the WT strain is more competitive than the SPI-1/SPI-2 mutant 
strains 
o The SPI-2 T3SS is not important for cecal colonization in chickens 
o The SPI-2 T3SS is important for systemic spread in chickens, but is obviously not the 
only factor involved 
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o SPI-2 T3SS structural and effector proteins are capable of eliciting a strong humoral 
immune response in chickens, as measured by protein specific serum IgY levels 
o Antibodies generated through vaccination with either SPI-2 T3SS structural or effector 
proteins are transferrable from hens to progeny, as measured by egg yolk IgY 
o SPI-2 T3SS proteins may be useful in a combination vaccine to protect chickens from 
colonization with Salmonella 
o The SPI-2 T3SS is not important for survival of S. Typhimurium or S. Enteritidis in the 
activated chicken macrophage-like cell line HD11 ! !
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